Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
  • A61K38/46—Hydrolases (3)
  • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07K—PEPTIDES
  • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • C07K14/795—Porphyrin- or corrin-ring-containing peptides
  • C07K14/805—Haemoglobins; Myoglobins
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
  • A61K31/7088—Compounds having three or more nucleosides or nucleotides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
  • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
  • A61K35/14—Blood; Artificial blood
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
  • A61K38/46—Hydrolases (3)
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K38/00—Medicinal preparations containing peptides
  • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
  • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
  • A61K38/46—Hydrolases (3)
  • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
  • A61P7/06—Antianaemics
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
  • C12N15/102—Mutagenizing nucleic acids
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
  • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
  • C12N15/90—Stable introduction of foreign DNA into chromosome
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
  • C12N15/09—Recombinant DNA-technology
  • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
  • C12N15/90—Stable introduction of foreign DNA into chromosome
  • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
  • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
  • C12N5/06—Animal cells or tissues; Human cells or tissues
  • C12N5/0602—Vertebrate cells
  • C12N5/0634—Cells from the blood or the immune system
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
  • C12N9/14—Hydrolases (3)
  • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
  • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
  • C12N9/14—Hydrolases (3)
  • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12Y—ENZYMES
  • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
  • C12Y305/04—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in cyclic amidines (3.5.4)
  • C12Y305/04004—Adenosine deaminase (3.5.4.4)
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2310/00—Structure or type of the nucleic acid
  • C12N2310/10—Type of nucleic acid
  • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2320/00—Applications; Uses
  • C12N2320/30—Special therapeutic applications
  • C12N2320/34—Allele or polymorphism specific uses
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2510/00—Genetically modified cells
• • C—CHEMISTRY; METALLURGY
  • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
  • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
  • C12N2800/00—Nucleic acids vectors
  • C12N2800/80—Vectors containing sites for inducing double-stranded breaks, e.g. meganuclease restriction sites

Definitions

• CRISPR clustered regularly interspaced short palindromic repeat
• a method for treating a genetic disorder in a subject comprises administering a base editor, or a polynucleotide encoding the base editor, to the subject, wherein the base editor comprises a polynucleotide-programmable nucleotide- binding domain and a deaminase domain; administering a guide polynucleotide to the subject, wherein the guide polynucleotide targets the base editor to a target nucleotide sequence of the subject; and editing a nucleobase of the target nucleotide sequence by deaminating the nucleobase upon targeting of the base editor to the target nucleotide sequence, thereby treating the genetic disorder by changing the nucleobase to another nucleobase; wherein the genetic disorder is caused by a pathogenic amino acid in a protein, and wherein another nucleobase substitutes the pathogenic amino acid with a benign amino acid that is different
• a method of producing a cell, tissue, or organ for treating a genetic disorder in a subject comprises contacting the cell, tissue, or organ with a base editor, or a polynucleotide encoding the base editor, wherein the base editor comprises a polynucleotide-programmable nucleotide-binding domain and a deaminase domain; contacting the cell, tissue, or organ with a guide polynucleotide, wherein the guide polynucleotide targets the base editor to a target nucleotide sequence of the cell, tissue, or organ; and editing a nucleobase of the target nucleotide sequence by deaminating the nucleobase upon targeting of the base editor to the target nucleotide sequence, thereby producing a cell, tissue, or organ for treating the genetic disorder by changing the nucleobase to another nucleobase; wherein the genetic disorder is caused by a pathogenic amino acid in a protein,
• the method further comprises administering the cell, tissue, or organ to the subject.
• the cell, tissue, or organ is autologous to the subject.
• the cell, tissue, or organ is allogeneic to the subject.
• the cell, tissue, or organ is xenogeneic to the subject.
• the nucleobase is located in a gene that is the cause of the genetic disorder.
• the editing comprises editing a plurality of nucleobases located in the gene, wherein the plurality of nucleobases is not the cause of the genetic disorder.
• the editing further comprises editing one or more additional nucleobases located in at least one other gene.
• the gene and the at least one other gene encode one or more subunits of the protein.
• the edited nucleobase is in a gene listed in Table 3A or 3B, and the editing results in an amino acid change in a protein encoded by the gene indicated in Table 3A or 3B.
• the genetic disorder is ACADM deficiency, sickle cell disease (SCD), a hemoglobin disease, beta-thalassemia, Pendred syndrome, autosomal dominant Parkinson’s disease, or alpha-1 antitrypsin deficiency (A1AD).
• compositions and methods for substituting pathogenic amino acids using a programmable nucleobase editor are provided.
• compositions and methods are provided for base editing a thymidine (T) to a cytidine (C) nucleobase in the codon of the sixth amino acid of a sickle cell disease variant of the b-globin protein (Sickle HbS; E6V), thereby substituting an alanine for a valine (E6A).
• compositions and methods of the invention are useful for the treatment of sickle cell disease.
• the edited nucleobase is in an HBB gene encoding beta (b)-globin
• the base editing results in an amino acid change from valine (Val) to alanine (Ala) at amino acid 6 in a b-globin (HBB) protein encoded by the HBB gene (b6Val®Ala).
• the genetic disorder is sickle cell disease or a hemoglobin disease.
• the base editing results in an E6V>E6A amino acid change in a beta subunit of hemoglobin.
• the invention provides a method of editing an HBB polynucleotide comprising a single nucleotide polymorphism (SNP) associated with sickle cell disease, in which the method comprises contacting the HBB polynucleotide with a base editor in complex with one or more guide polynucleotides, wherein the base editor comprises a polynucleotide programmable DNA binding domain and an adenosine deaminase domain, and wherein the one or more guide polynucleotides target the base editor to effect an A•T to G•C alteration of the SNP associated with sickle cell disease.
• SNP single nucleotide polymorphism
• the invention provides a cell, which is produced by introducing into the cell, or a progenitor thereof, a base editor, a polynucleotide encoding the base editor, which comprises a polynucleotide programmable DNA binding domain and an adenosine deaminase domain; and one or more guide polynucleotides that target the base editor to effect an A•T to G•C alteration of the SNP associated with sickle cell disease.
• the invention provides a method of treating sickle cell disease in a subject comprising administering to a subject in need thereof a cell according to any aspect delineated herein.
• the invention provides an isolated cell or population of cells propagated or expanded from the cell according to any aspect delineated herein.
• the invention provides a method of treating sickle cell disease in a subject in which the method comprises administering to a subject in need thereof a base editor, or a polynucleotide encoding the base editor, wherein the base editor comprises a polynucleotide programmable DNA binding domain and an adenosine deaminase domain; and one or more guide polynucleotides that target the base editor to effect an A•T to G•C alteration of the SNP associated with sickle cell disease.
• the invention provides a method of producing a red blood cell (erythrocyte), or progenitor thereof, in which the method comprises (a) introducing into a red blood cell progenitor comprising an SNP associated with sickle cell disease, a base editor, or a polynucleotide encoding the base editor, wherein the base editor comprises a polynucleotide- programmable nucleotide-binding domain and an adenosine deaminase domain, and one or more guide polynucleotides; wherein the one or more guide polynucleotides target the base editor to effect an A•T to G•C alteration of the SNP associated with sickle cell disease; and (b) differentiating the red blood cell progenitor into an erythrocyte.
• the invention provides a base editor comprising: (i) a polynucleotide programmable DNA binding domain comprising a Streptococcus thermophilus 1 Cas9
• the invention provides a guide RNA (gRNA) comprising a nucleic acid sequence selected from CUUCUCCACAGGAGUCAGAU;
• the invention provides a base editor comprising: (i) a polynucleotide programmable DNA binding domain comprising a modified Staphylococcus aureus Cas9 (SaCas9), and (ii) an adenosine deaminase domain.
• a base editor comprising: (i) a polynucleotide programmable DNA binding domain comprising a modified Staphylococcus aureus Cas9 (SaCas9), and (ii) an adenosine deaminase domain.
• the invention provides a guide RNA (gRNA) comprising a nucleic acid sequence selected from UCCACAGGAGUCAGAUGCAC and
• the invention provides a guide RNA (gRNA) comprising a nucleic acid sequence selected from UUCUCCACAGGAGUCAGA; CUUCUCCACAGGAGUCAGA; ACUUCUCCACAGGAGUCAGA; GACUUCUCCACAGGAGUCAGA; and
• the base editing results in an E342K>E342G amino acid change in the SERPINA1 gene-encoded alpha-1 antitrypsin protein.
• the genetic disorder is Medium-chain acyl-CoA dehydrogenase (ACADM) deficiency.
• the base editing results in a K329E>K329G amino acid change in the Medium-chain acyl-CoA dehydrogenase (ACADM) gene-encoded protein.
• the genetic disorder is a hemoglobin disease.
• the base editing results in an E26K>E26G amino acid change in a beta subunit of hemoglobin encoded by the HBB gene.
• the genetic disorder is Pendred syndrome.
• the base editing results in a T416P>T416F amino acid change in the SLC26A4; Solute Carrier Family 26 Member 4 (PDS) protein encoded by the PDS gene.
• the genetic disorder is autosomal dominant Parkinson’s disease.
• the editing results in an A30P>A30L amino acid change in the alpha synuclein (SNCA) protein encoded by the SNCA gene.
• SNCA alpha synuclein
• the A•T to G•C alteration at the SNP associated with sickle cell disease changes a valine to an alanine in the HBB polypeptide.
• the SNP associated with sickle cell disease results in expression of an HBB polypeptide having a valine at amino acid position 6.
• the SNP associated with sickle cell disease substitutes a glutamic acid with a valine.
• the contacting is in a cell, a eukaryotic cell, a mammalian cell, or human cell.
• the subject is a mammal or a human.
• the cell is in vivo or ex vivo.
• the cell or progenitor thereof is an embryonic stem cell, induced pluripotent stem cell hematopoietic stem cell, a common myeloid progenitor, proerythroblast, erythroblast, reticulocyte, or erythrocyte.
• the hematopoietic stem cell is a CD34 + cell.
• the cell is from a subject having sickle cell disease. In various embodiments, the cell is autologous to the subject. In various embodiments, the cell is allogeneic or xenogeneic to the subject. In various embodiments of any aspect delineated herein, the method comprises delivering the base editor, or polynucleotide encoding the base editor, and the one or more guide polynucleotides to a cell of the subject.
• the polynucleotide in various embodiments of any aspect delineated herein, the polynucleotide
• the programmable DNA binding domain is a modified Staphylococcus aureus Cas9 (SaCas9), Streptococcus thermophilus 1 Cas9 (St1Cas9), a modified Streptococcus pyogenes Cas9 (SpCas9), or variants thereof.
• the polynucleotide programmable DNA binding domain comprises a modified SaCas9 having an altered protospacer-adjacent motif (PAM) specificity.
• the altered PAM comprises the nucleic acid sequence 5’-NNNRRT-3’.
• the modified SaCas9 comprises amino acid substitutions E782K, N968K, and R1015H, or corresponding amino acid substitutions thereof.
• the polynucleotide programmable DNA binding domain comprises a variant of SpCas9 having an altered protospacer-adjacent motif (PAM) specificity.
• the altered PAM comprises the nucleic acid sequence 5’-NGC-3’.
• the modified SpCas9 comprises amino acid substitutions D1135M, S1136Q, G1218K, E1219F, A1322R, D1332A, R1335E, and T1337R, or
• the polynucleotide programmable DNA binding domain is a nuclease inactive or nickase variant.
• the nickase variant comprises an amino acid substitution D10A or a
• the base editor further comprises a zinc finger domain.
• the zinc finger domain comprises recognition helix sequences RNEHLEV, QSTTLKR, and RTEHLAR or recognition helix sequences RGEHLRQ, QSGTLKR, and RNDKLVP.
• the zinc finger domain is one or more of zf1ra or zf1rb.
• the adenosine deaminase domain is capable of deaminating adenine in deoxyribonucleic acid (DNA).
• the adenosine deaminase is a modified adenosine deaminase that does not occur in nature.
• the adenosine deaminase is a TadA deaminase. In various embodiments, TadA deaminase is TadA*7.10.
• the one or more guide RNAs comprises a CRISPR RNA (crRNA) and a trans-encoded small RNA (tracrRNA), wherein the crRNA comprises a nucleic acid sequence complementary to an HBB nucleic acid sequence comprising the SNP associated with sickle cell disease.
• the base editor is in complex with a single guide RNA (sgRNA) comprising a nucleic acid sequence
• the St1Cas9 comprises the following amino acid sequence:
• the base editor comprises a linker between the polynucleotide programmable DNA binding domain and the adenosine deaminase domain.
• the linker comprises the amino acid sequence:
• the base editor comprises one or more nuclear localization signals. In various embodiments, the base editor comprises the following amino acid sequence:
• the guide RNA further comprises the nucleic acid sequence:
• the guide RNA comprises a nucleic acid sequence selected from
• the protein nucleic acid complex comprises the base editor according to any aspect delineated herein and a guide RNA according to any aspect delineated herein.
• modified SaCas9 comprises amino acid substitutions E782K, N968K, and R1015H, or corresponding amino acid
• the SaCas9 comprises the amino acid sequence: KRNYILGLAIGITSVGYGIIDYETRDVIDAGVRLFKEANVENNEGRRSKRGARRLKRRRR HRIQRVKKLLFDYNLLTDHSELSGINPYEARVKGLSQKLSEEEFSAALLHLAKRRGVHN VNEVEEDTGNELSTKEQISRNSKALEEKYVAELQLERLKKDGEVRGSINRFKTSDYVKE AKQLLKVQKAYHQLDQSFIDTYIDLLETRRTYYEGPGEGSPFGWKDIKEWYEMLMGHC TYFPEELRSVKYAYNADLYNALNDLNNLVITRDENEKLEYYEKFQIIENVFKQKKKPTL KQIAKEILVNEEDIKGYRVTSTGKPEFTNLKVYHDIKDITARKEIIENAELLDQIAKILTIY QSSEDIQEELTNLNSELTQEEIEQISNLKGYTG
• the base editor comprises the amino acid sequence:
• the base editor comprises the amino acid sequence:
• the guide RNA further comprises the nucleic acid sequence
• the guide RNA comprises the nucleic acid sequence
• any of the methods provided herein further comprise a second editing of an additional nucleobase.
• the additional nucleobase is not the cause of the genetic disorder.
• the additional nucleobase is the cause of the genetic disorder.
• a method of treating a genetic disorder in a subject comprises administering a base editor to a subject in need thereof, wherein the base editor comprises a polynucleotide-programmable nucleotide-binding domain and a deaminase domain in conjunction with a guide polynucleotide; binding of the guide
• nucleobase is in a regulatory element or regulatory region of a gene.
• a method of producing a cell, tissue, or organ for treating a genetic disorder in a subject in need thereof comprises contacting the cell, tissue, or organ with a base editor, wherein the base editor comprises a polynucleotide- programmable nucleotide-binding domain and a deaminase domain in conjunction with a guide polynucleotide; binding of the guide polynucleotide to a target nucleotide sequence of a polynucleotide of the cell, tissue, or organ; and editing a nucleobase of the target nucleotide sequence by deaminating the nucleobase upon the binding of the guide polynucleotide to the target nucleotide sequence, thereby producing the cell, tissue, or organ for treating the genetic disorder by changing the nucleobase to another nucleobase; wherein the nucleobase is in a regulatory element of a gene.
• the method further comprises
• the cell, tissue, or organ is autologous to subject. In some embodiments, the cell, tissue, or organ is allogeneic to the subject. In some embodiments, the cell, tissue, or organ is xenogeneic to the subject.
• the gene is the cause of the genetic disorder. In some embodiments, the gene is not the cause of the genetic disorder. In some embodiments, the editing results in a change in an amount of transcription of the gene. In some embodiments, the change is an increase in the amount of transcription of the gene. In some embodiments, the change is a decrease in the amount of transcription of the gene. In some embodiments, the editing alters a binding pattern of at least one protein to the regulatory element.
• the regulatory element is a promoter, an enhancer, a repressor, a silencer, an insulator, a start codon, a stop codon, Kozak consensus sequence, a splice acceptor, a splice donor, a splice site, a 3’ untranslated region (UTR), a 5’ untranslated region (UTR), or an intergenic region of the gene.
• the editing results in removal of a splice site.
• the editing results in addition of a splice site.
• the editing results in an intron inclusion. In some embodiments, the editing results in an exon skipping. In some embodiments, the editing results in removal of a start codon, stop codon, or Kozak consensus sequence. In some embodiments, the editing results in addition of a start codon, stop codon, or Kozak consensus sequence. In some embodiments, the editing comprises editing a plurality of nucleobases located in the regulatory element of the gene.
• the editing comprises editing a plurality of nucleobases, wherein at least one nucleobase of the plurality of nucleobases is located in at least one additional regulatory element of at least one additional gene.
• the gene and the at least one additional gene encode one or more subunits of at least one protein.
• the editing is selected from any one of the changes as shown in Table 4 herein.
• the genetic disorder is sickle cell disease (SCD), also termed sickle cell anemia.
• the genetic disorder is Hereditary Persistence of Fetal Hemoglobin (HPFH).
• the nucleobase is located in c. -114 ⁇ -102 of HBG1/2. In some embodiments, the nucleobase is located in a promoter of HBG1/2.
• the method comprises a second editing of at least one additional nucleobase, wherein the at least one additional nucleobase is not in the regulatory element of the gene.
• the additional nucleobase is located in a protein coding region.
• the deaminase domain is an adenosine deaminase domain.
• the deaminase domain is a cytidine deaminase domain.
• the adenosine deaminase domain is capable of deaminating adenine in deoxyribonucleic acid (DNA).
• the guide polynucleotide comprises ribonucleic acid (RNA), or deoxyribonucleic acid (DNA).
• the guide polynucleotide comprises a CRISPR RNA (crRNA) sequence, a trans- activating CRISPR RNA (tracrRNA) sequence, or a combination thereof.
• any of methods provided herein further comprises a second guide polynucleotide.
• the second guide polynucleotide comprises ribonucleic acid (RNA), or deoxyribonucleic acid (DNA).
• the second guide polynucleotide comprises a CRISPR RNA (crRNA) sequence, a trans-activating CRISPR RNA (tracrRNA) sequence, or a combination thereof.
• the second guide polynucleotide targets the base editor to a second target nucleotide sequence.
• the polynucleotide-programmable DNA-binding domain comprises a Cas9 domain, a Cpf1 domain, a CasX domain, a CasY domain, a Cas12b/C2c1 domain, or a Cas12c/C2c3 domain.
• the polynucleotide-programmable DNA-binding domain is nuclease dead.
• the polynucleotide- programmable DNA-binding domain is a nickase.
• the polynucleotide- programmable DNA-binding domain comprises a Cas9 domain.
• the Cas9 domain comprises a nuclease dead Cas9 (dCas9), a Cas9 nickase (nCas9), or a nuclease active Cas9. In some embodiments, the Cas9 domain comprises a Cas9 nickase.
• the polynucleotide-programmable DNA-binding domain is an engineered or a modified polynucleotide-programmable DNA-binding domain.
• any of the methods provided herein further comprises a second base editor.
• the second base editor comprises a deaminase domain that is different from that of the other base editor.
• the base editing results in less than 20% indel formation. In some embodiments, the base editing results in less than 15% indel formation. In some embodiments, the base editing results in less than 10% indel formation. In some embodiments, the base editing results in less than 5% indel formation. In some embodiments, the base editing results in less than 4% indel formation. In some embodiments, the base editing results in less than 3% indel formation. In some embodiments, the base editing results in less than 2% indel formation.
• the base editing results in less than 1% indel formation. In some embodiments, the base editing results in less than 0.5% indel formation. In some embodiments, the base editing results in less than 0.1% indel formation. In some embodiments, the base editing does not result in translocations.
• FIG.1 is schematic diagram comparing a healthy subject and a patient with antitrypsin deficiency (A1AD).
• A1AT alpha-1 antitrypsin
• A1AT alpha-1 antitrypsin
• A1AD a deficiency of normal alpha-1 antitrypsin leads to lung tissue damage.
• An accumulation of abnormal alpha-1 antitrypsin in hepatocytes in the liver leads to cirrhosis.
• FIG.2 shows typical ranges of serum alpha-1 antitrypsin (A1AT) levels for different genotypes (normal (MM); heterozygous carriers of alpha-1 antitrypsin deficiency (MZ, SZ); and homozygous deficiency (SS, ZZ)).
• Serum alpha-1 antitrypsin (AAT) concentration is expressed in ⁇ M in the left“y” axis, which is common in the literature.
• the right“y” axis shows an approximate conversion of serum AAT concentration into mg/dL units, as commonly reported by clinical laboratories and by different measurement technologies (nephelometry or radial immunodiffusion).
• FIG.3 depicts the sequence of the target site for the correction of E342K within the SERPINA1 gene which encodes A1AT. Highlighted is the non-canonical spCas9 NGC PAM, as well as the target A nucleobase for which editing will result in the desired correction of E342K. Also noted are additional off-target A’s for which editing may result in benign alleles such as E342G or D341G.
• FIG.4 is a bar graph showing the level of secreted protein in culture supernatants of HEK293T transiently transfected with plasmids encoding different variants of the A1AT protein.
• A1AT concentrations were determined by ELISA using published methods (Borel et al., 2017,“Alpha-1 Antitrypsin Deficiency: Methods and Protocols,” 10.1007/978-1-4939-7163- 3).
• the two most common clinical variants (e.g., pathogenic mutations) of A1AT are E264V (PiS allele) and E342K (PiZ allele).
• the PiS and PiZ proteins are produced in lower abundance than wildtype protein.
• Either the D341G or the E342G proteins is produced at levels similar to wildtype. Accordingly, adenine base editors and base editing methods as described herein were used to produce these benign alleles that restore A1AT secretion from hepatocytes and can simultaneously ameliorate liver toxicity and increase circulation of A1AT to the lungs.
• A1AT alpha-1 antitrypsin
• A1AD alpha-1 antitrypsin deficiency
• “Z mutation” is the E342K (PiZ allele) mutation
• “S mutation” is the E264V (PiS allele).
• FIG.5 is a schematic diagram showing a strategy in which a DNA deoxyadenosine deaminase is evolved starting from TadA.
• a library of E. coli harbors a plasmid library of mutant ecTadA (TadA*) genes fused to dCas9 and a selection plasmid requiring targeted A•T to G•C mutations to repair antibiotic resistance genes. Mutations from surviving TadA* variants were imported into an ABE architecture for base editing in human cells.
• FIG.6 presents a table showing the first 8 amino acids of mature hemoglobin (Hb), including normal HbA, pathogenic variants Sickle HbS and HbC, and the HbG Makassar variant, which is phenotypically like HbA and does not polymerize like HbS. Shown in FIG.6 are the amino acids encoded at amino acid position 6 in each of the Hb types, as well as the DNA and mRNA sequences that encode the first 8 amino acids of these Hb proteins.
• Hb mature hemoglobin
• FIGS.7A and 7B depict the results of experiments to edit the nucleobase adenosine (A) to a guanosine (G) in the sequence (CAC) complementary to the codon encoding valine at amino acid position 6 of HbS using a variety of A-to-G base editors (ABEs) that recognize different PAM sequences.
• FIG.7A is a table describing features of the HBB gRNAs and corresponding ABEs tested, including positions of the desired edit and potential off-target edits.
• FIG.7B is a graph showing the results of using the ABEs for base editing at the sickle cell target site.
• FIGS.8A-8G depict the results of experiments to edit the adenosine (A) to a guanosine (G) in the codon encoding valine at amino acid position 6 of HbS (CAC) using a Staphylococcus aureus Cas9 variant having tolerance for NNNRRT (saKKH), either alone or fused to DNA binding domains having sequence specificity at the sickle cell target site.
• FIG. 8A presents schematic depictions of the ABE constructs showing the organization of the domains within the polypeptides, including saKKH ABE7.10, saKKH ABE7.10 zf1ra, and saKKH ABE7.10 zf1rb.
• FIG.8B shows the nucleic acid sequence at the sickle cell target site, as well as the target complementary sequence of the guide RNAs as depicted by the lines underneath (designated g1 and g4).
• FIG.8C is a graph depicting the results using saKKH ABE7.10, saKKH ABE7.10 zf1ra, and saKKH ABE7.10 zf1rb in combination with the guide RNA g1 having a nucleic acid sequence of 20 nucleotides (nt) in length, which is
• FIG.8C is the nucleic acid sequence at the sickle cell target site and target complementary sequence of the g1 guide RNAs.
• FIG.8D is a graph depicting the results using saKKH ABE7.10, saKKH ABE7.10 zf1ra, and saKKH ABE7.10 zf1rb in combination with the guide RNA g1 having a nucleic acid sequence of 21 nt in length, which is complementary to the sickle cell target site.
• FIG.8E is a graph depicting the results using saKKH ABE7.10, saKKH ABE7.10 zf1ra, and saKKH ABE7.10 zf1rb in combination with the guide RNA g4 having a nucleic acid sequence of 20 nt in length, which is complementary to the sickle cell target site.
• the guide RNA g4 having a nucleic acid sequence of 20 nt in length, which is complementary to the sickle cell target site.
• To the right of the FIG.8E graph is the nucleic acid sequence at the sickle cell target site and target complementary sequence of the g4 guide RNAs.
• FIG.8F is a graph depicting the results using saKKH ABE7.10, saKKH ABE7.10 zf1ra, and saKKH ABE7.10 zf1rb in combination with the guide RNA g4 having a nucleic acid sequence of 21 nt in length, which is complementary to the sickle cell target site.
• FIG.8G depicts base editing at a control HEK2 site.
• FIGS.9A-9E depict the development and evaluation of an adenosine base editor (ABE) having a Streptococcus thermophilus Cas9 (St1Cas9) DNA binding domain for base editing at the sickle cell target site.
• FIG.9A shows base editing using ABE St1Cas9 with the St1Cas9 canonical PAM sequence, NNAGAA (TTCTAG; reverse complement).
• the inset below shows indel percentages (Indel%) comparing ABE St1Cas9, St1Cas9 nuclease, and untreated at the base edited site.
• FIG.9B shows base editing using ABE St1Cas9 with the St1Cas9 canonical PAM sequence NNAGAA.
• FIG.9C shows base editing using ABE St1Cas9 with the St1Cas9 non-canonical PAM sequence, NNACCA (TGGTNN; reverse complement).
• FIG.9D shows base editing using ABE St1Cas9 with the St1Cas9 non-canonical PAM sequence, NNACCA (TGGTNN; reverse complement).
• FIG.9E depicts base editing using the ABE St1Cas9 with the St1Cas9 non-canonical PAM sequence, NNACCA, at the sickle cell target site.
• the arrow indicates an A•T to G•C mutation (Val ->Ala) was induced by the ABE-St1Cas9 base editor at the sickle cell target site in Hb.
• FIG.10 depicts percent base editing at the sickle cell target site using an ABE having an SpCas9 DNA binding domain evolved and engineered to accept NGC PAMs (ngcABE).
• the leftmost bar represents“Pro6Pro;” the middle bar represents“Val7Ala;” and the rightmost bar represents“Ser10Pro”.
• FIG.11 is a schematic depiction representing the promoter region of the HBG1/2 gene.
• the individual purple triangles indicate SNPs and deletions naturally found in patients with HPFH.
• the green arrows e.g.,“BCL11A,”“CCAAT”,“90 BCL11A” and“ZBTB7A” indicate potential transcription binding sites.
• the thick pointed lines (pink) clustered above and below the HBG1/2 sequences indicate guide RNAs that can target these regions of interest, e.g., target sequences of the gene.
• FIG.12 shows targeted base editing rates of target sequences in the HBG1/2 gene in 293T cells transfected with indicated gRNA and Cas9 base editors.
• the percentage of base editing efficacy was determined by Miseq. Shown in the figure is the percentage of editing that occurred in 293T cells using each type of gRNA, for which the gene and target sequences are shown in Table 4.
• The“Cs” indicate the position in relation to the gRNA in which edits with the CBEs in conjunction with the gRNAs would be made.
• The“As” indicate the position in relation to the gRNAs in which the ABEs would edit the sequence in conjunction with the respective gRNA.
• FIG.13 indicates the percentage of editing in primary bone marrow CD34+ cells performed by each type of gRNA which in which the gene and target sequences are shown in Table 4.
• CD34+ cells were transfected with the indicated gRNAs and base editors.
• The“Cs” indicate the position in relation to the gRNA in which edits with the CBEs such as BE4, in conjunction with the gRNAs would be made.
• The“As” indicate the position in relation to the gRNAs in which the ABEs edit the target sequence in conjunction with the respective gRNA. Percentage of base editing at both the HBG1 and HBG2 loci were assessed by Miseq.
• the present invention features compositions and methods for substituting pathogenic amino acids using a programmable nucleobase editor.
• the described compositions and methods are useful for the treatment of sickle cell disease, which is caused by a Glu -> Val mutation at the sixth amino acid of the b-globin protein encoded by the HBB gene.
• sickle cell disease which is caused by a Glu -> Val mutation at the sixth amino acid of the b-globin protein encoded by the HBB gene.
• precise correction of the diseased HBB gene to revert Val -> Glu remains elusive, and has yet to be achieved using either CRISPR/Cas nuclease or CRISPR/Cas base editing approaches.
• CRISPR/Cas nuclease approach requires cleavage of genomic DNA.
• cleavage of genomic DNA carries an increased risk of generating base insertions/deletions (indels), which have the potential to cause unintended and undesirable consequences, including generating premature stop codons, altering the codon reading frame, etc.
• generating double- stranded breaks at the b-globin locus has the potential to radically alter the locus through recombination events.
• the b-globin locus contains a cluster of globin genes (- 5 - e- ; G g- ; A g- ; d- ; and b-globin -3), which have sequence identity to one another.
• recombination repair of a double-stranded break within the locus has the potential to result in gene loss of intervening sequences between globin genes, for example between the d- and b-globin genes.
• Unintended alterations to the locus also carry a risk of causing thalassemia.
• CRISPR/Cas base editing approaches hold promise in that they have the ability to generate precise alterations at the nucleobase level.
• precise correction of Val -> Glu (GTG -> GAG) requires a T•A to A•T transversion editor, which is not presently known to exist.
• the specificity of CRISPR/Cas base editing is due, in part, to a limited window of editable nucleotides created by R-loop formation upon CRISPR/Cas binding to DNA.
• CRISPR/Cas targeting must occur at or near the sickle cell site to allow base editing to be possible, and there may be additional sequence requirements for optimal editing within the window.
• CRISPR/Cas targeting is the presence of a protospacer-adjacent motif (PAM) sequence flanking the site to be targeted.
• PAM protospacer-adjacent motif
• many base editors are based on SpCas9, which requires the PAM sequence NGG.
• T•A to A•T transversion were possible, no NGG PAM exists that would place the target“A” at a desirable position for such an SpCas9 base editor.
• PAM requirements remain a limiting factor in the ability to direct CRISPR/Cas base editors to specific nucleotides at any location in the genome.
• the present invention is based, at least in part, on several discoveries described herein that address the foregoing challenges for providing a genome editing approach for treatment of sickle cell anemia.
• the invention is based in part on the ability to replace the valine at amino acid position 6 of the Hb protein, which causes sickle cell disease, with an alanine, to thereby generate an Hb variant (Hb Makassar) that does not generate a sickle cell phenotype.
• T thymidine
• C cytidine
• V6A valine amino acid residue
• Substitution of alanine for valine at position 6 of HbS generates a b-globin protein variant that does not have a sickle cell phenotype (e.g., does not have the potential to polymerize as in the case of the pathogenic variant HbS). Accordingly, the compositions and methods of the invention are useful for the treatment of sickle cell disease.
• compositions and methods comprising the base editors and base editor systems as described herein for treating a disease or disorder caused by or associated with a gene provided in Tables 3A, 3B, or 4 herein.
• the words“comprising” (and any form of comprising, such as“comprise” and“comprises”),“having” (and any form of having, such as “have” and“has”),“including” (and any form of including, such as“includes” and“include”) or “containing” (and any form of containing, such as“contains” and“contain”) are inclusive or open-ended and do not exclude additional, unrecited elements or method steps. It is
• compositions of the present disclosure can be used to achieve methods of the present disclosure.
• the term“about” or“approximately” means within an acceptable error range for the particular value as determined by one of ordinary skill in the art, which will depend in part on how the value is measured or determined, i.e., the limitations of the measurement system.
• “about” can mean within 1 or more than 1 standard deviation, per the practice in the art.
• “about” can mean a range of up to 20%, up to 10%, up to 5%, or up to 1% of a given value.
• the term can mean within an order of magnitude, preferably within 5-fold, and more preferably within 2-fold, of a value.
• adenosine deaminase is meant a polypeptide or fragment thereof capable of catalyzing the hydrolytic deamination of adenine or adenosine.
• the deaminase or deaminase domain is an adenosine deaminase catalyzing the hydrolytic deamination of adenosine to inosine or deoxy adenosine to deoxyinosine.
• the adenosine deaminase catalyzes the hydrolytic deamination of adenine or adenosine in deoxyribonucleic acid (DNA).
• the adenosine deaminases e.g. engineered adenosine deaminases, evolved adenosine deaminases
• the adenosine deaminases may be from any organism, such as a bacterium.
• administering is referred to herein as providing one or more products or
• compositions described herein to a patient or a subject can be performed by intravenous (i.v.) injection, subcutaneous (s.c.) injection, intradermal (i.d.) injection,
• intraperitoneal (i.p.) injection or intramuscular (i.m.) injection.
• i.p. intraperitoneal
• intramuscular i.m.
• Parenteral administration can be, for example, by bolus injection or by gradual perfusion over time.
• administration can be by an oral route.
• Other modes of administration are also envisioned, such as, without limitation, intranasal, rectal, intracranial, intravaginal, buccal, thoracic, intradermal, transdermal, and the like.
• agent is meant any small molecule chemical compound, antibody, nucleic acid molecule, or polypeptide, or fragments thereof.
• alteration is meant a change (increase or decrease) in the expression levels or activity of a gene or polypeptide as detected by standard art known methods such as those described herein.
• an alteration includes a 10% change in expression levels, preferably a 25% change, more preferably a 40% change, and most preferably a 50% or greater change in expression levels.
• analog is meant a molecule that is not identical, but has analogous functional or structural features.
• a polypeptide analog retains the biological activity of a corresponding naturally-occurring polypeptide, while having certain biochemical modifications that enhance the analog's function relative to a naturally occurring polypeptide. Such biochemical modifications could increase the analog's protease resistance, membrane permeability, or half-life, without altering, for example, ligand binding.
• An analog may include an unnatural amino acid.
• base editor or “nucleobase editor (NBE)” is meant an agent that binds a polynucleotide and has nucleobase modifying activity.
• the base editor comprises a nucleobase modifying polypeptide (e.g., a deaminase) and a polynucleotide programmable nucleotide binding domain in conjunction with a guide polynucleotide (e.g., guide RNA).
• a nucleobase modifying polypeptide e.g., a deaminase
• a guide polynucleotide e.g., guide RNA
• the agent is a biomolecular complex comprising a protein domain having base editing activity, i.e., a domain capable of modifying a base (e.g., A, T, C, G, or U) within a nucleic acid molecule (e.g., DNA).
• a protein domain having base editing activity i.e., a domain capable of modifying a base (e.g., A, T, C, G, or U) within a nucleic acid molecule (e.g., DNA).
• the polynucleotide programmable DNA binding domain is fused or linked to a deaminase domain.
• the agent is a fusion protein comprising a domain having base editing activity.
• the protein domain having base editing activity is linked to the guide RNA (e.g., via an RNA binding motif on the guide RNA and an RNA binding domain fused to the deaminase).
• the domain having base editing activity is capable of deaminating a base within a nucleic acid molecule.
• the base editor is capable of deaminating a base within a DNA molecule.
• the base editor is capable of deaminating a cytosine (C) or an adenosine (A) within DNA.
• the base editor is a cytidine base editor (CBE).
• the base editor is an adenosine base editor (ABE).
• an adenosine deaminase is evolved from TadA.
• the polynucleotide programmable DNA binding domain is a CRISPR associated (e.g., Cas or Cpf1) enzyme.
• the base editor is a catalytically dead Cas9 (dCas9) fused to a deaminase domain.
• the base editor is a Cas9 nickase (nCas9) fused to a deaminase domain.
• the base editor is fused to an inhibitor of base excision repair (BER).
• the inhibitor of base excision repair is a uracil DNA glycosylase inhibitor (UGI).
• the inhibitor of base excision repair is an inosine base excision repair inhibitor. Details of base editors are described in International PCT Application Nos. PCT/2017/045381 (WO 2018/027078) and PCT/US2016/058344 (WO 2017/070632), each of which is
• cytidine deaminase is meant a polypeptide or fragment thereof capable of catalyzing a deamination reaction that converts an amino group to a carbonyl group.
• the cytidine deaminase converts cytosine to uracil or 5-methylcytosine to thymine.
• PmCDA1 which is derived from Petromyzon marinus (Petromyzon marinus cytosine deaminase 1,“PmCDA1”)
• AID Activation-induced cytidine deaminase; AICDA
• AICDA Activation-induced cytidine deaminases
• the cytidine base editor BE4 has the following nucleic acid sequence. Polynucleotide sequences having at least 95% or greater identity to the BE4 nucleic acid sequence are also encompassed.
• a codon-optimized BE4 nucleic acid sequence is provided below: atgtcatccgaaaccgggccagtggccgtagacccaacactcaggaggcggatagaaccccatgagtttgaagtgttcttcgaccccaga gagctgcgcaaagagacttgcctcctgtatgaaataaattgggggggtcgccattttggaggcacactagccagaatactaacaaac acgtggaggtaaattttatcgagaagtttaccaccgaaagatactttttgccccaatacacggtgttcaattacctggtttctgtcatggagtccat gtggagaatgcgataactgagttcctgtctctgtggggagtctcaattacctggtttctgt
• base editing activity is meant acting to chemically alter a base within a polynucleotide.
• a first base is converted to a second base.
• the base editing activity is cytidine deaminase activity, e.g., converting target C•G to T•A.
• the base editing activity is adenosine deaminase activity, e.g., converting A•T to G•C.
• the term“base editor system” refers to a system for editing a nucleobase of a target nucleotide sequence.
• the base editor (BE) system comprises (1) a polynucleotide programmable nucleotide binding domain and a deaminase domain for deaminating the nucleobase; and (2) a guide polynucleotide (e.g., guide RNA) in conjunction with the polynucleotide programmable nucleotide binding domain.
• the base editor system comprises (1) a base editor (BE) comprising a polynucleotide programmable DNA binding domain and a deaminase domain for deaminating the nucleobase; and (2) a guide RNA in conjunction with the polynucleotide programmable DNA binding domain.
• the polynucleotide programmable nucleotide binding domain is a polynucleotide programmable DNA binding domain.
• the base editor is a cytidine base editor (CBE).
• the base editor is an adenine or adenosine base editor (ABE).
• ⁇ b-globin (HBB) protein is meant a polypeptide or fragment thereof having at least about 95% amino acid sequence identity to the amino acid sequence of NCBI Accession No. NP_000509.
• a b-globin protein comprises one or more alterations relative to the following reference sequence.
• a b- globin protein associated with sickle cell disease comprises an E6V (also termed E7V) mutation.
• E6V also termed E7V
• An exemplary b-globin amino acid sequence is provided below.
• HBB polynucleotide is meant a nucleic acid molecule encoding ⁇ b-globin protein or a fragment thereof.
• sequence of an exemplary HBB polynucleotide which is available at NCBI Accession No. NM_000518, is provided below:
• HBG1 protein i.e., Homo sapiens hemoglobin subunit gamma 1 (HBG1) protein
• HBG1 protein a polypeptide or fragment thereof having at least about 95% amino acid sequence identity to the amino acid sequence of NCBI Reference Sequence No. NM_000559.2.
• an HBG1 protein may comprise one or more alterations relative to the following amino acid sequence.
• edits are made to a regulatory region, e.g., promoter, associated with the HBG1 protein to treat or ameliorate sickle cell disease as described herein.
• An exemplary HBG1 amino acid sequence is provided below:
• HBG1 polynucleotide is meant a nucleic acid molecule encoding the HBG1 protein or a fragment thereof.
• polynucleotide is provided below:
• HBG2 protein i.e., Homo sapiens hemoglobin subunit gamma 2 (HBG2) protein
• HBG2 protein a polypeptide or fragment thereof having at least about 95% amino acid sequence identity to the amino acid sequence of NCBI Reference Sequence No. NM_000184.3.
• an HBG2 protein may comprise one or more alterations relative to the following amino acid sequence.
• edits are made to a regulatory region, e.g., promoter, associated with the HBG2 protein to treat or ameliorate sickle cell disease as described herein.
• An exemplary HBG2 amino acid sequence is provided below:
• HBG2 polynucleotide is meant a nucleic acid molecule encoding the HBG2 protein or a fragment thereof.
• polynucleotide is provided below:
• an ALAS1 protein may comprise one or more alterations relative to the following amino acid sequence.
• edits are made to a regulatory region, e.g., promoter, associated with the ALAS1 protein to treat or ameliorate sickle cell disease as described herein.
• ALAS1 amino acid sequence is provided below: MESVVRRCPFLSRVPQAFLQKAGKSLLFYAQNCPKMMEVGAKPAPRALSTAA VHYQQIKETPPASEKDKTAKAKVQQTPDGSQQSPDGTQLPSGHPLPATSQGTA SKCPFLAAQMNQRGSSVFCKASLELQEDVQEMNAVRKEVAETSAGPSVVSVK TDGGDPSGLLKNFQDIMQKQRPERVSHLLQDNLPKSVSTFQYDRFFEKKIDEKK NDHTYRVFKTVNRRAHIFPMADDYSDSLITKKQVSVWCSNDYLGMSRHPRVCG AVMDTLKQHGAGAGGTRNISGTSKFHVDLERELADLHGKDAALLFSSCFVAND STLFTLAKMMPGCEIYSDSGNHASMIQGIRNSRVPKYIFRHNDVSHLRELLQRSD PSVPKIVAFETVHSMDGAVCPLEELCDVAHEFGAITFVDEVHAVGLY
• ALAS1 polynucleotide is meant a nucleic acid molecule encoding the ALAS1 protein or a fragment thereof.
• polynucleotide is provided below:
• a BCL11A protein may comprise one or more alterations relative to the following amino acid sequence.
• base editing occurs in a regulatory region, e.g., promoter, of or associated with the BCL11A protein to treat or ameliorate diseases such as beta thalassemia and sickle cell disease (SCD), e.g., by increasing fetal hemoglobin production.
• SCD sickle cell disease
• the BCL11A-encoding gene is highly expressed in several hematopoietic lineages and plays a role in the switch from g- to b-globin expression during the transition from fetal to adult erythropoiesis.
• BCL11A may play a role in the suppression of fetal hemoglobin production. It may also be involved in lymphoma pathogenesis; translocations associated with B-cell malignancies have been found to deregulate the expression of BCL11A.
• An exemplary human BCL11A amino acid sequence is provided below:
• BCL11A polynucleotide is meant a nucleic acid molecule encoding the BCL11A protein or a fragment thereof.
• the nucleic acid sequence of an exemplary human BCL11A (isoform 1) polynucleotide, Reference Sequence No. GU324937.1, is provided below:
• a nucleobase editor system may comprise more than one base editing component.
• a nucleobase editor system may include more than one deaminase.
• a nuclease base editor system may include one or more cytidine deaminase and/or one or more adenosine deaminases.
• a single guide polynucleotide may be utilized to target different deaminases to a target nucleic acid sequence.
• a single pair of guide polynucleotides may be utilized to target different deaminases to a target nucleic acid sequence.
• the nucleobase component and the polynucleotide programmable nucleotide binding component of a base editor system may be associated with each other covalently or non- covalently.
• a deaminase domain can be targeted to a target nucleotide sequence by a polynucleotide programmable nucleotide binding domain.
• a polynucleotide programmable nucleotide binding domain can be fused or linked to a deaminase domain.
• a polynucleotide programmable nucleotide binding domain can target a deaminase domain to a target nucleotide sequence by non- covalently interacting with or associating with the deaminase domain.
• the nucleobase editing component e.g. the deaminase component can comprise an additional heterologous portion or domain that is capable of interacting with, associating with, or capable of forming a complex with an additional heterologous portion or domain that is part of a polynucleotide programmable nucleotide binding domain.
• the additional heterologous portion may be capable of binding to, interacting with, associating with, or forming a complex with a polypeptide. In some embodiments, the additional heterologous portion may be capable of binding to, interacting with, associating with, or forming a complex with a polynucleotide. In some embodiments, the additional heterologous portion may be capable of binding to a guide polynucleotide. In some embodiments, the additional heterologous portion may be capable of binding to a polypeptide linker. In some embodiments, the additional heterologous portion may be capable of binding to a polynucleotide linker. The additional heterologous portion may be a protein domain.
• the additional heterologous portion may be a K Homology (KH) domain, a MS2 coat protein domain, a PP7 coat protein domain, a SfMu Com coat protein domain, a steril alpha motif, a telomerase Ku binding motif and Ku protein, a telomerase Sm7 binding motif and Sm7 protein, or a RNA recognition motif.
• KH K Homology
• a base editor system may further comprise a guide polynucleotide component. It should be appreciated that components of the base editor system may be associated with each other via covalent bonds, noncovalent interactions, or any combination of associations and interactions thereof.
• a deaminase domain can be targeted to a target nucleotide sequence by a guide polynucleotide.
• the nucleobase editing component of the base editor system e.g.
• the deaminase component can comprise an additional heterologous portion or domain (e.g., polynucleotide binding domain such as an RNA or DNA binding protein) that is capable of interacting with, associating with, or capable of forming a complex with a portion or segment (e.g., a polynucleotide motif) of a guide polynucleotide.
• the additional heterologous portion or domain e.g., polynucleotide binding domain such as an RNA or DNA binding protein
• the additional heterologous portion may be capable of binding to, interacting with, associating with, or forming a complex with a polypeptide. In some embodiments, the additional heterologous portion may be capable of binding to, interacting with, associating with, or forming a complex with a polynucleotide. In some embodiments, the additional heterologous portion may be capable of binding to a guide polynucleotide. In some embodiments, the additional heterologous portion may be capable of binding to a polypeptide linker. In some embodiments, the additional heterologous portion may be capable of binding to a polynucleotide linker. The additional heterologous portion may be a protein domain. In some embodiments, the additional heterologous portion may be a K
• Homology (KH) domain a MS2 coat protein domain, a PP7 coat protein domain, a SfMu Com coat protein domain, a sterile alpha motif, a telomerase Ku binding motif and Ku protein, a telomerase Sm7 binding motif and Sm7 protein, or a RNA recognition motif.
• a base editor system can further comprise an inhibitor of base excision repair (BER) component.
• BER base excision repair
• components of the base editor system may be associated with each other via covalent bonds, noncovalent interactions, or any combination of associations and interactions thereof.
• the inhibitor of BER component may comprise a base excision repair inhibitor.
• the inhibitor of base excision repair can be a uracil DNA glycosylase inhibitor (UGI).
• the inhibitor of base excision repair can be an inosine base excision repair inhibitor.
• the inhibitor of base excision repair can be targeted to the target nucleotide sequence by the polynucleotide programmable nucleotide binding domain.
• a base excision repair can be targeted to the target nucleotide sequence by the polynucleotide programmable nucleotide binding domain.
• polynucleotide programmable nucleotide binding domain can be fused or linked to an inhibitor of base excision repair. In some embodiments, a polynucleotide programmable nucleotide binding domain can be fused or linked to a deaminase domain and an inhibitor of base excision repair. In some embodiments, a polynucleotide programmable nucleotide binding domain can target an inhibitor of base excision repair to a target nucleotide sequence by non-covalently interacting with or associating with the inhibitor of base excision repair.
• the inhibitor of base excision repair component can comprise an additional heterologous portion or domain that is capable of interacting with, associating with, or capable of forming a complex with an additional heterologous portion or domain that is part of a polynucleotide programmable nucleotide binding domain.
• the inhibitor of base excision repair can be targeted to the target nucleotide sequence by the guide
• the inhibitor of base excision repair can comprise an additional heterologous portion or domain (e.g., polynucleotide binding domain such as an RNA or DNA binding protein) that is capable of interacting with, associating with, or capable of forming a complex with a portion or segment (e.g., a polynucleotide motif) of a guide polynucleotide.
• the additional heterologous portion or domain of the guide polynucleotide e.g., polynucleotide binding domain such as an RNA or DNA binding protein
• the additional heterologous portion may be capable of binding to, interacting with, associating with, or forming a complex with a polynucleotide. In some embodiments, the additional heterologous portion may be capable of binding to a guide polynucleotide. In some embodiments, the additional heterologous portion may be capable of binding to a polypeptide linker. In some embodiments, the additional heterologous portion may be capable of binding to a polynucleotide linker. The additional heterologous portion may be a protein domain.
• the additional heterologous portion may be a K Homology (KH) domain, a MS2 coat protein domain, a PP7 coat protein domain, a SfMu Com coat protein domain, a sterile alpha motif, a telomerase Ku binding motif and Ku protein, a telomerase Sm7 binding motif and Sm7 protein, or a RNA recognition motif.
• KH K Homology
• Cas9 or“Cas9 domain” refers to an RNA guided nuclease comprising a Cas9 protein, or a fragment thereof (e.g., a protein comprising an active, inactive, or partially active DNA cleavage domain of Cas9, and/or the gRNA binding domain of Cas9).
• a Cas9 nuclease is also referred to sometimes as a casnl nuclease or a CRISPR (clustered regularly interspaced short palindromic repeat) associated nuclease.
• An exemplary Cas9 is Streptococcus pyogenes Cas9, the amino acid sequence of which is provided below.:
• the term“conservative amino acid substitution” or“conservative mutation” refers to the replacement of one amino acid by another amino acid with a common property.
• a functional way to define common properties between individual amino acids is to analyze the normalized frequencies of amino acid changes between corresponding proteins of homologous organisms (Schulz, G. E. and Schirmer, R. H., Principles of Protein Structure, Springer-Verlag, New York (1979)). According to such analyses, groups of amino acids can be defined where amino acids within a group exchange preferentially with each other, and therefore resemble each other most in their impact on the overall protein structure (Schulz, G. E. and Schirmer, R. H., supra).
• Non-limiting examples of conservative mutations include amino acid substitutions of amino acids, for example, lysine for arginine and vice versa, such that a positive charge can be maintained; glutamic acid for aspartic acid and vice versa, such that a negative charge can be maintained; serine for threonine, such that a free–OH can be maintained; and glutamine for asparagine, such that a free–NH 2 can be maintained.
• coding sequence or“protein coding sequence” as used interchangeably herein, refers to a segment of a polynucleotide that codes for a protein. The region or sequence is bounded nearer the 5’ end by a start codon and nearer the 3’ end with a stop codon. Coding sequences can also be referred to as open reading frames.
• deaminase or“deaminase domain,” as used herein, refers to a protein or enzyme that catalyzes a deamination reaction.
• the deaminase or deaminase domain is a cytidine deaminase, catalyzing the hydrolytic deamination of cytidine or deoxycytidine to uridine or deoxyuridine, respectively.
• the deaminase or deaminase domain is a cytosine deaminase, catalyzing the hydrolytic deamination of cytosine to uracil.
• the deaminase is an adenosine deaminase, which catalyzes the hydrolytic deamination of adenine to hypoxanthine.
• the deaminase is an adenosine deaminase, which catalyzes the hydrolytic deamination of adenosine or adenine (A) to inosine (I).
• the deaminase or deaminase domain is an adenosine deaminase, catalyzing the hydrolytic deamination of adenosine or deoxyadenosine to inosine or deoxyinosine, respectively.
• the adenosine deaminase catalyzes the hydrolytic deamination of adenosine in deoxyribonucleic acid (DNA).
• the adenosine deaminases e.g. engineered adenosine deaminases, evolved adenosine deaminases
• the adenosine deaminases can be from any organism, such as a bacterium.
• the adenosine deaminase is from a bacterium, such as E. coli, S. aureus, S. typhi, S. putrefaciens, H. influenzae, or C. crescentus.
• the adenosine deaminase is a TadA deaminase.
• the deaminase or deaminase domain is a variant of a naturally occurring deaminase from an organism, such as a human, chimpanzee, gorilla, monkey, cow, dog, rat, or mouse. In some embodiments, the deaminase or deaminase domain does not occur in nature.
• the deaminase or deaminase domain is at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75% at least 80%, at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, at least 99.1%, at least 99.2%, at least 99.3%, at least 99.4%, at least 99.5%, at least 99.6%, at least 99.7%, at least 99.8%, or at least 99.9% identical to a naturally occurring deaminase.
• deaminase domains are described in International PCT Application Nos. PCT/2017/045381 (WO 2018/027078) and PCT/US2016/058344 (WO 2017/070632), each of which is incorporated herein by reference for its entirety.
• detectable label is meant a composition that when linked to a molecule of interest renders the latter detectable, via spectroscopic, photochemical, biochemical, immunochemical, or chemical means.
• useful labels include radioactive isotopes, magnetic beads, metallic beads, colloidal particles, fluorescent dyes, electron-dense reagents, enzymes (for example, as commonly used in an ELISA), biotin, digoxigenin, or haptens.
• disease is meant any condition or disorder that damages or interferes with the normal function of a cell, tissue, or organ.
• diseases include retinitis pigmentosa, Usher syndrome, sickle cell disease, beta-thalassemia, Hereditary Persistence of Fetal
• Hemoglobin HPFH
• alpha-1 antitrypsin deficiency A1AD
• hepatic porphyria medium-chain acyl-CoA dehydrogenase (ACADM) deficiency
• ACADM medium-chain acyl-CoA dehydrogenase
• LAL lysosomal acid lipase
• phenylketonuria hemochromatosis, Von Gierke disease, Pompe disease, Gaucher disease, Hurler syndrome, cystic fibrosis, or chronic pain.
• the disease is A1AD.
• the disease is sickle cell disease (SCD), also termed“sickle cell anemia.”
• an “effective amount” is meant the amount of an agent or active compound, e.g., a base editor as described herein, that is required to ameliorate the symptoms of a disease in a subject or patient in need thereof, relative to an untreated patient or an individual without disease, i.e., a healthy individual.
• the effective amount of active compound(s) used to practice the described methods for therapeutic treatment of a disease varies depending upon the manner of administration, the age, body weight, and general health of the subject. Ultimately, the attending physician or veterinarian will decide the appropriate amount and dosage regimen. Such amount is referred to as an“effective” amount.
• an effective amount is the amount of a base editor of the invention sufficient to introduce an alteration in a gene of interest in a cell (e.g., a cell in vitro or in vivo).
• an effective amount is the amount of a base editor required to achieve a therapeutic effect (e.g., to reduce or control retinitis pigmentosa, Usher syndrome, sickle cell disease (SCD), beta-thalassemia, Hereditary Persistence of Fetal Hemoglobin (HPFH), alpha-1 antitrypsin deficiency (A1AD), hepatic porphyria, medium-chain acyl-CoA dehydrogenase (ACADM) deficiency, lysosomal acid lipase (LAL) deficiency, phenylketonuria, hemochromatosis, Von Gierke disease, Pompe disease, Gaucher disease, Hurler syndrome, cystic fibrosis, or chronic pain.
• a therapeutic effect e.g., to reduce or
• Such therapeutic effect need not be sufficient to alter a pathogenic gene in all cells of a subject, tissue or organ, but only to alter the pathogenic gene in about 1%, 5%, 10%, 25%, 50%, 75% or more of the cells present in a subject, tissue or organ.
• an effective amount is sufficient to ameliorate one or more symptoms of a disease (e.g., retinitis pigmentosa, Usher syndrome, sickle cell disease (SCD), beta-thalassemia, Hereditary Persistence of Fetal Hemoglobin (HPFH), alpha-1 antitrypsin deficiency (A1AD), hepatic porphyria, medium-chain acyl-CoA dehydrogenase (ACADM) deficiency, lysosomal acid lipase (LAL) deficiency, phenylketonuria,
• a disease e.g., retinitis pigmentosa, Usher syndrome, sickle cell disease (SCD), beta-thalassemia, Hereditary Persistence of Fetal Hemoglobin (HPFH), alpha-1 antitrypsin deficiency (A1AD), hepatic porphyria, medium-chain acyl-CoA dehydrogenase (ACADM) de
• hemochromatosis Von Gierke disease, Pompe disease, Gaucher disease, Hurler syndrome, cystic fibrosis, or chronic pain).
• fragment is meant a portion of a polypeptide or nucleic acid molecule. This portion contains, preferably, at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, or 90% of the entire length of the reference nucleic acid molecule or polypeptide.
• a fragment may contain 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100, 200, 300, 400, 500, 600, 700, 800, 900, or 1000 nucleotides or amino acids.
• Hybridization means hydrogen bonding, which may be Watson-Crick, Hoogsteen or reversed Hoogsteen hydrogen bonding, between complementary nucleobases.
• adenine and thymine are complementary nucleobases that pair through the formation of hydrogen bonds
• IBR inhibitor of base repair
• nucleic acid repair enzyme for example a base excision repair enzyme.
• the IBR is an inhibitor of inosine base excision repair.
• Exemplary inhibitors of base repair include inhibitors of APE1, Endo III, Endo IV, Endo V, Endo VIII, Fpg, hOGGl, hNEILl, T7 Endol, T4PDG, UDG, hSMUGl, and hAAG.
• the IBR is an inhibitor of Endo V or hAAG.
• the IBR is a catalytically inactive EndoV or a catalytically inactive hAAG.
• the base repair inhibitor is an inhibitor of Endo V or hAAG.
• the base repair inhibitor is a catalytically inactive EndoV or a catalytically inactive hAAG.
• the base repair inhibitor is uracil glycosylase inhibitor (UGI).
• UGI refers to a protein that is capable of inhibiting a uracil-DNA glycosylase base-excision repair enzyme.
• a UGI domain comprises a wild-type UGI or a fragment of a wild-type UGI.
• the UGI proteins provided herein include fragments of UGI and proteins homologous to a UGI or a UGI fragment.
• the base repair inhibitor is an inhibitor of inosine base excision repair.
• the base repair inhibitor is a“catalytically inactive inosine specific nuclease” or“dead inosine specific nuclease.”
• catalytically inactive inosine glycosylases e.g., alkyl adenine glycosylase (AAG)
• AAG alkyl adenine glycosylase
• the catalytically inactive inosine specific nuclease can be capable of binding an inosine in a nucleic acid but does not cleave the nucleic acid.
• Non-limiting exemplary catalytically inactive inosine specific nucleases include catalytically inactive alkyl adenosine glycosylase (AAG nuclease), for example, from a human, and catalytically inactive endonuclease V (EndoV nuclease), for example, from E. coli.
• AAG nuclease catalytically inactive alkyl adenosine glycosylase
• EndoV nuclease catalytically inactive endonuclease V
• the catalytically inactive AAG nuclease comprises an E125Q mutation or a corresponding mutation in another AAG nuclease.
• the terms“isolated,”“purified,” or“biologically pure” refer to material that is free to varying degrees from components which normally accompany it as found in its native state. “Isolate” denotes a degree of separation from original source or surroundings.“Purify” denotes a degree of separation that is higher than isolation. A“purified” or“biologically pure” protein is sufficiently free of other materials such that any impurities do not materially affect the biological properties of the protein or cause other adverse consequences. That is, a nucleic acid or peptide of this invention is purified if it is substantially free of cellular material, viral material, or culture medium when produced by recombinant DNA techniques, or chemical precursors or other chemicals when chemically synthesized.
• Purity and homogeneity are typically determined using analytical chemistry techniques, for example, polyacrylamide gel electrophoresis or high-performance liquid chromatography.
• the term“purified” can denote that a nucleic acid or protein gives rise to essentially one band in an electrophoretic gel.
• modifications for example, phosphorylation or glycosylation, different modifications may give rise to different isolated proteins, which can be separately purified.
• isolated polynucleotide is meant a nucleic acid (e.g., a DNA) that is free of the genes which, in the naturally-occurring genome of the organism from which the nucleic acid molecule of the invention is derived, flank the gene.
• the term therefore includes, for example, a recombinant DNA that is incorporated into a vector; into an autonomously replicating plasmid or virus; or into the genomic DNA of a prokaryote or eukaryote; or that exists as a separate molecule (for example, a cDNA or a genomic or cDNA fragment produced by PCR or restriction endonuclease digestion) independent of other sequences.
• the term includes an RNA molecule that is transcribed from a DNA molecule, as well as a recombinant DNA that is part of a hybrid gene encoding additional polypeptide sequence.
• an“isolated polypeptide” is meant a polypeptide of the invention that has been separated from components that naturally accompany it.
• the polypeptide is isolated when it is at least 60%, by weight, free from the proteins and naturally-occurring organic molecules with which it is naturally associated.
• the preparation is at least 75%, more preferably at least 90%, and most preferably at least 99%, by weight, a polypeptide of the invention.
• An isolated polypeptide of the invention may be obtained, for example, by extraction from a natural source, by expression of a recombinant nucleic acid encoding such a polypeptide; or by chemically synthesizing the protein. Purity can be measured by any appropriate method, for example, column chromatography, polyacrylamide gel electrophoresis, or by HPLC analysis.
• linker can refer to a covalent linker (e.g., covalent bond), a non-covalent linker, a chemical group, or a molecule linking two molecules or moieties, e.g., two components of a protein complex or a ribonucleocomplex, or two domains of a fusion protein, such as, for example, a polynucleotide programmable DNA binding domain (e.g., dCas9) and a deaminase domain (e.g., an adenosine deaminase or a cytidine deaminase).
• a linker can join different components of, or different portions of components of, a base editor system.
• a linker can join a guide polynucleotide binding domain of a polynucleotide programmable nucleotide binding domain and a catalytic domain of a deaminase.
• a linker can join a CRISPR polypeptide and a deaminase.
• a linker can join a Cas9 and a deaminase.
• a linker can join a dCas9 and a deaminase.
• a linker can join a nCas9 and a deaminase. In some embodiments, a linker can join a guide polynucleotide and a deaminase. In some embodiments, a linker can join a deaminating component and a polynucleotide
• a linker can join a RNA-binding portion of a deaminating component and a polynucleotide programmable nucleotide binding component of a base editor system. In some embodiments, a linker can join a RNA-binding portion of a deaminating component and a RNA-binding portion of a polynucleotide programmable nucleotide binding component of a base editor system.
• a linker can be positioned between, or flanked by, two groups, molecules, or other moieties and connected to each one via a covalent bond or non-covalent interaction, thus connecting the two.
• the linker can be an organic molecule, group, polymer, or chemical moiety. In some embodiments, the linker can be a polynucleotide. In some embodiments, the linker can be a DNA linker. In some embodiments, the linker can be a RNA linker. In some embodiments, a linker can comprise an aptamer capable of binding to a ligand. In some embodiments, the ligand may be carbohydrate, a peptide, a protein, or a nucleic acid. In some embodiments, the linker may comprise an aptamer may be derived from a riboswitch.
• the riboswitch from which the aptamer is derived may be selected from a theophylline riboswitch, a thiamine pyrophosphate (TPP) riboswitch, an adenosine cobalamin (AdoCbl) riboswitch, an S- adenosyl methionine (SAM) riboswitch, an SAH riboswitch, a flavin mononucleotide (FMN) riboswitch, a tetrahydrofolate riboswitch, a lysine riboswitch, a glycine riboswitch, a purine riboswitch, a GlmS riboswitch, or a pre-queosine1 (PreQ1) riboswitch.
• TPP thiamine pyrophosphate
• AdoCbl adenosine cobalamin
• a linker may comprise an aptamer bound to a polypeptide or a protein domain, such as a polypeptide ligand.
• the polypeptide ligand may be a K Homology (KH) domain, a MS2 coat protein domain, a PP7 coat protein domain, a SfMu Com coat protein domain, a sterile alpha motif, a telomerase Ku binding motif and Ku protein, a telomerase Sm7 binding motif and Sm7 protein, or a RNA recognition motif.
• the polypeptide ligand may be a portion of a base editor system component.
• a nucleobase editing component may comprise a deaminase domain and a RNA recognition motif.
• the linker can be an amino acid or a plurality of amino acids (e.g., a peptide or protein).
• the linker can be about 5-100 amino acids in length, for example, about 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 20-30, 30-40, 40-50, 50-60, 60-70, 70-80, 80-90, or 90-100 amino acids in length.
• the linker can be about 100-150, 150-200, 200-250, 250-300, 300-350, 350-400, 400-450, or 450- 500 amino acids in length. Longer or shorter linkers can be also contemplated.
• a linker joins a gRNA binding domain of an RNA- programmable nuclease, including a Cas9 nuclease domain, and the catalytic domain of a nucleic-acid editing protein (e.g., cytidine or adenosine deaminase).
• a linker joins a dCas9 and a nucleic-acid editing protein.
• the linker is positioned between, or flanked by, two groups, molecules, or other moieties and connected to each one via a covalent bond, thus connecting the two.
• the linker is an amino acid or a plurality of amino acids (e.g., a peptide or protein).
• the linker is an organic molecule, group, polymer, or chemical moiety.
• the linker is 5- 200 amino acids in length, for example, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 25, 35, 45, 50, 55, 60, 60, 65, 70, 70, 75, 80, 85, 90, 90, 95, 100, 101, 102, 103, 104, 105, 110, 120, 130, 140, 150, 160, 175, 180, 190, or 200 amino acids in length. Longer or shorter linkers are also contemplated.
• a linker comprises the amino acid sequence SGSETPGTSESATPES, which may also be referred to as the XTEN linker.
• a linker comprises the amino acid sequence SGGS.
• a linker comprises (SGGS) n , (GGGS) n , (GGGGS) n , (G) n, (EAAAK) n , (GGS) n ,
• SGSETPGTSESATPES or (XP) n motif, or a combination of any of these, where n is independently an integer between 1 and 30, and where X is any amino acid.
• n is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15.
• a linker comprises a plurality of proline residues and is 5-21, 5-14, 5-9, 5-7 amino acids in length, e.g., PAPAP, PAPAPA, PAPAPAP, PAPAPAPA, P(AP) 4 , P(AP) 7 , P(AP) 10 .
• proline-rich linkers are also termed“rigid” linkers.
• the domains of a base editor are fused via a linker that comprises the amino acid sequence of SGGSSGSETPGTSESATPESSGGS,
• domains of the base editor are fused via a linker comprising the amino acid sequence
• the linker is 24 amino acids in length. In some embodiments, the linker comprises the amino acid sequence SGGSSGGSSGSETPGTSESATPES. In some
• the linker is 40 amino acids in length. In some embodiments, the linker comprises the amino acid sequence
• the linker is 64 amino acids in length. In some embodiments, the linker comprises the amino acid sequence
• the linker is 92 amino acids in length. In some embodiments, the linker comprises the amino acid sequence
• mutation refers to a substitution of a residue within a sequence, e.g., a nucleic acid or amino acid sequence, with another residue, or a deletion or insertion of one or more residues within a sequence. Mutations are typically described herein by identifying the original residue followed by the position of the residue within the sequence and by the identity of the newly substituted residue. Various methods for making the amino acid substitutions (mutations) provided herein are well known in the art, and are provided by, for example, Green and Sambrook, Molecular Cloning: A Laboratory Manual (4th ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. (2012)).
• an intended mutation such as a point mutation
• a nucleic acid e.g., a nucleic acid within a genome of a subject
• an intended mutation is a mutation that is generated by a specific base editor (e.g., a cytidine base editor or an adenosine base editor) bound to a guide polynucleotide (e.g., gRNA), specifically designed to generate the intended mutation.
• a specific base editor e.g., a cytidine base editor or an adenosine base editor
• a guide polynucleotide e.g., gRNA
• mutations made or identified in a sequence are numbered in relation to a reference (or wild type) sequence, i.e., a sequence that does not contain the mutations.
• a reference sequence i.e., a sequence that does not contain the mutations.
• the skilled practitioner in the art would readily understand how to determine the position of mutations in amino acid and nucleic acid sequences relative to a reference sequence.
• nuclear localization sequence refers to an amino acid sequence that promotes import of a protein into the cell nucleus.
• Nuclear localization sequences are known in the art and described, for example, in Plank et al.,
• an NLS comprises the amino acid sequence KRTADGSEFESPKKKRKV, KRPAATKKAGQAKKKK, KKTELQTTNAENKTKKL, KRGINDRNFWRGENGRKTR, RKSGKIAAIVVKRPRK, PKKKRKV, or
• nucleobase refers to a nitrogen-containing biological compound that forms a nucleoside, which, in turn, is a component of a nucleotide.
• RNA ribonucleic acid
• DNA deoxyribonucleic acid
• nucleobases adenine (A), cytosine (C), guanine (G), thymine (T), and uracil (U)– are called primary or canonical.
• Adenine and guanine are derived from purine, and cytosine, uracil, and thymine are derived from pyrimidine.
• DNA and RNA can also contain other (non-primary) bases that are modified.
• Non-limiting exemplary modified nucleobases can include hypoxanthine, xanthine, 7-methylguanine, 5,6-dihydrouracil, 5- methylcytosine (m5C), and 5-hydromethylcytosine.
• Hypoxanthine and xanthine can be created through mutagen presence, both of them through deamination (replacement of the amine group with a carbonyl group). Hypoxanthine can be modified from adenine.
• Xanthine can be modified from guanine. Uracil can result from deamination of cytosine.
• A“nucleoside” consists of a nucleobase and a five carbon sugar (either ribose or deoxyribose). Examples of a nucleoside include adenosine, guanosine, uridine, cytidine, 5-methyluridine (m5U),
• nucleoside with a modified nucleobase examples include inosine (I), xanthosine (X), 7-methylguanosine (m7G), dihydrouridine (D), 5-methylcytidine (m5C), and pseudouridine (Y).
• A“nucleotide” consists of a nucleobase, a five carbon sugar (either ribose or deoxyribose), and at least one phosphate group.
• nucleic acid and“nucleic acid molecule,” as used herein, refer to a compound comprising a nucleobase and an acidic moiety, e.g., a nucleoside, a nucleotide, or a polymer of nucleotides.
• polymeric nucleic acids e.g., nucleic acid molecules comprising three or more nucleotides are linear molecules, in which adjacent nucleotides are linked to each other via a phosphodiester linkage.
• “nucleic acid” refers to individual nucleic acid residues (e.g. nucleotides and/or nucleosides).
• nucleic acid refers to an oligonucleotide chain comprising three or more individual nucleotide residues.
• the terms“oligonucleotide”,“polynucleotide”, and“polynucleic acid” can be used interchangeably to refer to a polymer of nucleotides (e.g., a string of at least three nucleotides).
• “nucleic acid” encompasses RNA as well as single and/or double-stranded DNA.
• Nucleic acids can be naturally occurring, for example, in the context of a genome, a transcript, mRNA, tRNA, rRNA, siRNA, snRNA, a plasmid, cosmid, chromosome, chromatid, or other naturally occurring nucleic acid molecules.
• a nucleic acid molecule can be a non-naturally occurring molecule, e.g., a recombinant DNA or RNA, an artificial chromosome, an engineered genome, or fragment thereof, or a synthetic DNA, RNA, DNA/RNA hybrid, or including non-naturally occurring nucleotides or nucleosides.
• nucleic acid examples include nucleic acid analogs, e.g., analogs having other than a phosphodiester backbone.
• Nucleic acids can be purified from natural sources, produced using recombinant expression systems and optionally purified, chemically synthesized, etc. Where appropriate, e.g., in the case of chemically synthesized molecules, nucleic acids can comprise nucleoside analogs such as analogs having chemically modified bases or sugars, and backbone modifications. A nucleic acid sequence is presented in the 5 to 3 direction unless otherwise indicated.
• a nucleic acid is or comprises natural nucleosides (e.g.
• nucleoside analogs e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolopyrimidine, 3-methyl adenosine, 5- methylcytidine, 2-aminoadenosine, C5-bromouridine, C5-fluorouridine, C5-iodouridine, C5- propynyl-uridine, C5-propynyl-cytidine, C5-methylcytidine, 2-aminoadenosine, 7- deazaadenosine, 7-deazaguanosine, 8-oxoadenosine, 8-oxoguanosine, O(6)-methylguanine, and 2-thiocytidine
• nucleoside analogs e.g., 2-aminoadenosine, 2-thiothymidine, inosine, pyrrolopyrimidine, 3-methyl adenosine, 5- methylc
• nucleic acid programmable DNA binding protein or "napDNAbp” may be used interchangably with“polynucleotide programmable nucleotide binding domain” to refer to a protein that associates with a nucleic acid (e.g., DNA or RNA), such as a guide nucleic acid, that guides the napDNAbp to a specific nucleic acid sequence.
• a Cas9 protein can associate with a guide RNA that guides the Cas9 protein to a specific DNA sequence that is complementary to the guide RNA.
• the napDNAbp is a Cas9 domain, for example, a nuclease active Cas9, a Cas9 nickase (nCas9), or a nuclease inactive Cas9 (dCas9).
• the Cas9 domain comprises any one of the amino acid sequences as set forth herein.
• the Cas9 domain comprises an amino acid sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any one of the amino acid sequences set forth herein.
• the Cas9 domain comprises an amino acid sequence that has 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 21, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or more mutations compared to any one of the amino acid sequences set forth herein.
• the Cas9 domain comprises an amino acid sequence that has at least 10, at least 15, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 350, at least 400, at least 500, at least 600, at least 700, at least 800, at least 900, at least 1000, at least 1100, or at least 1200 identical contiguous amino acid residues as compared to any one of the amino acid sequences set forth herein.
• nucleic acid programmable DNA binding proteins include, without limitation, Cas9 (e.g., dCas9 and nCas9), Cas12a/Cpfl, Cas12b/C2cl, Cas12c/C2c3,
• nucleic acid programmable DNA binding proteins are also within the scope of this disclosure, although they may not be specifically listed in this disclosure. See, e.g., Makarova et al.“Classification and Nomenclature of CRISPR-Cas Systems: Where from Here?” CRISPR J.2018 Oct;1:325-336. doi:
• nucleobase editing domain or“nucleobase editing protein”, as used herein, refers to a protein or enzyme that can catalyze a nucleobase modification in RNA or DNA, such as cytosine (or cytidine) to uracil (or uridine) or thymine (or thymidine), and adenine (or adenosine) to hypoxanthine (or inosine) deaminations, as well as non-templated nucleotide additions and insertions.
• cytosine or cytidine
• uracil or uridine
• thymine or thymidine
• adenine or adenosine
• hypoxanthine or inosine
• the nucleobase editing domain is a deaminase domain (e.g., a cytidine deaminase, a cytosine deaminase, an adenine deaminase, or an adenosine deaminase).
• the nucleobase editing domain can be a naturally occurring nucleobase editing domain.
• the nucleobase editing domain can be an engineered or evolved nucleobase editing domain from the naturally occurring nucleobase editing domain.
• the nucleobase editing domain can be from any organism, such as a bacterium, human, chimpanzee, gorilla, monkey, cow, dog, rat, or mouse.
• nucleobase editing proteins are described in International PCT Application Nos. PCT/2017/045381 (WO
• “obtaining” as in“obtaining an agent” includes synthesizing, purchasing, isolating, or otherwise acquiring the agent.
• “Patient” or“subject” as used herein refers to a mammalian subject or individual diagnosed with, at risk of having or developing, or suspected of having or developing a disease or a disorder.
• the term“patient” refers to a mammalian subject with a higher than average likelihood of developing a disease or a disorder.
• Exemplary patients can be humans, non-human primates, cats, dogs, pigs, cattle, cats, horses, camels, llamas, goats, sheep, rodents (e.g., mice, rabbits, rats, or guinea pigs) and other mammalians that can benefit from the therapies disclosed herein.
• Exemplary human patients can be male and/or female.
• “Patient in need thereof” or“subject in need thereof” is referred to herein as a patient or subject diagnosed with, at risk of having, or suspected of having a disease or disorder, for instance, but not restricted to sickle cell disease (SCD) or alpha-1 antitrypsin Deficiency (A1AD), or a disease or disorder associated with the genes listed in Tables 3A, 3B, or 4 herein.
• SCD sickle cell disease
• A1AD alpha-1 antitrypsin Deficiency
• the terms“pathogenic mutation,”“pathogenic variant,”“disease causing (or disease- associated) mutation,”“disease causing (or disease-associated) variant,”“deleterious mutation,” or“predisposing mutation” refer to a genetic alteration or mutation that increases an individual’s susceptibility or predisposition to a certain disease or disorder.
• the pathogenic mutation comprises at least one wild-type amino acid substituted by at least one pathogenic amino acid in a protein encoded by a gene.
• non-conservative mutations refers to amino acid substitutions between different groups, for example, lysine for tryptophan, or phenylalanine for serine, etc. In this case, it is preferable for the non-conservative amino acid substitution to not interfere with, or inhibit the biological activity of, the functional variant.
• the non-conservative amino acid substitution can enhance the biological activity of the functional variant, such that the biological activity of the functional variant is increased as compared to the wild-type protein.
• protein refers to a polymer of amino acid residues linked together by peptide (amide) bonds.
• the terms refer to a protein, peptide, or polypeptide of any size, structure, or function. Typically, a protein, peptide, or polypeptide will be at least three amino acids long.
• a protein, peptide, or polypeptide can refer to an individual protein or a collection of proteins.
• One or more of the amino acids in a protein, peptide, or polypeptide can be modified, for example, by the addition of a chemical entity such as a carbohydrate group, a hydroxyl group, a phosphate group, a farnesyl group, an isofarnesyl group, a fatty acid group, a linker for conjugation, functionalization, or other modifications, etc.
• a protein, peptide, or polypeptide can also be a single molecule or can be a multi-molecular complex.
• a protein, peptide, or polypeptide can be just a fragment of a naturally occurring protein or peptide.
• a protein, peptide, or polypeptide can be naturally occurring, recombinant, or synthetic, or any combination thereof.
• fusion protein refers to a hybrid polypeptide which comprises protein domains from at least two different proteins.
• One protein can be located at the amino-terminal (N-terminal) portion of the fusion protein or at the carboxy- terminal (C-terminal) protein thus forming an amino-terminal fusion protein or a carboxy- terminal fusion protein, respectively.
• a protein can comprise different domains, for example, a nucleic acid binding domain (e.g., the gRNA binding domain of Cas9 that directs the binding of the protein to a target site) and a nucleic acid cleavage domain, or a catalytic domain of a nucleic acid editing protein.
• a protein comprises a proteinaceous part, e.g., an amino acid sequence constituting a nucleic acid binding domain, and an organic compound, e.g., a compound that can act as a nucleic acid cleavage agent.
• a protein is in a complex with, or is in association with, a nucleic acid, e.g., RNA or DNA.
• Any of the proteins provided herein can be produced by any method known in the art.
• the proteins provided herein can be produced via recombinant protein expression and purification, which is especially suited for fusion proteins comprising a peptide linker.
• Polypeptides and proteins disclosed herein can comprise synthetic amino acids in place of one or more naturally-occurring amino acids.
• synthetic amino acids are known in the art, and include, for example, aminocyclohexane carboxylic acid, norleucine, a-amino n-decanoic acid, homoserine, S-acetylaminomethyl-cysteine, trans-3- and trans-4-hydroxyproline, 4- aminophenylalanine, 4-nitrophenylalanine, 4-chlorophenylalanine, 4-carboxyphenylalanine, b- phenylserine b-hydroxyphenylalanine, phenylglycine, a-naphthylalanine, cyclohexylalanine, cyclohexylglycine, indoline-2-carboxylic acid, 1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid, aminomal
• polypeptides and proteins can be associated with post-translational modifications of one or more amino acids of the polypeptide constructs.
• post-translational modifications include phosphorylation, acylation including acetylation and formylation, glycosylation (including N-linked and O-linked), amidation, hydroxylation, alkylation including methylation and ethylation, ubiquitylation, addition of pyrrolidone carboxylic acid, formation of disulfide bridges, sulfation, myristoylation, palmitoylation, isoprenylation, farnesylation, geranylation, glypiation, lipoylation and iodination.
• the term“gene” as used herein refers to a polynucleotide that typically comprises a protein coding region and a protein non-coding region.
• the protein non-coding region can comprise one or more regulatory elements.
• Non-limiting examples of the regulatory elements comprise a promoter, an enhancer, a repressor, a silencer, an insulator, a start codon, a stop codon, Kozak consensus sequence, a slice acceptor, a splice donor, 3’ and/or 5’ untranslated region (UTR), a slice site, or an intergenic region.
• the regulatory element is located in a gene that is the cause of a genetic disease or disorder.
• Non-limiting examples of the regulator element located in a gene that is the cause of a genetic disease or disorder include a start codon, a stop codon, Kozak consensus sequence, an intergenic region, 3’ UTR, or 5’ UTR etc.
• the regulatory element is not located in a gene that is the cause of a genetic disease or disorder.
• Non-limiting examples of the regulatory element that is not located in a gene that is the cause of a genetic disorder include an enhancer, a repressor, or an insulator etc.
• polynucleotide programmable nucleotide binding domain refers to a protein that associates with a nucleic acid (e.g., DNA or RNA), such as a guide polynucleotide (e.g., guide RNA), that guides the polynucleotide programmable DNA binding domain to a specific nucleic acid sequence.
• a nucleic acid e.g., DNA or RNA
• guide polynucleotide e.g., guide RNA
• the polynucleotide programmable nucleotide binding domain is a polynucleotide programmable DNA binding domain.
• the polynucleotide programmable nucleotide binding domain is a polynucleotide programmable RNA binding domain.
• the polynucleotide programmable nucleotide binding domain is a Cas9 protein.
• a Cas9 protein can associate with a guide RNA that guides the Cas9 protein to a specific DNA sequence that has complementary to the guide RNA.
• the polynucleotide programmable nucleotide binding domain is a Cas9 domain, for example a nuclease active Cas9, a Cas9 nickase (nCas9), or a nuclease inactive Cas9 (dCas9).
• Non-limiting examples of nucleic acid programmable DNA binding proteins include Cas9 (e.g., dCas9 and nCas9), Cas12a/Cpfl, Cas12b/C2cl, Cas12c/C2c3, Cas12d/CasY, Cas12e/CasX, Cas12g, Cas12h, and Cas12i.
• Cas9 e.g., dCas9 and nCas9
• Cas12a/Cpfl Cas12b/C2cl
• Cas12c/C2c3 Cas12d/CasY
• Cas12e/CasX Cas12g, Cas12h, and Cas12i.
• Cas enzymes include Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas5d, Cas5t, Cas5h, Cas5a, Cas6, Cas7, Cas8, Cas8a, Cas8b, Cas8c, Cas9 (also known as Csn1 or Csx12), Cas10, Cas10d, Cas12a/Cpfl, Cas12b/C2cl, Cas12c/C2c3, Cas12d/CasY, Cas12e/CasX, Cas12g, Cas12h, Cas12i, Csy1 , Csy2, Csy3, Csy4, Cse1, Cse2, Cse3, Cse4, Cse5e, Csc1, Csc2, Csa5, Csn1, Csn2, Csm1, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3,
• programmable DNA binding proteins are also within the scope of this disclosure, though they are not specifically listed in this disclosure.
• a recombinant protein or nucleic acid molecule comprises an amino acid or nucleotide sequence that comprises at least one, at least two, at least three, at least four, at least five, at least six, or at least seven mutations as compared to any naturally occurring sequence.
• reference is meant a standard or control condition.
• an assay for the activity or function of a gene (and/or its encoded protein product) following base editing e.g., benign or regulatory base editing, as described herein is compared with the activity or function of the gene (and/or its encoded product) in which benign or regulatory base editing did not occur, or with the activity or function of a wild type gene (and/or its encoded product) as a reference.
• the reference is a wild-type or healthy cell.
• A“reference sequence” is a defined sequence used as a basis for sequence comparison.
• a reference sequence may be a subset of or the entirety of a specified sequence; for example, a segment of a full-length cDNA or gene sequence, or the complete cDNA or gene sequence.
• the length of the reference polypeptide sequence will generally be at least about 16 amino acids, preferably at least about 20 amino acids, more preferably at least about 25 amino acids, and even more preferably about 35 amino acids, about 50 amino acids, or about 100 amino acids.
• the length of the reference nucleic acid sequence will generally be at least about 50 nucleotides, preferably at least about 60 nucleotides, more preferably at least about 75 nucleotides, and even more preferably about 100 nucleotides or about 300 nucleotides or any integer thereabout or therebetween.
• RNA-programmable nuclease and "RNA-guided nuclease” are used with (e.g., binds or associates with) one or more RNA(s) that is not a target for cleavage.
• an RNA-programmable nuclease when in a complex with an RNA, may be referred to as a nuclease:RNA complex.
• the bound RNA(s) is referred to as a guide RNA (gRNA).
• Guide RNAs can exist as a complex of two or more RNAs, or as a single RNA molecule.
• gRNAs that exist as a single RNA molecule may be referred to as single- guide RNAs (sgRNAs), although "gRNA” is used interchangeably to refer to guide RNAs that exist as either single molecules or as a complex of two or more molecules.
• gRNAs that exist as single RNA species comprise two domains: (1) a domain that shares homology to a target nucleic acid (e.g., and directs binding of a Cas9 complex to the target); and (2) a domain that binds a Cas9 protein.
• domain (2) corresponds to a sequence known as a tracrRNA, and comprises a stem-loop structure.
• domain (2) is identical or homologous to a tracrRNA as provided in Jinek et al., Science
• gRNAs e.g., those including domain 2
• U.S. Provisional Patent Application No.61/874,682 filed September 6, 2013, entitled “Switchable Cas9 Nucleases and Uses Thereof”
• a gRNA comprises two or more of domains (1) and (2), and may be referred to as an "extended gRNA.”
• an extended gRNA will bind two or more Cas9 proteins and will bind a target nucleic acid at two or more distinct regions, as described herein.
• the gRNA comprises a nucleotide sequence that complements a target site, which mediates binding of the nuclease/RNA complex to the target site, providing the sequence specificity of the nuclease:RNA complex.
• the RNA-programmable nuclease is the (CRISPR-associated system) Cas9 endonuclease, for example, Cas9 (Csnl) from Streptococcus pyogenes (see, e.g., "Complete genome sequence of an Ml strain of Streptococcus pyogenes.” Ferretti J.J., McShan W.M., Ajdic D.J., Savic D.J., Savic G., Lyon K., Primeaux C, Sezate S., Suvorov A.N., Kenton S., Lai H.S., Lin S.P., Qian Y., Jia H.G., Najar F.Z., Ren Q., Zhu H., Song L., White J., Yuan X., Clifton S.W., Roe B.A., McLaughlin R.E., Proc.
• Cas9 endonuclease for example, Cas
• SNP single nucleotide polymorphism
• SNPs can fall within coding regions of genes, non-coding regions of genes, or in the intergenic regions (regions between genes). In some embodiments, SNPs within a coding sequence do not necessarily change the amino acid sequence of the protein that is produced, due to degeneracy of the genetic code.
• SNPs in the coding region are of two types: synonymous and nonsynonymous SNPs. Synonymous SNPs do not affect the protein sequence, while nonsynonymous SNPs change the amino acid sequence of protein. The nonsynonymous SNPs are of two types: missense and nonsense. SNPs that are not in protein-coding regions can still affect gene splicing, transcription factor binding, messenger RNA degradation, or the sequence of noncoding RNA.
• eSNP expression SNP
• SNP expression SNP
• a single nucleotide variant is a variation in a single nucleotide without any limitations of frequency and can arise in somatic cells.
• a somatic single nucleotide variation (e.g., caused by cancer) can also be called a single-nucleotide alteration.
• nucleic acid molecule e.g., a nucleic acid programmable DNA binding domain and guide nucleic acid
• compound e.g., a nucleic acid programmable DNA binding domain and guide nucleic acid
• molecule that recognizes and binds a polypeptide and/or nucleic acid molecule of the invention, but which does not substantially recognize and bind other molecules in a sample, for example, a biological sample.
• Nucleic acid molecules useful in the methods of the invention include any nucleic acid molecule that encodes a polypeptide of the invention or a fragment thereof. Such nucleic acid molecules need not be 100% identical with an endogenous nucleic acid sequence, but will typically exhibit substantial identity. Polynucleotides having“substantial identity” to an endogenous sequence are typically capable of hybridizing with at least one strand of a double- stranded nucleic acid molecule. Nucleic acid molecules useful in the methods of the invention include any nucleic acid molecule that encodes a polypeptide of the invention or a fragment thereof. Such nucleic acid molecules need not be 100% identical with an endogenous nucleic acid sequence, but will typically exhibit substantial identity. Polynucleotides having
• substantially identical to an endogenous sequence are typically capable of hybridizing with at least one strand of a double-stranded nucleic acid molecule.
• hybridize is meant pair to form a double-stranded molecule between complementary polynucleotide sequences (e.g., a gene described herein), or portions thereof, under various conditions of stringency.
• complementary polynucleotide sequences e.g., a gene described herein
• stringent salt concentration will ordinarily be less than about 750 mM NaCl and 75 mM trisodium citrate, preferably less than about 500 mM NaCl and 50 mM trisodium citrate, and more preferably less than about 250 mM NaCl and 25 mM trisodium citrate.
• Low stringency hybridization can be obtained in the absence of organic solvent, e.g., formamide, while high stringency hybridization can be obtained in the presence of at least about 35% formamide, and more preferably at least about 50% formamide.
• Stringent temperature conditions will ordinarily include temperatures of at least about 30°C, more preferably of at least about 37°C, and most preferably of at least about 42° C.
• hybridization time occurs at 30°C in 750 mM NaCl, 75 mM trisodium citrate, and 1% SDS.
• hybridization occurs at 37°C in 500 mM NaCl, 50 mM trisodium citrate, 1% SDS, 35% formamide, and 100 ⁇ g/ml denatured salmon sperm DNA (ssDNA).
• hybridization occurs at 42° C in 250 mM NaCl, 25 mM trisodium citrate, 1% SDS, 50% formamide, and 200 mg/ml ssDNA. Useful variations on these conditions will be readily apparent to those skilled in the art.
• washing steps that follow hybridization will also vary in stringency. Wash stringency conditions can be defined by salt concentration and by
• wash stringency can be increased by decreasing salt concentration or by increasing temperature.
• stringent salt concentration for the wash steps will be less than about 30 mM NaCl and 3 mM trisodium citrate, and may be less than about 15 mM NaCl and 1.5 mM trisodium citrate.
• Stringent temperature conditions for the wash steps will ordinarily include a temperature of at least about 25°C, more preferably of at least about 42°C, and even more preferably of at least about 68°C. In a preferred embodiment, wash steps occur at 25°C in 30 mM NaCl, 3 mM trisodium citrate, and 0.1% SDS.
• wash steps occur at 42 C in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. In a more preferred embodiment, wash steps occur at 68°C in 15 mM NaCl, 1.5 mM trisodium citrate, and 0.1% SDS. Additional variations on these conditions will be readily apparent to those skilled in the art. Hybridization techniques are well known to those skilled in the art and are described, for example, in Benton and Davis (Science 196:180, 1977); Grunstein and Hogness (Proc. Natl. Acad. Sci., USA 72:3961, 1975); Ausubel et al.
• substantially identical is meant a polypeptide or nucleic acid molecule exhibiting at least 50% identity to a reference amino acid sequence (for example, any one of the amino acid sequences described herein) or nucleic acid sequence (for example, any one of the nucleic acid sequences described herein).
• a reference amino acid sequence for example, any one of the amino acid sequences described herein
• nucleic acid sequence for example, any one of the nucleic acid sequences described herein.
• such a sequence is at least 60%, more preferably 80% or 85%, and more preferably 90%, 95% or even 99% identical at the amino acid level or nucleic acid to the sequence used for comparison.
• Sequence identity is typically measured using sequence analysis software (for example, Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis.53705, BLAST, BESTFIT, COBALT, EMBOSS Needle, GAP, or PILEUP/PRETTYBOX programs). Such software matches identical or similar sequences by assigning degrees of homology to various sequence analysis software (for example, Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis.53705, BLAST, BESTFIT, COBALT, EMBOSS Needle, GAP, or PILEUP/PRETTYBOX programs). Such software matches identical or similar sequences by assigning degrees of homology to various sequence analysis software (for example, Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, Wis.53705, BLAST, BESTFIT, COBALT, EMBOSS Needle, GAP, or PILEUP/PRETTYBOX programs).
• Conservative substitutions typically include substitutions within the following groups: glycine, alanine; valine, isoleucine, leucine; aspartic acid, glutamic acid, asparagine, glutamine; serine, threonine; lysine, arginine; and
• BLAST program may be used, with a probability score between e -3 and e -100 indicating a closely related sequence.
• COBALT is used, for example, with the following parameters:
• CDD Parameters Use RPS BLAST on; Blast E-value 0.003; Find conserveed columns and Recompute on, and c) Query Clustering Parameters: Use query clusters on; Word Size 4; Max cluster distance 0.8; Alphabet Regular.
• EMBOSS Needle is used, for example, with the following parameters:
• subject is meant a mammal, including, but not limited to, a human or non-human mammal, such as a bovine, equine, canine, ovine, or feline.
• target site refers to a sequence within a nucleic acid molecule that is modified by a nucleobase editor.
• the target site is deaminated by a deaminase or a fusion protein comprising a deaminase (e.g., a cytidine or an adenine
• RNA-programmable nucleases e.g., Cas9
• Cas9 RNA:DNA hybridization to target DNA cleavage sites
• these proteins are able to be targeted, in principle, to any sequence specified by the guide RNA.
• Methods of using RNA-programmable nucleases, such as Cas9, for site-specific cleavage (e.g., to modify a genome) are known in the art (see e.g., Cong, L. et al., Multiplex genome engineering using CRISPR/Cas systems. Science 339, 819-823 (2013); Mali, P. et al., RNA-guided human genome engineering via Cas9. Science 339, 823-826 (2013); Hwang, W.Y.
• the terms“treat,” treating,”“treatment,” and the like refer to reducing or ameliorating a disease or disorder and/or symptoms associated therewith or obtaining a desired pharmacologic and/or physiologic effect. It will be appreciated that, although not precluded, treating a disorder or condition does not require that the disorder, condition or symptoms associated therewith be completely eliminated. In some embodiments, the effect is therapeutic, i.e., without limitation, the effect partially or completely reduces, diminishes, abrogates, abates, alleviates, decreases the intensity of, or cures a disease or disorder and/or adverse symptom attributable to the disease or disorder.
• the effect is preventative, i.e., the effect protects or prevents an occurrence or reoccurrence of a disease, disorder, or condition.
• the presently disclosed methods comprise administering a therapeutically effective amount of a compositions as described herein.
• uracil glycosylase inhibitor is meant an agent that inhibits the uracil-excision repair system.
• the agent is a protein or fragment thereof that binds a host uracil-DNA glycosylase and prevents removal of uracil residues from DNA.
• Ranges provided herein are understood to be shorthand for all of the values within the range, inclusive of the first and last values, as well as values therebetween.
• a range of 1 to 50 is understood to include any number, combination of numbers, or sub-range from the group consisting of 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, or 50.
• any compositions or methods provided herein can be combined with one or more of any of the other compositions and methods provided herein.
• DNA editing has emerged as a viable means to modify disease states by correcting pathogenic mutations at the genetic level.
• all DNA editing platforms have functioned by inducing a DNA double strand break (DSB) at a specified genomic site and have relied on endogenous DNA repair pathways to determine the product outcome in a semi- stochastic manner, resulting in complex populations of genetic products.
• DSB DNA double strand break
• HDR homology directed repair
• a base editor or a nucleobase editor for editing, modifying or altering a target nucleotide sequence of a polynucleotide. Described herein is a nucleobase editor or a base editor comprising a polynucleotide programmable nucleotide binding domain and a nucleobase editing domain.
• a polynucleotide programmable nucleotide binding domain when in conjunction with a bound guide polynucleotide (e.g., gRNA), can specifically bind to a target polynucleotide sequence (i.e., via complementary base pairing between bases of the bound guide nucleic acid and bases of the target polynucleotide sequence) and thereby localize the base editor to the target nucleic acid sequence desired to be edited.
• the target polynucleotide sequence comprises single-stranded DNA or double-stranded DNA.
• the target polynucleotide sequence comprises RNA.
• the target polynucleotide sequence comprises a DNA-RNA hybrid.
• polynucleotide programmable nucleotide binding domain or“nucleic acid programmable DNA binding protein (napDNAbp)” refers to a protein that associates with a nucleic acid (e.g., DNA or RNA), such as a guide polynucleotide (e.g., guide RNA), that guides the polynucleotide programmable nucleotide binding domain to a specific nucleic acid sequence.
• a guide polynucleotide e.g., guide RNA
• the polynucleotide programmable nucleotide binding domain is a polynucleotide programmable DNA binding domain.
• the polynucleotide programmable nucleotide binding domain is a polynucleotide programmable RNA binding domain. In some embodiments, the polynucleotide programmable nucleotide binding domain is a Cas9 protein. In some embodiments, the polynucleotide programmable nucleotide binding domain is a Cpf1 protein.
• CRISPR is an adaptive immune system that provides protection against mobile genetic elements (viruses, transposable elements and conjugative plasmids).
• CRISPR clusters contain spacers, sequences complementary to antecedent mobile elements, and target invading nucleic acids.
• CRISPR clusters are transcribed and processed into CRISPR RNA (crRNA).
• crRNA CRISPR RNA
• type II CRISPR systems correct processing of pre-crRNA requires a trans-encoded small RNA
• tracrRNA endogenous ribonuclease 3
• Cas9 protein a protein that is synthesized by endogenous ribonuclease 3 (rnc) and a Cas9 protein.
• the tracrRNA serves as a guide for ribonuclease 3-aided processing of pre-crRNA.
• Cas9/crRNA/tracrRNA endonucleolytically cleaves linear or circular dsDNA target complementary to the spacer.
• the target strand not complementary to crRNA is first cut endonucleolytically, and then trimmed 3’- 5’ exonucleolytically.
• DNA-binding and cleavage typically requires protein and both RNAs.
• single guide RNAs (“sgRNA”, or simply“gRNA”) can be engineered so as to incorporate aspects of both the crRNA and tracrRNA into a single RNA species. See, e.g., Jinek M., Chylinski K., Fonfara I., Hauer M., Doudna J. A., Charpentier E. Science 337:816- 821(2012), the entire contents of which is hereby incorporated by reference.
• Cas9 recognizes a short motif in the CRISPR repeat sequences (the PAM or protospacer adjacent motif) to help distinguish“self” from“non-self”. Cas9 domains of Nucleobase Editors
• Cas9 nuclease sequences and structures are well known to those of skill in the art (see, e.g.,“Complete genome sequence of an Ml strain of Streptococcus pyogenes.” Ferretti et al., J.J., McShan W.M., Ajdic D.J., Savic D.J., Savic G., Lyon K., Primeaux C, Sezate S., Suvorov A.N., Kenton S., Lai H.S ., Lin S.P., Qian Y., Jia H.G., Najar F.Z., Ren Q., Zhu H., Song L.,. Natl. Acad. Sci.
• Cas9 orthologs have been described in various species, including, but not limited to, S. pyogenes and S. thermophilus. Additional suitable Cas9 nucleases and sequences can be apparent to those of skill in the art based on this disclosure, and such Cas9 nucleases and sequences include Cas9 sequences from the organisms and loci disclosed in Chylinski, Rhun, and Charpentier,“The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems” (2013) RNA Biology 10:5, 726-737; the entire contents of which are incorporated herein by reference.
• a Cas9 nuclease has an inactive (e.g., an inactivated) DNA cleavage domain, that is, the Cas9 is a nickase, referred to as an“nCas9” protein (for“nickase” Cas9).
• a nuclease-inactivated Cas9 protein can interchangeably be referred to as a“dCas9” protein (for nuclease-dead Cas9).
• Methods for generating a Cas9 protein (or a fragment thereof) having an inactive DNA cleavage domain are known (See, e.g., Jinek et al, Science.337:816- 821(2012); Qi et al,“Repurposing CRISPR as an RNA-Guided Platform for Sequence-Specific Control of Gene Expression” (2013) Cell.28; 152(5): 1173-83, the entire contents of each of which are incorporated herein by reference).
• the DNA cleavage domain of Cas9 is known to include two subdomains, the HNH nuclease subdomain and the RuvC1 subdomain.
• the HNH subdomain cleaves the strand complementary to the gRNA, whereas the RuvCl subdomain cleaves the non-complementary strand. Mutations within these subdomains can silence the nuclease activity of Cas9. For example, the mutations D10A and H840A completely inactivate the nuclease activity of S. pyogenes Cas9 (Jinek et al, Science.337:816-821(2012); Qi et al, Cell.28;152(5): 1173-83 (2013)). In some embodiments, proteins comprising fragments of Cas9 are provided.
• a protein comprises one of two Cas9 domains: (1) the gRNA binding domain of Cas9; or (2) the DNA cleavage domain of Cas9.
• proteins comprising Cas9 or fragments thereof are referred to as“Cas9 variants.”
• a Cas9 variant shares homology to Cas9, or a fragment thereof.
• a Cas9 variant is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% identical to wild type Cas9.
• the Cas9 variant may have 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 21, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or more amino acid changes compared to wild type Cas9.
• the Cas9 variant comprises a fragment of Cas9 (e.g., a gRNA binding domain or a DNA-cleavage domain), such that the fragment is at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 96% identical, at least about 97% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% identical to the corresponding fragment of wild type Cas9.
• a fragment of Cas9 e.g., a gRNA binding domain or a DNA-cleavage domain
• the fragment is at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% identical, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% of the amino acid length of a corresponding wild type Cas9.
• the fragment is at least 100 amino acids in length. In some embodiments, the fragment is at least 100, 150, 200, 250, 300, 350, 400, 450, 500, 550, 600, 650, 700, 750, 800, 850, 900, 950, 1000, 1050, 1100, 1150, 1200, 1250, or at least 1300 amino acids in length.
• wild type Cas9 corresponds to Cas9 from Streptococcus pyogenes (NCBI Reference Sequence: NC_017053.1, nucleotide and amino acid sequences as follows):
• wild type Cas9 corresponds to, or comprises the following nucleotide and/or amino acid sequences:
• wild type Cas9 corresponds to Cas9 from Streptococcus pyogenes (NCBI Reference Sequence: NC_002737.2 (nucleotide sequence as follows); and Uniprot Reference Sequence: Q99ZW2 (amino acid sequence as follows).
• Cas9 refers to Cas9 from: Corynebacterium ulcerans (NCBI Refs: NC_015683.1, NC_017317.1); Corynebacterium diphtheria (NCBI Refs: NC_016782.1, NC_016786.1); Spiroplasma syrphidicola (NCBI Ref: NC_021284.1); Prevotella intermedia (NCBI Ref: NC_017861.1); Spiroplasma taiwanense (NCBI Ref: NC_021846.1); Streptococcus iniae (NCBI Ref: NC_021314.1); Belliella baltica (NCBI Ref: NC_018010.1); Psychroflexus torquisI (NCBI Ref: NC_018721.1); Streptococcus thermophilus (NCBI Ref: YP_820832.1), Listeria innocua (NCBI Ref: NP_472073.1), Camp
• YP_002344900.1 or Neisseria meningitidis (NCBI Ref: YP_002342100.1) or to a Cas9 from any other organism.
• the Cas9 domain comprises a D10A mutation, while the residue at position 840 remains a histidine in the amino acid sequence provided above, or at
• dCas9 corresponds to, or comprises, in part or in whole, a Cas9 amino acid sequence having one or more mutations that inactivate the Cas9 nuclease activity.
• a dCas9 domain comprises D10A and an H840A mutation or corresponding mutations in another Cas9.
• the dCas9 comprises the amino acid sequence of dCas9 (D10A and H840A):
• the Cas9 domain comprises a D10A mutation, while the residue at position 840 remains a histidine in the amino acid sequence provided above, or at
• dCas9 variants having mutations other than D10A and H840A are provided, which, e.g., result in nuclease inactivated Cas9 (dCas9).
• Such mutations include other amino acid substitutions at D10 and H840, or other substitutions within the nuclease domains of Cas9 (e.g., substitutions in the HNH nuclease subdomain and/or the RuvC1 subdomain).
• variants or homologues of dCas9 are provided which are at least about 70% identical, at least about 80% identical, at least about 90% identical, at least about 95% identical, at least about 98% identical, at least about 99% identical, at least about 99.5% identical, or at least about 99.9% identical.
• variants of dCas9 are provided having amino acid sequences which are shorter, or longer, by about 5 amino acids, by about 10 amino acids, by about 15 amino acids, by about 20 amino acids, by about 25 amino acids, by about 30 amino acids, by about 40 amino acids, by about 50 amino acids, by about 75 amino acids, by about 100 amino acids or more.
• Cas9 fusion proteins as provided herein comprise the full-length amino acid sequence of a Cas9 protein, e.g., one of the Cas9 sequences provided herein. In other embodiments, however, fusion proteins as provided herein do not comprise a full-length Cas9 sequence, but only one or more fragments thereof. Exemplary amino acid sequences of suitable Cas9 domains and Cas9 fragments are provided herein, and additional suitable sequences of Cas9 domains and fragments will be apparent to those of skill in the art. [0181] A Cas9 protein can associate with a guide RNA that guides the Cas9 protein to a specific DNA sequence that has complementary to the guide RNA.
• the polynucleotide programmable nucleotide binding domain is a Cas9 domain, for example a nuclease active Cas9, a Cas9 nickase (nCas9), or a nuclease inactive Cas9 (dCas9).
• nucleic acid programmable DNA binding proteins include, without limitation, Cas9 (e.g., dCas9 and nCas9), Cas12a/Cpfl, Cas12b/C2cl, Cas12c/C2c3, Cas12d/CasY, Cas12e/CasX, Cas12g, Cas12h, and Cas12i.
• a nuclease-inactivated Cas9 protein may interchangeably be referred to as a“dCas9” protein (for nuclease-“dead” Cas9) or catalytically inactive Cas9.
• Methods for generating a Cas9 protein (or a fragment thereof) having an inactive DNA cleavage domain are known (See, e.g., Jinek et al., Science.337:816-821(2012); Qi et al.,“Repurposing CRISPR as an RNA- Guided Platform for Sequence-Specific Control of Gene Expression” (2013) Cell.
• the DNA cleavage domain of Cas9 is known to include two subdomains, the HNH nuclease subdomain and the RuvC1 subdomain.
• the HNH subdomain cleaves the strand complementary to the gRNA, whereas the RuvC1 subdomain cleaves the non-complementary strand. Mutations within these subdomains can silence the nuclease activity of Cas9.
• the mutations D10A and H840A completely inactivate the nuclease activity of S.
• the Cas9 domain is a Cas9 nickase.
• the Cas9 nickase may be a Cas9 protein that is capable of cleaving only one strand of a duplexed nucleic acid molecule (e.g., a duplexed DNA molecule).
• the Cas9 nickase cleaves the target strand of a duplexed nucleic acid molecule, meaning that the Cas9 nickase cleaves the strand that is base paired to (complementary to) a gRNA (e.g., an sgRNA) that is bound to the Cas9.
• a gRNA e.g., an sgRNA
• a Cas9 nickase comprises a D10A mutation and has a histidine at position 840.
• the Cas9 nickase cleaves the non-target, non-base-edited strand of a duplexed nucleic acid molecule, meaning that the Cas9 nickase cleaves the strand that is not base paired to a gRNA (e.g., an sgRNA) that is bound to the Cas9.
• a Cas9 nickase comprises an H840A mutation and has an aspartic acid residue at position 10, or a corresponding mutation.
• the Cas9 nickase comprises an amino acid sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any one of the Cas9 nickases provided herein. Additional suitable Cas9 nickases will be apparent to those of skill in the art based on this disclosure and knowledge in the field, and are within the scope of this disclosure.
• the Cas9 domain is a nuclease-inactive Cas9 domain (dCas9).
• the dCas9 domain may bind to a duplexed nucleic acid molecule (e.g., via a gRNA molecule) without cleaving either strand of the duplexed nucleic acid molecule.
• the nuclease-inactive dCas9 domain comprises a D10X mutation and a H840X mutation of the amino acid sequence set forth herein, or a corresponding mutation in any of the amino acid sequences provided herein, wherein X is any amino acid change.
• the nuclease-inactive dCas9 domain comprises a D10A mutation and a H840A mutation of the amino acid sequence set forth herein, or a corresponding mutation in any of the amino acid sequences provided herein.
• a nuclease-inactive Cas9 domain comprises the amino acid sequence set forth in Cloning vector pPlatTET-gRNA2 (Accession No. BAV54124):
• Cas9 proteins e.g., a nuclease dead Cas9 (dCas9), a Cas9 nickase (nCas9), or a nuclease active Cas9), including variants and homologs thereof, are within the scope of this disclosure.
• Exemplary Cas9 proteins include, without limitation, those provided below.
• the Cas9 protein is a nuclease dead Cas9 (dCas9).
• the Cas9 protein is a Cas9 nickase (nCas9).
• the Cas9 protein is a nuclease active Cas9.
• Cas9 refers to a Cas9 from archaea (e.g. nanoarchaea), which constitute a domain and kingdom of single-celled prokaryotic microbes.
• a nucleic acid programmable DNA binding protein refers to CasX or CasY, which have been described in, for example, Burstein et al., "New CRISPR-Cas systems from uncultivated microbes.” Cell Res.2017 Feb 21. doi: 10.1038/cr.2017.21, the entire contents of which is hereby incorporated by reference.
• CRISPR-Cas system In bacteria, two previously unknown systems were discovered, CRISPR- CasX and CRISPR-CasY, which are among the most compact systems yet discovered.
• Cas9 in a base editor system described herein Cas9 is replaced by CasX, or a variant of CasX.
• Cas9 in a base editor system described herein Cas9 is replaced by CasY, or a variant of CasY. It should be appreciated that other RNA-guided DNA binding proteins may be used as a nucleic acid programmable DNA binding protein (napDNAbp), and are within the scope of this disclosure.
• the nucleic acid programmable DNA binding protein [0190] In some embodiments, the nucleic acid programmable DNA binding protein
• napDNAbp of any of the fusion proteins provided herein may be a CasX or CasY protein.
• the napDNAbp is a CasX protein.
• the napDNAbp is a CasY protein.
• the napDNAbp comprises an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at ease 99.5% identical to a naturally- occurring CasX or CasY protein.
• the napDNAbp is a naturally-occurring CasX or CasY protein.
• the napDNAbp comprises an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at ease 99.5% identical to any CasX or CasY protein described herein. It should be appreciated that CasX and CasY from other bacterial species may also be used in accordance with the present disclosure.
• the nucleic acid programmable DNA binding protein [0198] In some embodiments, the nucleic acid programmable DNA binding protein
• napDNAbp is a single effector of a microbial CRISPR-Cas system.
• Single effectors of microbial CRISPR-Cas systems include, without limitation, Cas9, Cpf1, Cas12b/C2c1, and Cas12c/C2c3.
• microbial CRISPR-Cas systems are divided into Class 1 and Class 2 systems. Class 1 systems have multisubunit effector complexes, while Class 2 systems have a single protein effector.
• Cas9 and Cpf1 are Class 2 effectors.
• Cas12c/C2c3 contain RuvC-like endonuclease domains related to Cpf1.
• a third system contains an effector with two predicated HEPN RNase domains. Production of mature CRISPR RNA is tracrRNA-independent, unlike production of CRISPR RNA by Cas12b/C2c1.
• Cas12b/C2c1 depends on both CRISPR RNA and tracrRNA for DNA cleavage.
• AcC2c1 The crystal structure of Alicyclobaccillus acidoterrestris Cas12b/C2c1 (AacC2c1) has been reported in complex with a chimeric single-molecule guide RNA (sgRNA). See e.g., Liu et al.,“C2c1-sgRNA Complex Structure Reveals RNA-Guided DNA Cleavage Mechanism”, Mol. Cell, 2017 Jan.19; 65(2):310-322, the entire contents of which are hereby incorporated by reference. The crystal structure has also been reported in Alicyclobacillus acidoterrestris C2c1 bound to target DNAs as ternary complexes.
• sgRNA chimeric single-molecule guide RNA
• the nucleic acid programmable DNA binding protein [0200] In some embodiments, the nucleic acid programmable DNA binding protein
• napDNAbp of any of the fusion proteins provided herein may be a Cas12b/C2c1, or a
• the napDNAbp is a Cas12b/C2c1 protein. In some embodiments, the napDNAbp is a Cas12c/C2c3 protein. In some embodiments, the napDNAbp comprises an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at ease 99.5% identical to a naturally-occurring Cas12b/C2c1 or Cas12c/C2c3 protein.
• the napDNAbp is a naturally-occurring Cas12b/C2c1 or Cas12c/C2c3 protein.
• the napDNAbp comprises an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at ease 99.5% identical to any one of the napDNAbp sequences provided herein.
• Cas12b/C2c1 or Cas12c/C2c3 from other bacterial species may also be used in accordance with the present disclosure.
• a Cas12b/C2c1 (uniprot.org/uniprot/T0D7A2#2) sp
• C2c1 OS Alicyclobacillus acido-terrestris (strain ATCC 49025 / DSM 3922/ CIP 106132 / NCIMB 13137/GD3B)
• GN c2c1
• the Cas12b is BvCas12B, which is a variant of BhCas12b and comprises the following changes relative to BhCas12B: S893R, K846R, and E837G.
• BvCas12b (Bacillus sp. V3-13), NCBI Reference Sequence: WP_101661451.1, amino acid sequence is provided:
• polynucleotide programmable nucleotide binding domains can also include nucleic acid programmable proteins that bind RNA.
• the polynucleotide programmable nucleotide binding domain can be associated with a nucleic acid that guides the polynucleotide programmable nucleotide binding domain to an RNA.
• Other nucleic acid programmable DNA binding proteins are also within the scope of this disclosure, though they are not specifically listed in this disclosure.
• Cas proteins that can be used herein include class 1 and class 2.
• Non-limiting examples of Cas proteins include Cas1, Cas1B, Cas2, Cas3, Cas4, Cas5, Cas5d, Cas5t, Cas5h, Cas5a, Cas6, Cas7, Cas8, Cas9 (also known as Csn1 or Csx12), Cas10, Csy1 , Csy2, Csy3, Csy4, Cse1, Cse2, Cse3, Cse4, Cse5e, Csc1, Csc2, Csa5, Csn1, Csn2, Csm1, Csm2, Csm3, Csm4, Csm5, Csm6, Cmr1, Cmr3, Cmr4, Cmr5, Cmr6, Csb1, Csb2, Csb3, Csx17, Csx14, Csx10, Csx16, CsaX, Csx3, Csx1, Csx1S, C
• An unmodified CRISPR enzyme can have DNA cleavage activity, such as Cas9, which has two functional endonuclease domains: RuvC and HNH.
• a CRISPR enzyme can direct cleavage of one or both strands at a target sequence, such as within a target sequence and/or within a complement of a target sequence.
• a CRISPR enzyme can direct cleavage of one or both strands within about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25, 50, 100, 200, 500, or more base pairs from the first or last nucleotide of a target sequence.
• a vector that encodes a CRISPR enzyme that is mutated to with respect to a corresponding wild-type enzyme such that the mutated CRISPR enzyme lacks the ability to cleave one or both strands of a target polynucleotide containing a target sequence can be used.
• Cas9 can refer to a polypeptide with at least or at least about 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity and/or sequence homology to a wild type exemplary Cas9 polypeptide (e.g., Cas9 from S. pyogenes).
• Cas9 can refer to a polypeptide with at most or at most about 50%, 60%, 70%, 80%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99%, or 100% sequence identity and/or sequence homology to a wild type exemplary Cas9 polypeptide (e.g., from S. pyogenes).
• Cas9 can refer to the wild type or a modified form of the Cas9 protein that can comprise an amino acid change such as a deletion, insertion, substitution, variant, mutation, fusion, chimera, or any combination thereof.
• the methods described herein can utilize an engineered Cas protein.
• a guide RNA is a short synthetic RNA composed of a scaffold sequence necessary for Cas-binding and a user-defined ⁇ 20 nucleotide spacer that defines the genomic target to be modified.
• gRNA guide RNA
• changing the genomic target of the Cas protein specificity is partially determined by the specificity of the gRNA targeting sequence for the genomic target compared to the rest of the genome.
• the Cas9 nuclease has two functional endonuclease domains: RuvC and HNH. Cas9 undergoes a second conformational change upon target binding that positions the nuclease domains to cleave opposite strands of the target DNA.
• the end result of Cas9-mediated DNA cleavage is a double-strand break (DSB) within the target DNA ( ⁇ 3-4 nucleotides upstream of the PAM sequence).
• the resulting DSB is then repaired by one of two general repair pathways: (1) the efficient but error-prone non-homologous end joining (NHEJ) pathway; or (2) the less efficient but high-fidelity homology directed repair (HDR) pathway.
• NHEJ efficient but error-prone non-homologous end joining
• HDR homology directed repair
• The“efficiency” of non-homologous end joining (NHEJ) and/or homology directed repair (HDR) can be calculated by any convenient method. For example, in some cases, efficiency can be expressed in terms of percentage of successful HDR.
• a surveyor nuclease assay can be used can be used to generate cleavage products and the ratio of products to substrate can be used to calculate the percentage.
• a surveyor nuclease enzyme can be used that directly cleaves DNA containing a newly integrated restriction sequence as the result of successful HDR. More cleaved substrate indicates a greater percent HDR (a greater efficiency of HDR).
• a fraction (percentage) of HDR can be calculated using the following equation [(cleavage products)/(substrate plus cleavage products)] (e.g., (b+c)/(a+b+c), where“a” is the band intensity of DNA substrate, and“b” and“c” are the cleavage products).
• efficiency can be expressed in terms of percentage of successful NHEJ.
• a T7 endonuclease I assay can be used to generate cleavage products and the ratio of products to substrate can be used to calculate the percentage NHEJ.
• T7 endonuclease I cleaves mismatched heteroduplex DNA which arises from hybridization of wild-type and mutant DNA strands (NHEJ generates small random insertions or deletions (indels) at the site of the original break). More cleavage indicates a greater percent NHEJ (a greater efficiency of NHEJ).
• a fraction (percentage) of NHEJ can be calculated using the following equation: (1-(1-(b+c)/(a+b+c)) 1/2 ) ⁇ 100, where“a” is the band intensity of DNA substrate and“b” and“c” are the cleavage products (Ran et. al., Cell.2013 Sep.12;
• the NHEJ repair pathway is the most active repair mechanism, and it frequently causes small nucleotide insertions or deletions (indels) at the DSB site.
• the randomness of NHEJ- mediated DSB repair has important practical implications, because a population of cells expressing Cas9 and a gRNA or a guide polynucleotide can result in a diverse array of mutations.
• NHEJ gives rise to small indels in the target DNA that result in amino acid deletions, insertions, or frameshift mutations leading to premature stop codons within the open reading frame (ORF) of the targeted gene.
• ORF open reading frame
• HDR homology directed repair
• a DNA repair template containing the desired sequence can be delivered into the cell type of interest with the gRNA(s) and Cas9 or Cas9 nickase.
• the repair template can contain the desired edit as well as additional homologous sequence immediately upstream and downstream of the target (termed left & right homology arms).
• the length of each homology arm can be dependent on the size of the change being introduced, with larger insertions requiring longer homology arms.
• the repair template can be a single-stranded oligonucleotide, a double-stranded oligonucleotide, or a double-stranded DNA plasmid.
• the efficiency of HDR is generally low ( ⁇ 10% of modified alleles) even in cells that express Cas9, gRNA and an exogenous repair template.
• the efficiency of HDR can be enhanced by synchronizing the cells, since HDR takes place during the S and G2 phases of the cell cycle. Chemically or genetically inhibiting genes involved in NHEJ can also increase HDR frequency.
• Cas9 is a modified Cas9.
• a given gRNA targeting sequence can have additional sites throughout the genome where partial homology exists. These sites are called off-target sites (“off-targets”) and need to be considered when designing a gRNA.
• CRISPR specificity can also be increased through modifications to Cas9.
• Cas9 generates double-strand breaks (DSBs) through the combined activity of the two nuclease domains, RuvC and HNH.
• Cas9 nickase a D10A mutant of SpCas9, retains one nuclease domain and generates a DNA nick rather than a DSB.
• the nickase system can also be combined with HDR-mediated gene editing for specific gene edits.
• Cas9 is a variant Cas9 protein.
• a variant Cas9 polypeptide has an amino acid sequence that is different by one amino acid (e.g., has a deletion, insertion, substitution, fusion) when compared to the amino acid sequence of a wild type Cas9 protein.
• the variant Cas9 polypeptide has an amino acid change (e.g., deletion, insertion, or substitution) that reduces the nuclease activity of the Cas9 polypeptide.
• the variant Cas9 polypeptide has less than 50%, less than 40%, less than 30%, less than 20%, less than 10%, less than 5%, or less than 1% of the nuclease activity of the corresponding wild-type Cas9 protein. In some cases, the variant Cas9 protein has no substantial nuclease activity.
• a subject Cas9 protein is a variant Cas9 protein that has no substantial nuclease activity, it can be referred to as“dCas9.”
• a variant Cas9 protein has reduced nuclease activity.
• a variant Cas9 protein exhibits less than about 20%, less than about 15%, less than about 10%, less than about 5%, less than about 1%, or less than about 0.1%, of the endonuclease activity of a wild-type Cas9 protein, e.g., a wild-type Cas9 protein.
• a variant Cas9 protein can cleave the complementary strand of a guide target sequence but has reduced ability to cleave the non-complementary strand of a double stranded guide target sequence.
• the variant Cas9 protein can have a mutation (amino acid substitution) that reduces the function of the RuvC domain.
• a variant Cas9 protein has a D10A (aspartate to alanine at amino acid position 10) and can therefore cleave the complementary strand of a double stranded guide target sequence but has reduced ability to cleave the non-complementary strand of a double stranded guide target sequence (thus resulting in a single strand break (SSB) instead of a double strand break (DSB) when the variant Cas9 protein cleaves a double stranded target nucleic acid) (see, for example, Jinek et al., Science.2012 Aug.17; 337(6096):816-21).
• SSB single strand break
• DSB double strand break
• a variant Cas9 protein can cleave the non-complementary strand of a double stranded guide target sequence but has reduced ability to cleave the complementary strand of the guide target sequence.
• the variant Cas9 protein can have a mutation (amino acid substitution) that reduces the function of the HNH domain (RuvC/HNH/RuvC domain motifs).
• the variant Cas9 protein has an H840A (histidine to alanine at amino acid position 840) mutation and can therefore cleave the non-complementary strand of the guide target sequence but has reduced ability to cleave the complementary strand of the guide target sequence (thus resulting in a SSB instead of a DSB when the variant Cas9 protein cleaves a double stranded guide target sequence).
• H840A histidine to alanine at amino acid position 840
• Such a Cas9 protein has a reduced ability to cleave a guide target sequence (e.g., a single stranded guide target sequence) but retains the ability to bind a guide target sequence (e.g., a single stranded guide target sequence).
• a variant Cas9 protein has a reduced ability to cleave both the complementary and the non-complementary strands of a double stranded target DNA.
• the variant Cas9 protein harbors both the D10A and the H840A mutations such that the polypeptide has a reduced ability to cleave both the complementary and the non-complementary strands of a double stranded target DNA.
• Such a Cas9 protein has a reduced ability to cleave a target DNA (e.g., a single stranded target DNA) but retains the ability to bind a target DNA (e.g., a single stranded target DNA).
• the variant Cas9 protein harbors W476A and W1126A mutations such that the polypeptide has a reduced ability to cleave a target DNA.
• a Cas9 protein has a reduced ability to cleave a target DNA (e.g., a single stranded target DNA) but retains the ability to bind a target DNA (e.g., a single stranded target DNA).
• the variant Cas9 protein harbors P475A, W476A, N477A, D1125A, W1126A, and D1127A mutations such that the polypeptide has a reduced ability to cleave a target DNA.
• a Cas9 protein has a reduced ability to cleave a target DNA (e.g., a single stranded target DNA) but retains the ability to bind a target DNA (e.g., a single stranded target DNA).
• the variant Cas9 protein harbors H840A, W476A, and W1126A mutations such that the polypeptide has a reduced ability to cleave a target DNA.
• a Cas9 protein has a reduced ability to cleave a target DNA (e.g., a single stranded target DNA) but retains the ability to bind a target DNA (e.g., a single stranded target DNA).
• the variant Cas9 protein harbors H840A, D10A, W476A, and W1126A mutations such that the polypeptide has a reduced ability to cleave a target DNA.
• Such a Cas9 protein has a reduced ability to cleave a target DNA (e.g., a single stranded target DNA) but retains the ability to bind a target DNA (e.g., a single stranded target DNA).
• the variant Cas9 has restored catalytic His residue at position 840 in the Cas9 HNH domain (A840H).
• the variant Cas9 protein harbors, H840A, P475A, W476A, N477A, D1125A, W1126A, and D1127A mutations such that the polypeptide has a reduced ability to cleave a target DNA.
• a Cas9 protein has a reduced ability to cleave a target DNA (e.g., a single stranded target DNA) but retains the ability to bind a target DNA (e.g., a single stranded target DNA).
• the variant Cas9 protein harbors D10A, H840A, P475A, W476A, N477A, D1125A, W1126A, and D1127A mutations such that the polypeptide has a reduced ability to cleave a target DNA.
• a Cas9 protein has a reduced ability to cleave a target DNA (e.g., a single stranded target DNA) but retains the ability to bind a target DNA (e.g., a single stranded target DNA).
• the variant Cas9 protein when a variant Cas9 protein harbors W476A and W1126A mutations or when the variant Cas9 protein harbors P475A, W476A, N477A, D1125A, W1126A, and D1127A mutations, the variant Cas9 protein does not bind efficiently to a PAM sequence. Thus, in some such cases, when such a variant Cas9 protein is used in a method of binding, the method does not require a PAM sequence.
• the method when such a variant Cas9 protein is used in a method of binding, can include a guide RNA, but the method can be performed in the absence of a PAM sequence (and the specificity of binding is therefore provided by the targeting segment of the guide RNA).
• Other residues can be mutated to achieve the above effects (i.e., inactivate one or the other nuclease portions).
• residues D10, G12, G17, E762, H840, N854, N863, H982, H983, A984, D986, and/or A987 can be altered (i.e., substituted).
• mutations other than alanine substitutions are suitable.
• a variant Cas9 protein that has reduced catalytic activity e.g., when a Cas9 protein has a D10, G12, G17, E762, H840, N854, N863, H982, H983, A984, D986, and/or a A987 mutation, e.g., D10A, G12A, G17A, E762A, H840A, N854A, N863A, H982A, H983A, A984A, and/or D986A), can still bind to target DNA in a site-specific manner (because it is still guided to a target DNA sequence by a guide RNA) as long as it retains the ability to interact with the guide RNA.
• CRISPR/Cpf1 RNA-guided endonucleases from the Cpf1 family that display cleavage activity in mammalian cells.
• CRISPR from Prevotella and Francisella 1 (CRISPR/Cpf1) is a DNA-editing technology analogous to the CRISPR/Cas9 system.
• Cpf1 is an RNA-guided endonuclease of a class II CRISPR/Cas system. This acquired immune mechanism is found in Prevotella and Francisella bacteria.
• Cpf1 represents an example of a nucleic acid programmable DNA-binding protein that has different PAM
• Cpf1 is also a class 2 CRISPR effector. It has been shown that Cpf1 mediates robust DNA interference with features distinct from Cas9.
• Cpf1 is a single RNA-guided endonuclease lacking tracrRNA, and it utilizes a T-rich protospacer-adjacent motif (TTN, TTTN, or YTN). Moreover, Cpf1 cleaves DNA via a staggered DNA double- stranded break.
• TTN T-rich protospacer-adjacent motif
• TTTN T-rich protospacer-adjacent motif
• YTN T-rich protospacer-adjacent motif
• Cpf1 proteins are described, for example, in Yamano et al.,“Crystal structure of Cpf1 in complex with guide RNA and target DNA.” Cell (165) 2016, p.949-962; the entire contents of which is hereby incorporated by reference.
• Cpf1 genes are associated with the CRISPR locus, coding for an endonuclease that use a guide RNA to find and cleave viral DNA. Because Cpf1 is a smaller and simpler
• Cpf1 can overcome some of the CRISPR/Cas9 system limitations. Unlike Cas9 nucleases, the result of Cpf1-mediated DNA cleavage is a double-strand break with a short 3 overhang. Cpf1’s staggered cleavage pattern can open up the possibility of directional gene transfer, analogous to traditional restriction enzyme cloning, which can increase the efficiency of gene editing. Like the Cas9 variants and orthologues described above, Cpf1 can also expand the number of sites that can be targeted by CRISPR to AT-rich regions or AT-rich genomes that lack the NGG PAM sites favored by SpCas9.
• the Cpf1 locus contains a mixed alpha/beta domain, a RuvC-I followed by a helical region, a RuvC-II and a zinc finger-like domain.
• the Cpf1 protein has a RuvC-like endonuclease domain that is similar to the RuvC domain of Cas9. Furthermore, Cpf1 does not have a HNH endonuclease domain, and the N- terminal of Cpf1 does not have the alpha-helical recognition lobe of Cas9.
• Cpf1 CRISPR-Cas domain architecture shows that Cpf1 is functionally unique, being classified as a Class 2, type V CRISPR system.
• Cpf1 loci encode Cas1, Cas2 and Cas4 proteins more similar to types I and III than from type II systems. Functional Cpf1 does not need the trans-activating CRISPR RNA (tracrRNA); therefore, only CRISPR (crRNA) is required. This benefits genome editing because Cpf1 is not only smaller than Cas9, but also it has a smaller sgRNA molecule
• Cpf1-crRNA complex cleaves target DNA or RNA by identification of a protospacer adjacent motif 5’-YTN-3’ in contrast to the G- rich PAM targeted by Cas9. After identification of PAM, Cpf1 introduces a sticky-end-like, DNA double-stranded break of 4 or 5 nucleotides overhang.
• nuclease-inactive Cpf1 (dCpf1) variants that may be used as a guide nucleotide sequence-programmable DNA-binding protein domain.
• the Cpf1 protein has a RuvC-like endonuclease domain that is similar to the RuvC domain of Cas9, but does not have a HNH endonuclease domain, and the N-terminal of Cpf1 does not have the a-helical recognition lobe of Cas9.
• the dCpf1 of the present disclosure comprises mutations corresponding to D917A, E1006A, D1255A, D917A/E1006A, D917A/D1255A, E1006A/D1255A, or D917A/E1006A/D1255A. It is to be understood that any mutations, e.g., substitution mutations, deletions, or insertions that inactivate the RuvC domain of Cpf1, may be used in accordance with the present disclosure.
• nucleic acid programmable DNA binding protein [0229] In some embodiments, the nucleic acid programmable DNA binding protein
• nCpf1 protein a Cpf1 nickase (nCpf1).
• Cpf1 protein is a nuclease inactive Cpf1 (dCpf1).
• the Cpf1, the nCpf1, or the dCpf1 comprises an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to a Cpf1 sequence disclosed herein.
• the dCpf1 comprises an amino acid sequence that is at least 85%, at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to a Cpf1 sequence disclosed herein, and comprises mutations corresponding to D917A, E1006A, D1255A, D917A/E1006A, D917A/D1255A,
• E1006A/D1255A or D917A/E1006A/D1255A.
• Cpf1 from other bacterial species may also be used in accordance with the present disclosure. Accordingly, the following exemplary Cpf1 sequences from other bacterial species may also be used in accordance with the present disclosure:
• Francisella novicida Cpf1 D1255A (D917, E1006, and A1255 are bolded and underlined)
• Francisella novicida Cpf1 D917A/E1006A (A917, A1006, and D1255 are bolded and underlined)
• Francisella novicida Cpf1 E1006A/D1255A (D917, A1006, and A1255 are bolded and underlined)
• Francisella novicida Cpf1 D917A/E1006A/D1255A (A917, A1006, and A1255 are bolded and underlined)
• a polynucleotide programmable nucleotide binding domain of a base editor can itself comprise one or more domains.
• a polynucleotide programmable nucleotide binding domain can comprise one or more nuclease domains.
• the nuclease domain of a polynucleotide programmable nucleotide binding domain can comprise an endonuclease or an exonuclease.
• an endonuclease refers to a protein or polypeptide capable of digesting a nucleic acid (e.g., RNA or DNA) from free ends
• the term“endonuclease” refers to a protein or polypeptide capable of catalyzing (e.g. cleaving) internal regions in a nucleic acid (e.g., DNA or RNA).
• an endonuclease can cleave a single strand of a double-stranded nucleic acid.
• an endonuclease can cleave both strands of a double-stranded nucleic acid molecule.
• a polynucleotide programmable nucleotide binding domain can be a
• a polynucleotide programmable nucleotide binding domain can be a ribonuclease.
• a nuclease domain of a polynucleotide programmable nucleotide binding domain can cut zero, one, or two strands of a target polynucleotide.
• the polynucleotide programmable nucleotide binding domain can comprise a nickase domain.
• nickase refers to a polynucleotide programmable nucleotide binding domain comprising a nuclease domain that is capable of cleaving only one strand of the two strands in a duplexed nucleic acid molecule (e.g. DNA).
• a nickase can be derived from a fully catalytically active (e.g. natural) form of a polynucleotide programmable nucleotide binding domain by introducing one or more mutations into the active polynucleotide
• a polynucleotide programmable nucleotide binding domain comprises a nickase domain derived from Cas9
• the Cas9-derived nickase domain can include a D10A mutation and a histidine (H) at position 840.
• the residue H840 retains catalytic activity and can thereby cleave a single strand of the nucleic acid duplex.
• a Cas9-derived nickase domain can comprise an H840A mutation, while the amino acid residue at position 10 remains a D.
• a nickase can be derived from a fully catalytically active (e.g.
• a polynucleotide programmable nucleotide binding domain comprises a nickase domain derived from Cas9
• the Cas9-derived nickase domain can comprise a deletion of all or a portion of the RuvC domain or the HNH domain.
• a base editor comprising a polynucleotide programmable nucleotide binding domain comprising a nickase domain is thus able to generate a single-strand DNA break (nick) at a specific polynucleotide target sequence (e.g. determined by the complementary sequence of a bound guide nucleic acid).
• a specific polynucleotide target sequence e.g. determined by the complementary sequence of a bound guide nucleic acid.
• the strand of a nucleic acid duplex target polynucleotide sequence that is cleaved by a base editor comprising a nickase domain e.g.
• Cas9-derived nickase domain is the strand that is not edited by the base editor (i.e., the strand that is cleaved by the base editor is opposite to a strand comprising a base to be edited).
• a base editor comprising a nickase domain e.g. Cas9-derived nickase domain
• base editors comprising a polynucleotide programmable nucleotide binding domain which is catalytically dead (i.e., incapable of cleaving a target polynucleotide sequence).
• catalytically dead and“nuclease dead” are used interchangeably to refer to a polynucleotide programmable nucleotide binding domain which has one or more mutations and/or deletions resulting in its inability to cleave a strand of a nucleic acid.
• a catalytically dead polynucleotide programmable nucleotide binding domain base editor can lack nuclease activity as a result of specific point mutations in one or more nuclease domains.
• the Cas9 can comprise both a D10A mutation and an H840A mutation. Such mutations inactivate both nuclease domains, thereby resulting in the loss of nuclease activity.
• a catalytically dead polynucleotide programmable nucleotide binding domain can comprise one or more deletions of all or a portion of a catalytic domain (e.g.
• a catalytically dead polynucleotide programmable nucleotide binding domain comprises a point mutation (e.g. D10A or H840A) as well as a deletion of all or a portion of a nuclease domain.
• mutations capable of generating a catalytically dead polynucleotide programmable nucleotide binding domain from a previously functional version of the polynucleotide programmable nucleotide binding domain.
• dCas9 catalytically dead Cas9
• variants having mutations other than D10A and H840A are provided, which result in nuclease inactivated Cas9.
• Such mutations include other amino acid substitutions at D10 and H840, or other substitutions within the nuclease domains of Cas9 (e.g., substitutions in the HNH nuclease subdomain and/or the RuvC1 subdomain).
• nuclease-inactive dCas9 domains can be apparent to those of skill in the art based on this disclosure and knowledge in the field, and are within the scope of this disclosure.
• Such additional exemplary suitable nuclease-inactive Cas9 domains include, but are not limited to, D10A/H840A, D10A/D839A/H840A, and D10A/D839A/H840A/N863A mutant domains (See, e.g., Prashant et al., CAS9 transcriptional activators for target specificity screening and paired nickases for cooperative genome engineering. Nature Biotechnology.2013; 31(9): 833-838, the entire contents of which are incorporated herein by reference).
• the dCas9 domain comprises an amino acid sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any one of the dCas9 domains provided herein.
• the Cas9 domain comprises an amino acid sequences that has 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 21, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50 or more or more mutations compared to any one of the amino acid sequences set forth herein.
• the Cas9 domain comprises an amino acid sequence that has at least 10, at least 15, at least 20, at least 30, at least 40, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 150, at least 200, at least 250, at least 300, at least 350, at least 400, at least 500, at least 600, at least 700, at least 800, at least 900, at least 1000, at least 1100, or at least 1200 identical contiguous amino acid residues as compared to any one of the amino acid sequences set forth herein.
• Non-limiting examples of a polynucleotide programmable nucleotide binding domain which can be incorporated into a base editor include a CRISPR protein-derived domain, a restriction nuclease, a meganuclease, TAL nuclease (TALEN), and a zinc finger nuclease (ZFN).
• a base editor comprises a polynucleotide programmable nucleotide binding domain comprising a natural or modified protein or portion thereof which via a bound guide nucleic acid is capable of binding to a nucleic acid sequence during CRISPR (i.e., Clustered Regularly Interspaced Short Palindromic Repeats)-mediated modification of a nucleic acid.
• CRISPR Clustered Regularly Interspaced Short Palindromic Repeats
• a protein is referred to herein as a“CRISPR protein”.
• a base editor comprising a polynucleotide programmable nucleotide binding domain comprising all or a portion of a CRISPR protein (i.e. a base editor comprising as a domain all or a portion of a CRISPR protein, also referred to as a“CRISPR protein-derived domain” of the base editor).
• a CRISPR protein-derived domain incorporated into a base editor can be modified compared to a wild-type or natural version of the CRISPR protein.
• a CRISPR protein-derived domain can comprise one or more mutations, insertions, deletions, rearrangements and/or recombinations relative to a wild-type or natural version of the CRISPR protein.
• a CRISPR protein-derived domain incorporated into a base editor is an endonuclease (e.g., deoxyribonuclease or ribonuclease) capable of binding a target polynucleotide when in conjunction with a bound guide nucleic acid.
• a CRISPR protein-derived domain incorporated into a base editor is a nickase capable of binding a target polynucleotide when in conjunction with a bound guide nucleic acid.
• a CRISPR protein-derived domain incorporated into a base editor is a
• a target polynucleotide bound by a CRISPR protein derived domain of a base editor is DNA. In some embodiments, a target polynucleotide bound by a CRISPR protein-derived domain of a base editor is RNA.
• a CRISPR protein-derived domain of a base editor can include all or a portion of Cas9 from Corynebacterium ulcerans (NCBI Refs: NC_015683.1,
• NC_017317.1 Corynebacterium diphtheria (NCBI Refs: NC_016782.1, NC_016786.1);
• NCBI Ref NC_021284.1
• Prevotella intermedia NCBI Ref:
• NCBI Ref NC_017861.1
• Spiroplasma taiwanense NCBI Ref: NC_021846.1
• Streptococcus iniae NCBI Ref: NC_021314.1
• Belliella baltica NCBI Ref: NC_018010.1
• Psychroflexus torquis NCBI Ref: NC_018721.1
• Streptococcus thermophilus NCBI Ref: YP_820832.1
• Listeria innocua NCBI Ref: NP_472073.1
• Campylobacter jejuni NCBI Ref: YP_002344900.1
• Neisseria meningitidis NCBI Ref: YP_002342100.1
• Streptococcus pyogenes or Staphylococcus aureus.
• a Cas9-derived domain ofof a base editor is a Cas9 domain from Staphylococcus aureus (SaCas9).
• the SaCas9 domain is a nuclease active SaCas9, a nuclease inactive SaCas9 (SaCas9d), or a SaCas9 nickase (SaCas9n).
• the SaCas9 domain comprises a N579X mutation.
• the SaCas9 domain comprises a N579A mutation.
• the SaCas9 domain, the SaCas9d domain, or the SaCas9n domain can bind to a nucleic acid sequence having a non- canonical PAM. In some embodiments, the SaCas9 domain, the SaCas9d domain, or the SaCas9n domain can bind to a nucleic acid sequence having a NNGRRT PAM sequence. In some embodiments, the SaCas9 domain comprises one or more of a E781X, a N967X, and a R1014X mutation.
• the Cas9 domain is a Cas9 domain from Staphylococcus aureus (SaCas9).
• the SaCas9 domain is a nuclease active SaCas9, a nuclease inactive SaCas9 (SaCas9d), or a SaCas9 nickase (SaCas9n).
• the SaCas9 comprises a N579A mutation, or a corresponding mutation in any of the amino acid sequences provided herein.
• the SaCas9 domain, the SaCas9d domain, or the SaCas9n domain can bind to a nucleic acid sequence having a non-canonical PAM.
• the SaCas9 domain, the SaCas9d domain, or the SaCas9n domain can bind to a nucleic acid sequence having a NNGRRT or a NNNRRT PAM sequence.
• the SaCas9 domain comprises one or more of a E781X, a N967X, and a R1014X mutation, or a corresponding mutation in any of the amino acid sequences provided herein, wherein X is any amino acid.
• the SaCas9 domain comprises one or more of a E781K, a N967K, and a R1014H mutation, or one or more corresponding mutation in any of the amino acid sequences provided herein.
• the SaCas9 domain comprises a E781K, a N967K, or a R1014H mutation, or corresponding mutations in any of the amino acid sequences provided herein.
• a base editor can comprise a domain derived from all or a portion of a Cas9 that is a high fidelity Cas9.
• high fidelity Cas9 domains of a base editor are engineered Cas9 domains comprising one or more mutations that decrease electrostatic interactions between the Cas9 domain and the sugar-phosphate backbone of a DNA, relative to a corresponding wild-type Cas9 domain.
• High fidelity Cas9 domains that have decreased electrostatic interactions with the sugar-phosphate backbone of DNA can have less off-target effects.
• the Cas9 domain (e.g., a wild type Cas9 domain) comprises one or more mutations that decrease the association between the Cas9 domain and the sugar- phosphate backbone of a DNA.
• a Cas9 domain comprises one or more mutations that decreases the association between the Cas9 domain and the sugar-phosphate backbone of DNA by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, or more.
• the variant Cas protein can be spCas9, spCas9-VRQR, spCas9- VRER, xCas9 (sp), saCas9, saCas9-KKH, spCas9-MQKSER, spCas9-LRKIQK, or spCas9- LRVSQL.
• An exemplary saCas9 sequence is provided below:
• the modified Cas9 is a high fidelity Cas9 enzyme.
• the high fidelity Cas9 enzyme is SpCas9(K855A), eSpCas9(1.1), SpCas9-HF1, or hyper accurate Cas9 variant (HypaCas9).
• the modified Cas9 eSpCas9(1.1) contains alanine substitutions that weaken the interactions between the HNH/RuvC groove and the non-target DNA strand, preventing strand separation and cutting at off-target sites.
• SpCas9-HF1 lowers off-target editing through alanine substitutions that disrupt Cas9's interactions with the DNA phosphate backbone.
• HypaCas9 contains mutations (SpCas9
• N692A/M694A/Q695A/H698A in the REC3 domain that increase Cas9 proofreading and target discrimination. All three high fidelity enzymes generate less off-target editing than wildtype Cas9.
• An exemplary high fidelity Cas9 is provided below. High Fidelity Cas9 domain mutations relative to Cas9 are shown in bold and underlining.
• the term“guide polynucleotide(s)” refer to a polynucleotide which can be specific for a target sequence and can form a complex with a polynucleotide programmable nucleotide binding domain protein (e.g., Cas9 or Cpf1).
• the guide polynucleotide is a guide RNA.
• the term“guide RNA (gRNA)” and its grammatical equivalents can refer to an RNA which can be specific for a target DNA and can form a complex with Cas protein.
• An RNA/Cas complex can assist in“guiding” Cas protein to a target DNA.
• Cas9/crRNA/tracrRNA endonucleolytically cleaves linear or circular dsDNA target complementary to the spacer.
• the target strand not complementary to crRNA is first cut endonucleolytically, then trimmed 3’-5’ exonucleolytically.
• DNA-binding and cleavage typically requires protein and both RNAs.
• single guide RNAs (“sgRNA”, or simply“gRNA”) can be engineered so as to incorporate aspects of both the crRNA and tracrRNA into a single RNA species. See, e.g., Jinek M. et al., Science 337:816-821(2012), the entire contents of which is hereby incorporated by reference.
• Cas9 recognizes a short motif in the CRISPR repeat sequences (the PAM or protospacer adjacent motif) to help distinguish“self” versus“non-self.”
• Cas9 nuclease sequences and structures are well known to those of skill in the art (see e.g.,“Complete genome sequence of an M1 strain of Streptococcus pyogenes.” Ferretti, J.J. et al., Natl. Acad. Sci. U.S.A.98:4658-4663(2001);“CRISPR RNA maturation by trans-encoded small RNA and host factor RNase III.” Deltcheva E.
• Cas9 nucleases and sequences can be apparent to those of skill in the art based on this disclosure, and such Cas9 nucleases and sequences include Cas9 sequences from the organisms and loci disclosed in Chylinski, Rhun, and Charpentier,“The tracrRNA and Cas9 families of type II CRISPR-Cas immunity systems” (2013) RNA Biology 10:5, 726-737; the entire contents of which are incorporated herein by reference.
• a Cas9 nuclease has an inactive (e.g., an inactivated) DNA cleavage domain, that is, the Cas9 is a nickase.
• the guide polynucleotide is at least one single guide RNA (“sgRNA” or“gRNA”). In some embodiments, the guide polynucleotide is at least one tracrRNA. In some embodiments, the guide polynucleotide does not require PAM sequence to guide the polynucleotide-programmable DNA-binding domain (e.g., Cas9 or Cpf1) to the target nucleotide sequence.
• the polynucleotide programmable nucleotide binding domain (e.g., a CRISPR-derived domain) of the base editors disclosed herein can recognize a target polynucleotide sequence by associating with a guide polynucleotide.
• a guide polynucleotide e.g., gRNA
• a guide polynucleotide is typically single-stranded and can be programmed to site-specifically bind (i.e., via complementary base pairing) to a target sequence of a polynucleotide, thereby directing a base editor that is in conjunction with the guide nucleic acid to the target sequence.
• a guide polynucleotide can be DNA.
• a guide polynucleotide can be RNA.
• the guide polynucleotide comprises natural nucleotides (e.g., adenosine). In some cases, the guide polynucleotide comprises non- natural (or unnatural) nucleotides (e.g., peptide nucleic acid or nucleotide analogs).
• the targeting region of a guide nucleic acid sequence can be at least 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 nucleotides in length. A targeting region of a guide nucleic acid can be between 10-30 nucleotides in length, or between 15-25 nucleotides in length, or between 15-20 nucleotides in length.
• a guide polynucleotide comprises two or more individual polynucleotides, which can interact with one another via, for example, complementary base pairing (e.g. a dual guide polynucleotide).
• a guide polynucleotide can comprise a CRISPR RNA (crRNA) and a trans-activating CRISPR RNA (tracrRNA).
• a guide polynucleotide can comprise one or more trans-activating CRISPR RNA (tracrRNA).
• RNA molecules comprising a sequence that recognizes the target sequence
• trRNA second RNA molecule
• Such dual guide RNA systems can be employed as a guide polynucleotide to direct the base editors disclosed herein to a target polynucleotide sequence.
• the base editor provided herein utilizes a single guide polynucleotide (e.g., gRNA). In some embodiments, the base editor provided herein utilizes a dual guide polynucleotide (e.g., dual gRNAs). In some embodiments, the base editor provided herein utilizes one or more guide polynucleotide (e.g., multiple gRNA). In some embodiments, a single guide polynucleotide is utilized for different base editors described herein. For example, a single guide polynucleotide can be utilized for a cytidine base editor and an adenosine base editor.
• a single guide polynucleotide can be utilized for a cytidine base editor and an adenosine base editor.
• a guide polynucleotide can comprise both the polynucleotide targeting portion of the nucleic acid and the scaffold portion of the nucleic acid in a single molecule (i.e., a single-molecule guide nucleic acid).
• a single-molecule guide polynucleotide can be a single guide RNA (sgRNA or gRNA).
• sgRNA or gRNA single guide RNA
• guide polynucleotide sequence contemplates any single, dual or multi-molecule nucleic acid capable of interacting with and directing a base editor to a target polynucleotide sequence.
• a guide polynucleotide (e.g., crRNA/trRNA complex or a gRNA) comprises a“polynucleotide-targeting segment” that includes a sequence capable of recognizing and binding to a target polynucleotide sequence, and a“protein-binding segment” that stabilizes the guide polynucleotide within a polynucleotide programmable nucleotide binding domain component of a base editor.
• the polynucleotide targeting segment of the guide polynucleotide recognizes and binds to a DNA polynucleotide, thereby facilitating the editing of a base in DNA.
• the polynucleotide targeting segment of the guide polynucleotide recognizes and binds to an RNA polynucleotide, thereby facilitating the editing of a base in RNA.
• a“segment” refers to a section or region of a molecule, e.g., a contiguous stretch of nucleotides in the guide polynucleotide.
• a segment can also refer to a region/section of a complex such that a segment can comprise regions of more than one molecule.
• a protein-binding segment of a DNA-targeting RNA that comprises two separate molecules can comprise (i) base pairs 40-75 of a first RNA molecule that is 100 base pairs in length; and (ii) base pairs 10-25 of a second RNA molecule that is 50 base pairs in length.
• RNA molecules are of any total length and can include regions with complementarity to other molecules.
• a guide RNA or a guide polynucleotide can comprise two or more RNAs, e.g., CRISPR RNA (crRNA) and transactivating crRNA (tracrRNA).
• crRNA CRISPR RNA
• tracrRNA transactivating crRNA
• a guide RNA or a guide polynucleotide can sometimes comprise a single-chain RNA, or single guide RNA (sgRNA) formed by fusion of a portion (e.g., a functional portion) of crRNA and tracrRNA.
• sgRNA single guide RNA
• a guide RNA or a guide polynucleotide can also be a dual RNA comprising a crRNA and a tracrRNA.
• a crRNA can hybridize with a target DNA.
• a guide RNA or a guide polynucleotide can be an expression product.
• a DNA that encodes a guide RNA can be a vector comprising a sequence coding for the guide RNA.
• a guide RNA or a guide polynucleotide can be transferred into a cell by transfecting the cell with an isolated guide RNA or plasmid DNA comprising a sequence coding for the guide RNA and a promoter.
• a guide RNA or a guide polynucleotide can also be transferred into a cell in other way, such as using virus-mediated gene delivery.
• a guide RNA or a guide polynucleotide can be isolated.
• a guide RNA can be transfected in the form of an isolated RNA into a cell or organism.
• a guide RNA can be prepared by in vitro transcription using any in vitro transcription system known in the art.
• a guide RNA can be transferred to a cell in the form of isolated RNA rather than in the form of plasmid comprising encoding sequence for a guide RNA.
• a guide RNA or a guide polynucleotide can comprise three regions: a first region at the 5’ end that can be complementary to a target site in a chromosomal sequence, a second internal region that can form a stem loop structure, and a third 3’ region that can be single- stranded.
• a first region of each guide RNA can also be different such that each guide RNA guides a fusion protein to a specific target site.
• second and third regions of each guide RNA can be identical in all guide RNAs.
• a first region of a guide RNA or a guide polynucleotide can be complementary to sequence at a target site in a chromosomal sequence such that the first region of the guide RNA can base pair with the target site.
• a first region of a guide RNA can comprise from or from about 10 nucleotides to 25 nucleotides (i.e., from 10 nucleotides to nucleotides; or from about 10 nucleotides to about 25 nucleotides; or from 10 nucleotides to about 25 nucleotides; or from about 10 nucleotides to 25 nucleotides) or more.
• a region of base pairing between a first region of a guide RNA and a target site in a chromosomal sequence can be or can be about 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 22, 23, 24, 25, or more nucleotides in length.
• a first region of a guide RNA can be or can be about 19, 20, or 21 nucleotides in length.
• a guide RNA or a guide polynucleotide can also comprise a second region that forms a secondary structure.
• a secondary structure formed by a guide RNA can comprise a stem (or hairpin) and a loop.
• a length of a loop and a stem can vary.
• a loop can range from or from about 3 to 10 nucleotides in length
• a stem can range from or from about 6 to 20 base pairs in length.
• a stem can comprise one or more bulges of 1 to 10 or about 10 nucleotides.
• the overall length of a second region can range from or from about 16 to 60 nucleotides in length.
• a loop can be or can be about 4 nucleotides in length and a stem can be or can be about 12 base pairs.
• a guide RNA or a guide polynucleotide can also comprise a third region at the 3' end that can be essentially single-stranded.
• a third region is sometimes not complementary to any chromosomal sequence in a cell of interest and is sometimes not complementary to the rest of a guide RNA.
• the length of a third region can vary.
• a third region can be more than or more than about 4 nucleotides in length.
• the length of a third region can range from or from about 5 to 60 nucleotides in length.
• a guide RNA or a guide polynucleotide can target any exon or intron of a gene target.
• a guide can target exon 1 or 2 of a gene; in other cases, a guide can target exon 3 or 4 of a gene.
• a composition can comprise multiple guide RNAs that all target the same exon or, in some cases, multiple guide RNAs that can target different exons. An exon and an intron of a gene can be targeted.
• a guide RNA or a guide polynucleotide can target a nucleic acid sequence of or of about 20 nucleotides.
• a target nucleic acid can be less than or less than about 20 nucleotides.
• a target nucleic acid can be at least or at least about 5, 10, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, or anywhere between 1-100 nucleotides in length.
• a target nucleic acid can be at most or at most about 5, 10, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 30, 40, 50, or anywhere between 1-100 nucleotides in length.
• a target nucleic acid sequence can be or can be about 20 bases immediately 5’ of the first nucleotide of the PAM.
• a guide RNA can target a nucleic acid sequence.
• a target nucleic acid can be at least or at least about 1-10, 1-20, 1-30, 1-40, 1-50, 1- 60, 1-70, 1-80, 1-90, or 1-100 nucleotides.
• a guide polynucleotide for example, a guide RNA, can refer to a nucleic acid that can hybridize to another nucleic acid, for example, the target nucleic acid or protospacer in a genome of a cell.
• a guide polynucleotide can be RNA.
• a guide polynucleotide can be DNA.
• the guide polynucleotide can be programmed or designed to bind to a sequence of nucleic acid site-specifically.
• a guide polynucleotide can comprise a polynucleotide chain and can be called a single guide polynucleotide.
• a guide polynucleotide can comprise two polynucleotide chains and can be called a double guide polynucleotide.
• a guide RNA can be introduced into a cell or embryo as an RNA molecule.
• a RNA molecule can be transcribed in vitro and/or can be chemically synthesized.
• An RNA can be transcribed from a synthetic DNA molecule, e.g., a gBlocks® gene fragment.
• a guide RNA can then be introduced into a cell or embryo as an RNA molecule.
• a guide RNA can also be introduced into a cell or embryo in the form of a non-RNA nucleic acid molecule, e.g., DNA molecule.
• a DNA encoding a guide RNA can be operably linked to promoter control sequence for expression of the guide RNA in a cell or embryo of interest.
• a RNA coding sequence can be operably linked to a promoter sequence that is recognized by RNA polymerase III (Pol III).
• Plasmid vectors that can be used to express guide RNA include, but are not limited to, px330 vectors and px333 vectors.
• a plasmid vector (e.g., px333 vector) can comprise at least two guide RNA-encoding DNA sequences.
• unintentionally be targeted for deamination may be minimized.
• software tools can be used to optimize the gRNAs corresponding to a target nucleic acid sequence, e.g., to minimize total off-target activity across the genome. For example, for each possible targeting domain choice using S. pyogenes Cas9, all off-target sequences (preceding selected PAMs, e.g. NAG or NGG) may be identified across the genome that contain up to certain number (e.g., 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10) of mismatched base-pairs.
• First regions of gRNAs complementary to a target site can be identified, and all first regions (e.g. crRNAs) can be ranked according to its total predicted off-target score; the top-ranked targeting domains represent those that are likely to have the greatest on-target and the least off-target activity.
• candidate targeting gRNAs can be functionally evaluated by using methods known in the art and/or as set forth herein.
• target DNA hybridizing sequences in crRNAs of a guide RNA for use with Cas9s may be identified using a DNA sequence searching algorithm.
• gRNA design may be carried out using custom gRNA design software based on the public tool cas- offinder as described in Bae S., Park J., & Kim J.-S. Cas-OFFinder: A fast and versatile algorithm that searches for potential off-target sites of Cas9 RNA-guided endonucleases.
• a target gene may be obtained and repeat elements may be screened using publically available tools, for example, the RepeatMasker program.
• RepeatMasker searches input DNA sequences for repeated elements and regions of low complexity. The output is a detailed annotation of the repeats present in a given query sequence.
• first regions of guide RNAs may be ranked into tiers based on their distance to the target site, their orthogonality and presence of 5’ nucleotides for close matches with relevant PAM sequences (for example, a 5 G based on identification of close matches in the human genome containing a relevant PAM e.g., NGG PAM for S.
• orthogonality refers to the number of sequences in the human genome that contain a minimum number of mismatches to the target sequence.
• A“high level of orthogonality” or“good orthogonality” may, for example, refer to 20-mer targeting domains that have no identical sequences in the human genome besides the intended target, nor any sequences that contain one or two mismatches in the target sequence. Targeting domains with good orthogonality may be selected to minimize off-target DNA cleavage.
• a reporter system may be used for detecting base-editing activity and testing candidate guide polynucleotides.
• a reporter system may comprise a reporter gene based assay where base editing activity leads to expression of the reporter gene.
• a reporter system may include a reporter gene comprising a deactivated start codon, e.g., a mutation on the template strand from 3'-TAC-5' to 3'-CAC-5'. Upon successful deamination of the target C, the corresponding mRNA will be transcribed as 5'- AUG-3' instead of 5'-GUG-3', enabling the translation of the reporter gene.
• Suitable reporter genes will be apparent to those of skill in the art.
• Non-limiting examples of reporter genes include gene encoding green fluorescence protein (GFP), red fluorescence protein (RFP), luciferase, secreted alkaline phosphatase (SEAP), or any other gene whose expression are detectable and apparent to those skilled in the art.
• the reporter system can be used to test many different gRNAs, e.g., in order to determine which residue(s) with respect to the target DNA sequence the respective deaminase will target.
• sgRNAs that target non-template strand can also be tested in order to assess off-target effects of a specific base editing protein, e.g. a Cas9 deaminase fusion protein.
• gRNAs can be designed such that the mutated start codon will not be base-paired with the gRNA.
• the guide polynucleotides can comprise standard ribonucleotides, modified ribonucleotides (e.g., pseudouridine),
• the guide polynucleotide can comprise at least one detectable label.
• the detectable label can be a fluorophore (e.g., FAM, TMR, Cy3, Cy5, Texas Red, Oregon Green, Alexa Fluors, Halo tags, or suitable fluorescent dye), a detection tag (e.g., biotin, digoxigenin, and the like), quantum dots, or gold particles.
• the guide polynucleotides can be synthesized chemically, synthesized enzymatically, or a combination thereof.
• the guide RNA can be synthesized using standard phosphoramidite-based solid-phase synthesis methods.
• the guide RNA can be synthesized in vitro by operably linking DNA encoding the guide RNA to a promoter control sequence that is recognized by a phage RNA polymerase. Examples of suitable phage promoter sequences include T7, T3, SP6 promoter sequences, or variations thereof.
• the guide RNA comprises two separate molecules (e.g.., crRNA and tracrRNA)
• the crRNA can be chemically synthesized and the tracrRNA can be enzymatically synthesized.
• a base editor system may comprise multiple guide
• polynucleotides e.g. gRNAs.
• the gRNAs may target to one or more target loci (e.g., at least 1 gRNA, at least 2 gRNA, at least 5 gRNA, at least 10 gRNA, at least 20 gRNA, at least 30 g RNA, at least 50 gRNA) comprised in a base editor system.
• target loci e.g., at least 1 gRNA, at least 2 gRNA, at least 5 gRNA, at least 10 gRNA, at least 20 gRNA, at least 30 g RNA, at least 50 gRNA
• Said multiple gRNA sequences can be tandemly arranged and are preferably separated by a direct repeat.
• a DNA sequence encoding a guide RNA or a guide polynucleotide can also be part of a vector. Further, a vector can comprise additional expression control sequences (e.g., enhancer sequences, Kozak sequences, polyadenylation sequences, transcriptional termination sequences, etc.), selectable marker or reporter sequences (e.g., GFP or antibiotic resistance genes such as puromycin), origins of replication, and the like.
• a DNA molecule encoding a guide RNA can also be linear.
• a DNA molecule encoding a guide RNA or a guide polynucleotide can also be circular.
• one or more components of a base editor system may be encoded by DNA sequences.
• DNA sequences may be introduced into an expression system, e.g. a cell, together or separately.
• each DNA sequence can be part of a separate molecule (e.g., one vector containing the polynucleotide programmable nucleotide binding domain coding sequence and a second vector containing the guide RNA coding sequence) or both can be part of a same molecule (e.g., one vector containing coding (and regulatory) sequence for both the polynucleotide
• each DNA sequence can be part of a separate molecule (e.g., one vector containing an RNA-guided endonuclease coding sequence and a second vector containing a guide RNA coding sequence) or both can be part of a same molecule (e.g., one vector containing coding (and regulatory) sequences for both an RNA-guided endonuclease and a guide RNA).
• a guide polynucleotide can comprise one or more modifications to provide a nucleic acid with a new or enhanced feature.
• a guide polynucleotide can comprise a nucleic acid affinity tag.
• a guide polynucleotide can comprise synthetic nucleotide, synthetic nucleotide analog, nucleotide derivatives, and/or modified nucleotides.
• a gRNA or a guide polynucleotide can comprise modifications.
• a modification can be made at any location of a gRNA or a guide polynucleotide. More than one modification can be made to a single gRNA or a guide polynucleotide.
• a gRNA or a guide polynucleotide can undergo quality control after a modification. In some cases, quality control can include PAGE, HPLC, MS, or any combination thereof.
• a modification of a gRNA or a guide polynucleotide can be a substitution, insertion, deletion, chemical modification, physical modification, stabilization, purification, or any combination thereof.
• a gRNA or a guide polynucleotide can also be modified by 5’adenylate, 5’ guanosine- triphosphate cap, 5’N7-Methylguanosine-triphosphate cap, 5’triphosphate cap, 3’phosphate, 3’thiophosphate, 5’phosphate, 5’thiophosphate, Cis-Syn thymidine dimer, trimers, C12 spacer, C3 spacer, C6 spacer, dSpacer, PC spacer, rSpacer, Spacer 18, Spacer 9,3’-3’ modifications, 5’- 5’ modifications, abasic, acridine, azobenzene, biotin, biotin BB, biotin TEG, cholesteryl TEG, desthiobiotin TEG, DNP TEG, DNP-X, DOTA, dT-Biotin, dual biotin, PC biotin, psoralen C2, psoralen C6, TINA
• wobble/universal bases fluorescent dye label
• 2’-fluoro RNA 2’-O-methyl RNA, methylphosphonate, phosphodiester DNA, phosphodiester RNA, phosphothioate DNA, phosphorothioate RNA, UNA, pseudouridine-5’-triphosphate, 5’-methylcytidine-5’- triphosphate, or any combination thereof.
• a modification is permanent. In other cases, a modification is transient. In some cases, multiple modifications are made to a gRNA or a guide polynucleotide.
• a gRNA or a guide polynucleotide modification can alter physiochemical properties of a nucleotide, such as their conformation, polarity, hydrophobicity, chemical reactivity, base ⁇ pairing interactions, or any combination thereof.
• a modification can also be a phosphorothioate substitute.
• a natural phosphodiester bond can be susceptible to rapid degradation by cellular nucleases and; a modification of internucleotide linkage using phosphorothioate (PS) bond substitutes can be more stable toward hydrolysis by cellular degradation.
• PS phosphorothioate
• a modification can increase stability in a gRNA or a guide polynucleotide.
• a modification can also enhance biological activity.
• a phosphorothioate enhanced RNA gRNA can inhibit RNase A, RNase T1, calf serum nucleases, or any combinations thereof.
• PS-RNA gRNAs can be used in applications where exposure to nucleases is of high probability in vivo or in vitro.
• phosphorothioate (PS) bonds can be introduced between the last 3-5 nucleotides at the 5 - or‘'-end of a gRNA which can inhibit exonuclease degradation.
• phosphorothioate bonds can be added throughout an entire gRNA to reduce attack by endonucleases.
• The“protospacer adjacent motif (PAM)” or PAM-like motif refers to a 2-6 base pair DNA sequence immediately following the DNA sequence targeted by the Cas9 nuclease in the CRISPR bacterial adaptive immune system.
• the PAM can be a 5’ PAM (i.e., located upstream of the 5’ end of the protospacer).
• the PAM can be a 3’ PAM (i.e., located downstream of the 5’ end of the protospacer).
• the protospacer adjacent motif (PAM) or PAM-like motif refers to a 2-6 base pair DNA sequence immediately following the DNA sequence targeted by the Cas9 nuclease in the CRISPR bacterial adaptive immune system.
• the PAM can be a 5’ PAM (i.e., located upstream of the 5’ end of the protospacer).
• the PAM can be a 3’ PAM (i.e., located downstream of the 5’ end of the protospacer).
• the PAM sequence is essential for target binding, but the exact sequence depends on a type of Cas protein.
• a base editor provided herein can comprise a CRISPR protein-derived domain that is capable of binding a nucleotide sequence that contains a canonical or non-canonical protospacer adjacent motif (PAM) sequence.
• a PAM site is a nucleotide sequence in proximity to a target polynucleotide sequence.
• pyogenes typically require a canonical NGG PAM sequence to bind a particular nucleic acid region, where the“N” in“NGG” is adenine (A), thymine (T), guanine (G), or cytosine (C), and the G is guanine.
• a PAM can be CRISPR protein-specific and can be different between different base editors comprising different CRISPR protein-derived domains.
• a PAM can be 5’ or 3’ of a target sequence.
• a PAM can be upstream or downstream of a target sequence.
• a PAM can be 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more nucleotides in length. Often, a PAM is between 2-6 nucleotides in length.
• the Cas9 domain is a Cas9 domain from Streptococcus pyogenes (SpCas9).
• the SpCas9 domain is a nuclease active SpCas9, a nuclease inactive SpCas9 (SpCas9d), or a SpCas9 nickase (SpCas9n).
• the SpCas9 comprises a D9XD9X mutation, or a corresponding mutation in any of the amino acid sequences provided herein, wherein X is amino acid except for D.
• the SpCas9 comprises a D9AD9A mutation, or a corresponding mutation in any of the amino acid sequences provided herein.
• the SpCas9 domain, the SpCas9d domain, or the SpCas9n domain can bind to a nucleic acid sequence having a non-canonical PAM.
• the SpCas9 domain, the SpCas9d domain, or the SpCas9n domain can bind to a nucleic acid sequence having an NGG, a NGA, or a NGCG PAM sequence.
• the SpCas9 domain comprises one or more of a D1135X, a R1335X, and a T1337X mutation, or a corresponding mutation mutationin any of the amino acid sequences provided hereinherein, wherein X is any amino acid.
• the SpCas9 domain comprises one or more of a D1135E, R1335Q, and T1337R mutation, or a corresponding mutation in any of the amino acid sequences provided herein.
• the SpCas9 domain comprises a D1135E, a R1335Q, and a T1337R mutation, or corresponding mutations in any of the aminosequences provided herein.
• the SpCas9 domaindomain comprises one or more of a D1135X, a R1335X, and a T1337X mutation, or a corresponding mutation in any of the amino acid sequences provided hereinherein, wherein X is any amino acid.
• the SpCas9 domain comprises one or more of a D1135V, a R1335Q, and a T1337R mutation, or a corresponding mutation in any ofof the amino acid sequences provided herein.
• the SpCas9 domain comprises a D1135V, a R1335Q, and a T1337R mutation, or corresponding mutations in any of the amino acid sequences provided herein.
• the SpCas9SpCas9 domain comprises one or more of a D1135X, a G1218X, a R1335X, and a T1337X mutation, or a corresponding mutation in any of the amino acid sequences provided herein, wherein X is any amino acid.
• the SpCas9 domain comprises one or more of a D1135V, a G1218R, a R1335Q, and a T1337R mutation, or a corresponding mutation in any of the aminosequences provided herein.
• the SpCas9In some embodiments, the SpCas9 domain comprises a D1135V, a G1218R, a R1335Q, and a T1337R mutation, or corresponding mutations in any of the amino acid sequences provided hereinherein.
• the Cas9 domains of any of the fusion proteins provided herein comprises an amino acid sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to a Cas9 polypeptide described herein.
• the Cas9 domains of any of the fusion proteins provided herein comprises the amino acid sequence of any Cas9 polypeptide described herein.
• the Cas9 domains of any of the fusion proteins provided herein consists of the amino acid sequence of any Cas9 polypeptide described herein.
• Residues V1135, R1218, Q1335, and R1337 above, which can be mutated from D1135, G1218, R1335, and T1337 to yield a SpVRQR Cas9, are underlined and in bold.
• the Cas9 domain is a recombinant Cas9 domain.
• the recombinant Cas9 domain is a SpyMacCas9 domain.
• the SpyMacCas9 domain is a nuclease active SpyMacCas9, a nuclease inactive SpyMacCas9 (SpyMacCas9d), or a SpyMacCas9 nickase (SpyMacCas9n).
• the SaCas9 domain, the SaCas9d domain, or the SaCas9n domain can bind to a nucleic acid sequence having a non-canonical PAM.
• the SpyMacCas9 domain, the SpCas9d domain, or the SpCas9n domain can bind to a nucleic acid sequence having a NAA PAM sequence.
• high fidelity Cas9 domains are engineered Cas9 domains comprising one or more mutations that decrease electrostatic interactions between the Cas9 domain and a sugar- phosphate backbone of a DNA, as compared to a corresponding wild-type Cas9 domain.
• a Cas9 domain (e.g., a wild type Cas9 domain) comprises one or more mutations that decreases the association between the Cas9 domain and a sugar- phosphate backbone of a DNA.
• a Cas9 domain comprises one or more mutations that decreases the association between the Cas9 domain and a sugar-phosphate backbone of a DNA by at least 1%, at least 2%, at least 3%, at least 4%, at least 5%, at least10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, or at least 70%.
• any of the Cas9 fusion proteins provided herein comprise one or more of a N497X, a R661X, a Q695X, and/or a Q926X mutation, or a corresponding mutation in any of the amino acid sequences provided herein, wherein X is any amino acid.
• any of the Cas9 fusion proteins provided herein comprise one or more of a N497A, a R661A, a Q695A, and/or a Q926A mutation, or a corresponding mutation in any of the amino acid sequences provided herein.
• the Cas9 domain comprises a D10A mutation, or a corresponding mutation in any of the amino acid sequences provided herein.
• Cas9 domains with high fidelity are known in the art and would be apparent to the skilled artisan. For example, Cas9 domains with high fidelity have been described in
• a variant Cas9 protein harbors, H840A, P475A, W476A, N477A, D1125A, W1126A, and D1127A mutations such that the polypeptide has a reduced ability to cleave a target DNA or RNA.
• a Cas9 protein has a reduced ability to cleave a target DNA (e.g., a single stranded target DNA) but retains the ability to bind a target DNA (e.g., a single stranded target DNA).
• the variant Cas9 protein harbors D10A, H840A, P475A, W476A, N477A, D1125A, W1126A, and D1127A mutations such that the polypeptide has a reduced ability to cleave a target DNA.
• a Cas9 protein has a reduced ability to cleave a target DNA (e.g., a single stranded target DNA) but retains the ability to bind a target DNA (e.g., a single stranded target DNA).
• the variant Cas9 protein when a variant Cas9 protein harbors W476A and W1126A mutations or when the variant Cas9 protein harbors P475A, W476A, N477A, D1125A, W1126A, and D1127A mutations, the variant Cas9 protein does not bind efficiently to a PAM sequence. Thus, in some such cases, when such a variant Cas9 protein is used in a method of binding, the method does not require a PAM sequence.
• the method when such a variant Cas9 protein is used in a method of binding, can include a guide RNA, but the method can be performed in the absence of a PAM sequence (and the specificity of binding is therefore provided by the targeting segment of the guide RNA).
• Other residues can be mutated to achieve the above effects (i.e., inactivate one or the other nuclease portions).
• residues D10, G12, G17, E762, H840, N854, N863, H982, H983, A984, D986, and/or A987 can be altered (i.e., substituted).
• mutations other than alanine substitutions are suitable.
• a CRISPR protein-derived domain of a base editor can comprise all or a portion of a Cas9 protein with a canonical PAM sequence (NGG).
• NGS canonical PAM sequence
• a Cas9-derived domain of a base editor can employ a non-canonical PAM sequence.
• Such sequences have been described in the art and would be apparent to the skilled artisan.
• Cas9 domains that bind non-canonical PAM sequences have been described in Kleinstiver, B. P., et al.,“Engineered CRISPR-Cas9 nucleases with altered PAM specificities” Nature, 523, 481-485 (2015); and Kleinstiver, B. P., et al.,“Broadening the targeting range of Staphylococcus aureus CRISPR-Cas9 by modifying PAM recognition” Nature Biotechnology, 33, 1293-1298 (2015); the entire contents of each are hereby
• a PAM recognized by a CRISPR protein-derived domain of a base editor disclosed herein can be provided to a cell on a separate oligonucleotide to an insert (e.g. an AAV insert) encoding the base editor.
• an insert e.g. an AAV insert
• providing PAM on a separate oligonucleotide can allow cleavage of a target sequence that otherwise would not be able to be cleaved, because no adjacent PAM is present on the same polynucleotide as the target sequence.
• S. pyogenes Cas9 can be used as a CRISPR endonuclease for genome engineering. However, others can be used. In some cases, a different endonuclease can be used to target certain genomic targets. In some cases, synthetic SpCas9-derived variants with non-NGG PAM sequences can be used. Additionally, other Cas9 orthologues from various species have been identified and these“non-SpCas9s” can bind a variety of PAM sequences that can also be useful for the present disclosure.
• the relatively large size of SpCas9 can lead to plasmids carrying the SpCas9 cDNA that cannot be efficiently expressed in a cell.
• the coding sequence for Staphylococcus aureus Cas9 (SaCas9) is approximately1 kilo base shorter than SpCas9, possibly allowing it to be efficiently expressed in a cell.
• the SaCas9 endonuclease is capable of modifying target genes in mammalian cells in vitro and in mice in vivo.
• a Cas protein can target a different PAM sequence.
• a target gene can be adjacent to a Cas9 PAM, 5’-NGG, for example.
• Cas9 orthologs can have different PAM requirements.
• other PAMs such as those of S. thermophilus (5’-NNAGAA for CRISPR1 and 5’-NGGNG for CRISPR3) and Neisseria meningiditis (5’-NNNNGATT) can also be found adjacent to a target gene.
• a target gene sequence can precede (i.e., be 5’ to) a 5’-NGG PAM, and a 20-nt guide RNA sequence can base pair with an opposite strand to mediate a Cas9 cleavage adjacent to a PAM.
• an adjacent cut can be or can be about 3 base pairs upstream of a PAM.
• an adjacent cut can be or can be about 10 base pairs upstream of a PAM.
• an adjacent cut can be or can be about 0-20 base pairs upstream of a PAM.
• an adjacent cut can be next to, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, or 30 base pairs upstream of a PAM.
• An adjacent cut can also be downstream of a PAM by 1 to 30 base pairs.
• Fusion proteins comprising a nuclear localization sequence (NLS)
• the fusion proteins provided herein further comprise one or more (e.g., 2, 3, 4, 5) nuclear targeting sequences, for example a nuclear localization sequence (NLS).
• a nuclear localization sequence for example a nuclear localization sequence (NLS).
• a bipartite NLS is used.
• a NLS comprises an amino acid sequence that facilitates the importation of a protein, that comprises an NLS, into the cell nucleus (e.g., by nuclear transport).
• any of the fusion proteins provided herein further comprise a nuclear localization sequence (NLS).
• the NLS is fused to the N-terminus of the fusion protein.
• the NLS is fused to the C-terminus of the fusion protein.
• the NLS is fused to the N-terminus of the Cas9 domain. In some embodiments, the NLS is fused to the C-terminus of an nCas9 domain or a dCas9 domain. In some embodiments, the NLS is fused to the N-terminus of the deaminase. In some embodiments, the NLS is fused to the C-terminus of the deaminase. In some embodiments, the NLS is fused to the fusion protein via one or more linkers. In some embodiments, the NLS is fused to the fusion protein without a linker. In some embodiments, the NLS comprises an amino acid sequence of any one of the NLS sequences provided or referenced herein. Additional nuclear localization sequences are known in the art and would be apparent to the skilled artisan. For example, NLS sequences are described in Plank et al.,
• an NLS comprises the amino acid sequence PKKKRKVEGADKRTADGSEFES PKKKRKV,
• KRTADGSEFESPKKKRKV KRPAATKKAGQAKKKK, KKTELQTTNAENKTKKL, KRGINDRNFWRGENGRKTR, RKSGKIAAIVVKRPRKPKKKRKV, or
• the NLS is present in a linker or the NLS is flanked by linkers, for example, the linkers described herein.
• the N-terminus or C-terminus NLS is a bipartite NLS.
• a bipartite NLS comprises two basic amino acid clusters, which are separated by a relatively short spacer sequence (hence bipartite - 2 parts, while monopartite NLSs are not).
• KR[PAATKKAGQA]KKKK is the prototype of the ubiquitous bipartite signal: two clusters of basic amino acids, separated by a spacer of about 10 amino acids.
• the sequence of an exemplary bipartite NLS follows: PKKKRKVEGADKRTADGSEFES PKKKRKV.
• the fusion proteins of the invention do not comprise a linker sequence. In some embodiments, linker sequences between one or more of the domains or proteins are present.
• the fusion proteins of the present disclosure may comprise one or more additional features.
• the fusion protein may comprise inhibitors, cytoplasmic localization sequences, export sequences, such as nuclear export sequences, or other localization sequences, as well as sequence tags that are useful for solubilization, purification, or detection of the fusion proteins.
• Suitable protein tags include, but are not limited to, biotin carboxylase carrier protein (BCCP) tags, myc-tags, calmodulin-tags, FLAG-tags, hemagglutinin (HA)-tags, polyhistidine tags, also referred to as histidine tags or His-tags, maltose binding protein (MBP)-tags, nus-tags, glutathione-S- transferase (GST)-tags, green fluorescent protein (GFP)-tags, thioredoxin-tags, S-tags, Softags (e.g., Softag 1, Softag 3), strep-tags , biotin ligase tags, FlAsH tags, V5 tags, and SBP-tags. Additional suitable sequences will be apparent to those of skill in the art.
• the fusion protein comprises one or more His tags.
• a vector that encodes a CRISPR enzyme comprising one or more nuclear localization sequences can be used.
• NLSs nuclear localization sequences
• a CRISPR enzyme can comprise the NLSs at or near the amino-terminus, about or more than about 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 NLSs at or near the carboxy-terminus, or any combination of these (e.g., one or more NLS at the amino-terminus and one or more NLS at the carboxy terminus).
• each can be selected independently of others, such that a single NLS can be present in more than one copy and/or in combination with one or more other NLSs present in one or more copies.
• CRISPR enzymes used in the methods can comprise about 6 NLSs.
• An NLS is considered near the N- or C-terminus when the nearest amino acid to the NLS is within about 50 amino acids along a polypeptide chain from the N- or C-terminus, e.g., within 1, 2, 3, 4, 5, 10, 15, 20, 25, 30, 40, or 50 amino acids.
• the NLS is present in a linker or the NLS is flanked by linkers, for example, the linkers described herein.
• the N-terminus or C-terminus NLS is a bipartite NLS.
• a bipartite NLS comprises two basic amino acid clusters, which are separated by a relatively short spacer sequence (hence bipartite - 2 parts, while monopartite NLSs are not).
• the NLS of nucleoplasmin, KR[PAATKKAGQA]KKKK is the prototype of the ubiquitous bipartite signal: two clusters of basic amino acids, separated by a spacer of about 10 amino acids.
• the sequence of an exemplary bipartite NLS follows:
• PKKKRKVEGADKRTADGSEFES PKKKRKV PKKKRKV.
• the NLS is present in a linker or the NLS is flanked by linkers, for example, the linkers described herein.
• the N-terminus or C-terminus NLS is a bipartite NLS.
• a bipartite NLS comprises two basic amino acid clusters, which are separated by a relatively short spacer sequence (hence bipartite - 2 parts, while monopartite NLSs are not).
• the NLS of nucleoplasmin, KR[PAATKKAGQA]KKKK is the prototype of the ubiquitous bipartite signal: two clusters of basic amino acids, separated by a spacer of about 10 amino acids.
• the sequence of an exemplary bipartite NLS is as follows:
• PKKKRKVEGADKRTADGSEFES PKKKRKV PKKKRKV.
• the PAM sequence can be any PAM sequence known in the art. Suitable PAM sequences include, but are not limited to, NGG, NGA, NGC, NGN, NGT, NGCG, NGAG, NGAN, NGNG, NGCN, NGCG, NGTN, NNGRRT, NNNRRT, NNGRR(N), TTTV, TYCV, TYCV, TATV, NNNNGATT, NNAGAAW, or NAAAAC.
• Y is a pyrimidine; N is any nucleotide base; W is A or T.
• Cas9 proteins such as Cas9 from S. pyogenes (spCas9)
• spCas9 require a canonical NGG PAM sequence to bind a particular nucleic acid region, where the“N” in“NGG” is adenosine (A), thymidine (T), or cytosine (C), and the G is guanosine.
• A adenosine
• T thymidine
• C cytosine
• G guanosine
• the base editing fusion proteins provided herein may need to be placed at a precise location, for example a region comprising a target base that is upstream of the PAM.
• any of the fusion proteins provided herein may contain a Cas9 domain that is capable of binding a nucleotide sequence that does not contain a canonical (e.g., NGG) PAM sequence.
• Cas9 domains that bind to non-canonical PAM sequences have been described in the art and would be apparent to the skilled artisan.
• Cas9 domains that bind non- canonical PAM sequences have been described in Kleinstiver, B. P., et al.,“Engineered
• base editors comprising a fusion protein that includes a polynucleotide programmable nucleotide binding domain and a nucleobase (base) editing domain (e.g., deaminase domain).
• the base editor can be programmed to edit one or more bases in a target polynucleotide sequence by interacting with a guide polynucleotide capable of recognizing the target sequence. Once the target sequence has been recognized, the base editor is anchored on the polynucleotide where editing is to occur and the deaminase domain component of the base editor can then edit a target base.
• the nucleobase editing domain is a deaminase domain.
• a deaminase domain can be a cytosine deaminase or a cytidine deaminase.
• the terms“cytosine deaminase” and“cytidine deaminase” can be used
• a deaminase domain can be an adenine deaminase or an adenosine deaminase.
• the terms“adenine deaminase” and“adenosine deaminase” can be used interchangeably. Details of nucleobase editing proteins are described in International PCT Application Nos. PCT/2017/045381 (WO2018/027078) and
• a base editor disclosed herein comprises a fusion protein comprising cytidine deaminase capable of deaminating a target cytidine (C) base of a polynucleotide to produce uridine (U), which has the base pairing properties of thymine.
• the uridine base can then be substituted with a thymidine base (e.g. by cellular repair machinery) to give rise to a C:G to a T:A transition.
• deamination of a C to U in a nucleic acid by a base editor cannot be accompanied by substitution of the U to a T.
• the deamination of a target C in a polynucleotide to give rise to a U is a non-limiting example of a type of base editing that can be executed by a base editor described herein.
• a base editor comprising a cytidine deaminase domain can mediate conversion of a cytosine (C) base to a guanine (G) base.
• a U of a polynucleotide produced by deamination of a cytidine by a cytidine deaminase domain of a base editor can be excised from the polynucleotide by a base excision repair mechanism (e.g., by a uracil DNA glycosylase (UDG) domain), producing an abasic site.
• the nucleobase opposite the abasic site can then be substituted (e.g. by base repair machinery) with another base, such as a C, by, for example, a translesion polymerase.
• base repair machinery e.g. by base repair machinery
• substitutions e.g. A, G or T
• substitutions e.g. A, G or T
• a base editor described herein comprises a deamination domain (e.g., cytidine deaminase domain) capable of deaminating a target C to a U in a polynucleotide.
• a deamination domain e.g., cytidine deaminase domain
• the base editor can comprise additional domains which facilitate conversion of the U resulting from deamination to, in some
• a T or a G a T or a G.
• a base editor comprising a cytidine deaminase domain can further comprise a uracil glycosylase inhibitor (UGI) domain to mediate substitution of a U by a T, completing a C-to-T base editing event.
• a base editor can incorporate a translesion polymerase to improve the efficiency of C-to-G base editing, since a translesion polymerase can facilitate incorporation of a C opposite an abasic site (i.e., resulting in incorporation of a G at the abasic site, completing the C-to-G base editing event).
• a base editor comprising a cytidine deaminase as a domain can deaminate a target C in any polynucleotide, including DNA, RNA and DNA-RNA hybrids.
• a cytidine deaminase catalyzes a C nucleobase that is positioned in the context of a single-stranded portion of a polynucleotide.
• the entire polynucleotide comprising a target C can be single-stranded.
• a cytidine deaminase incorporated into the base editor can deaminate a target C in a single-stranded RNA polynucleotide.
• a base editor comprising a cytidine deaminase domain can act on a double-stranded polynucleotide, but the target C can be positioned in a portion of the polynucleotide which at the time of the deamination reaction is in a single-stranded state.
• the NAGPB domain comprises a Cas9 domain
• several nucleotides can be left unpaired during formation of the Cas9-gRNA-target DNA complex, resulting in formation of a Cas9“R-loop complex”.
• These unpaired nucleotides can form a bubble of single-stranded DNA that can serve as a substrate for a single-strand specific nucleotide deaminase enzyme (e.g., cytidine deaminase).
• a single-strand specific nucleotide deaminase enzyme e.g., cytidine deaminase
• a cytidine deaminase of a base editor can comprise all or a portion of an apolipoprotein B mRNA editing complex (APOBEC) family deaminase.
• APOBEC apolipoprotein B mRNA editing complex
• APOBEC is a family of evolutionarily conserved cytidine deaminases. Members of this family are C-to-U editing enzymes.
• the N-terminal domain of APOBEC like proteins is the catalytic domain, while the C-terminal domain is a pseudocatalytic domain. More specifically, the catalytic domain is a zinc dependent cytidine deaminase domain and is important for cytidine deamination.
• APOBEC family members include APOBEC1, APOBEC2, APOBEC3A,
• APOBEC3B APOBEC3C
• APOBEC3D APOBEC3D
• APOBEC3F APOBEC3F
• APOBEC3G APOBEC3H
• APOBEC4 Activation-induced (cytidine) deaminase.
• a deaminase incorporated into a base editor comprises all or a portion of an APOBEC1 deaminase.
• a deaminase incorporated into a base editor comprises all or a portion of APOBEC2 deaminase. In some embodiments, a deaminase incorporated into a base editor comprises all or a portion of is an APOBEC3 deaminase. In some embodiments, a deaminase incorporated into a base editor comprises all or a portion of an APOBEC3A deaminase. In some embodiments, a deaminase incorporated into a base editor comprises all or a portion of APOBEC3B deaminase. In some embodiments, a deaminase incorporated into a base editor comprises all or a portion of
• a deaminase incorporated into a base editor comprises all or a portion of APOBEC3D deaminase. In some embodiments, a deaminase incorporated into a base editor comprises all or a portion of APOBEC3E deaminase. In some embodiments, a deaminase incorporated into a base editor comprises all or a portion of
• a deaminase incorporated into a base editor comprises all or a portion of APOBEC3G deaminase. In some embodiments, a deaminase incorporated into a base editor comprises all or a portion of APOBEC3H deaminase. In some embodiments, a deaminase incorporated into a base editor comprises all or a portion of
• a deaminase incorporated into a base editor comprises all or a portion of an activation-induced deaminase (AID).
• AID activation-induced deaminase
• a deaminase incorporated into a base editor comprises all or a portion of cytidine deaminase 1 (CDA1). It should be appreciated that a base editor can comprise a deaminase from any suitable organism (e.g., a human or a rat). In some
• a deaminase domain of a base editor is from a human, chimpanzee, gorilla, monkey, cow, dog, rat, or mouse. In some embodiments, the deaminase domain of the base editor is derived from rat (e.g., rat APOBEC1). In some embodiments, the deaminase domain of the base editor is human APOBEC1. In some embodiments, the deaminase domain of the base editor is pmCDA1.
• the active domain of the respective sequence can be used, e.g., the domain without a localizing signal (nuclear localization sequence, without nuclear export signal, cytoplasmic localizing signal).
• Human AID Human AID:
• Canine AID
• Bovine AID
• Rhesus macaque APOBEC-3G MVEPMDPRTFVSNFNNRPILSGLNTVWLCCEVKTKDPSGPPLDAKIFQGKVYSKAKYH PEMRFLRWFHKWRQLHHDQEYKVTWYVSWSPCTRCANSVATFLAKDPKVTLTIFVARLY YFWKPDYQQALRILCQKRGGPHATMKIMNYNEFQDCWNKFVDGRGKPFKPRNNLPKH YTLLQATLGELLRHLMDPGTFTSNFNNKPWVSGQHETYLCYKVERLHNDTWVPLNQH RGFLRNQAPNIHGFPKGRHAELCFLDLIPFWKLDGQQYRVTCFTSWSPCFSCAQEMAKFIS NNEHVSLCIFAARIYDDQGRYQEGLRALHRDGAKIAMMNYSEFEYCWDTFVDRQGRPF QPWDGLDEHSQALSGRLRAI (SEQ ID NO: )
• Bovine APOBEC-3B DGWEVAFRSGTVLKAGVLGVSMTEGWAGSGHPGQGACVWTPGTRNTMNLLREVLFK QQFGNQPRVPAPYYRRKTYLCYQLKQRNDLTLDRGCFRNKKQRHAERFIDKINSLDLN PSQSYKIICYITWSPCPNCANELVNFITRNNHLKLEIFASRLYFHWIKSFKMGLQDLQNA GISVAVMTHTEFEDCWEQFVDNQSRPFQPWDKLEQYSASIRRRLQRILTAPI (SEQ ID NO: )
• Bovine APOBEC-3A Bovine APOBEC-3A
• Some aspects of the present disclosure are based on the recognition that modulating the deaminase domain catalytic activity of any of the fusion proteins described herein, for example, by making point mutations in the deaminase domain, affect the processivity of the fusion proteins (e.g., base editors).
• mutations that reduce, but do not eliminate, the catalytic activity of a deaminase domain within a base editing fusion protein can make it less likely that the deaminase domain will catalyze the deamination of a residue adjacent to a target residue, thereby narrowing the deamination window.
• the ability to narrow the deamination window can prevent unwanted deamination of residues adjacent to specific target residues, which can decrease or prevent off-target effects.
• an APOBEC deaminase incorporated into a base editor can comprise one or more mutations selected from the group consisting of H121X, H122X, R126X, R126X, R118X, W90X, W90X, and R132X of rAPOBEC1, or one or more corresponding mutations in another APOBEC deaminase, wherein X is any amino acid.
• an APOBEC deaminase incorporated into a base editor can comprise one or more mutations selected from the group consisting of H121R, H122R, R126A, R126E, R118A, W90A, W90Y, and R132E of rAPOBEC1, or one or more corresponding mutations in another APOBEC deaminase.
• an APOBEC deaminase incorporated into a base editor can comprise one or more mutations selected from the group consisting of D316X, D317X, R320X, R320X, R313X, W285X, W285X, R326X of hAPOBEC3G, or one or more corresponding mutations in another APOBEC deaminase, wherein X is any amino acid.
• any of the fusion proteins provided herein comprise an APOBEC deaminase comprising one or more mutations selected from the group consisting of D316R, D317R, R320A, R320E, R313A, W285A, W285Y, R326E of hAPOBEC3G, or one or more corresponding mutations in another APOBEC deaminase.
• an APOBEC deaminase incorporated into a base editor can comprise a H121R and a H122R mutation of rAPOBEC1, or one or more corresponding mutations in another APOBEC deaminase.
• an APOBEC deaminase incorporated into a base editor can comprise an APOBEC deaminase comprising a R126A mutation of rAPOBEC1, or one or more corresponding mutations in another APOBEC deaminase.
• an APOBEC deaminase incorporated into a base editor can comprise an APOBEC deaminase comprising a R126E mutation of rAPOBEC1, or one or more corresponding mutations in another APOBEC deaminase.
• an APOBEC deaminase incorporated into a base editor can comprise an APOBEC deaminase comprising a R118A mutation of rAPOBEC1, or one or more corresponding mutations in another APOBEC deaminase.
• an APOBEC deaminase incorporated into a base editor can comprise an APOBEC deaminase comprising a W90A mutation of rAPOBEC1, or one or more corresponding mutations in another APOBEC deaminase.
• an APOBEC deaminase incorporated into a base editor can comprise an APOBEC deaminase comprising a W90Y mutation of rAPOBEC1, or one or more corresponding mutations in another APOBEC deaminase.
• an APOBEC deaminase incorporated into a base editor can comprise an APOBEC deaminase comprising a R132E mutation of rAPOBEC1, or one or more corresponding mutations in another APOBEC deaminase.
• an APOBEC deaminase incorporated into a base editor can comprise an APOBEC deaminase comprising a W90Y and a R126E mutation of rAPOBEC1, or one or more corresponding mutations in another APOBEC deaminase.
• an APOBEC deaminase incorporated into a base editor can comprise an APOBEC deaminase comprising a R126E and a R132E mutation of rAPOBEC1, or one or more corresponding mutations in another APOBEC deaminase.
• an APOBEC deaminase incorporated into a base editor can comprise an APOBEC deaminase comprising a W90Y and a R132E mutation of rAPOBEC1, or one or more corresponding mutations in another APOBEC deaminase.
• an APOBEC deaminase incorporated into a base editor can comprise an APOBEC deaminase comprising a W90Y, R126E, and R132E mutation of rAPOBEC1, or one or more corresponding mutations in another APOBEC deaminase.
• an APOBEC deaminase incorporated into a base editor can comprise an APOBEC deaminase comprising a D316R and a D317R mutation of hAPOBEC3G, or one or more corresponding mutations in another APOBEC deaminase.
• any of the fusion proteins provided herein comprise an APOBEC deaminase comprising a R320A mutation of hAPOBEC3G, or one or more corresponding mutations in another APOBEC deaminase.
• an APOBEC deaminase incorporated into a base editor can comprise an APOBEC deaminase comprising a R320E mutation of
• an APOBEC deaminase incorporated into a base editor can comprise an APOBEC deaminase comprising a R313A mutation of hAPOBEC3G, or one or more corresponding mutations in another APOBEC deaminase.
• an APOBEC deaminase incorporated into a base editor can comprise an APOBEC deaminase comprising a W285A mutation of hAPOBEC3G, or one or more corresponding mutations in another
• an APOBEC deaminase incorporated into a base editor can comprise an APOBEC deaminase comprising a W285Y mutation of hAPOBEC3G, or one or more corresponding mutations in another APOBEC deaminase.
• an APOBEC deaminase incorporated into a base editor can comprise an APOBEC deaminase comprising a R326E mutation of hAPOBEC3G, or one or more corresponding mutations in another APOBEC deaminase.
• an APOBEC deaminase incorporated into a base editor can comprise an APOBEC deaminase comprising a W285Y and a R320E mutation of hAPOBEC3G, or one or more corresponding mutations in another APOBEC deaminase.
• an APOBEC deaminase incorporated into a base editor can comprise an APOBEC deaminase comprising a R320E and a R326E mutation of hAPOBEC3G, or one or more corresponding mutations in another APOBEC deaminase.
• an APOBEC deaminase incorporated into a base editor can comprise an APOBEC deaminase comprising a W285Y and a R326E mutation of hAPOBEC3G, or one or more corresponding mutations in another APOBEC deaminase.
• an APOBEC deaminase incorporated into a base editor can comprise an APOBEC deaminase comprising a W285Y, R320E, and R326E mutation of hAPOBEC3G, or one or more corresponding mutations in another APOBEC deaminase.
• a number of modified cytidine deaminases are commercially available, including, but not limited to, SaBE3, SaKKH-BE3, VQR-BE3, EQR-BE3, VRER-BE3, YE1-BE3, EE-BE3, YE2-BE3, and YEE-BE3, from Addgene (plasmids 85169, 85170, 85171, 85172, 85173, 85174, 85175, 85176, 85177).
• a base editor described herein can comprise a deaminase domain which includes an adenosine deaminase.
• a deaminase domain of a base editor can facilitate the editing of an adenine (A) nucleobase to a guanine (G) nucleobase by deaminating the A to form inosine (I), which exhibits base pairing properties of G.
• Adenosine deaminase is capable of deaminating (i.e., removing an amine group) adenine of a deoxyadenosine residue in deoxyribonucleic acid (DNA).
• the nucleobase editors provided herein can be made by fusing together one or more protein domains, thereby generating a fusion protein.
• the fusion proteins provided herein comprise one or more features that improve the base editing activity (e.g., efficiency, selectivity, and specificity) of the fusion proteins.
• the fusion proteins provided herein can comprise a Cas9 domain that has reduced nuclease activity.
• the fusion proteins provided herein can have a Cas9 domain that does not have nuclease activity (dCas9), or a Cas9 domain that cuts one strand of a duplexed DNA molecule, referred to as a Cas9 nickase (nCas9).
• the presence of the catalytic residue maintains the activity of the Cas9 to cleave the non-edited (e.g., non-deaminated) strand containing a T opposite the targeted A.
• Mutation of the catalytic residue (e.g., D10 to A10) of Cas9 prevents cleavage of the edited strand containing the targeted A residue.
• Such Cas9 variants are able to generate a single- strand DNA break (nick) at a specific location based on the gRNA-defined target sequence, leading to repair of the non-edited strand, ultimately resulting in a T to C change on the non- edited strand.
• an A-to-G base editor further comprises an inhibitor of inosine base excision repair, for example, a uracil glycosylase inhibitor (UGI) domain or a catalytically inactive inosine specific nuclease.
• a uracil glycosylase inhibitor UGI domain
• a catalytically inactive inosine specific nuclease can inhibit or prevent base excision repair of a deaminated adenosine residue (e.g., inosine), which can improve the activity or efficiency of the base editor.
• a base editor comprising an adenosine deaminase can act on any polynucleotide, including DNA, RNA and DNA-RNA hybrids.
• a base editor comprising an adenosine deaminase can deaminate a target A of a polynucleotide comprising RNA.
• the base editor can comprise an adenosine deaminase domain capable of deaminating a target A of an RNA polynucleotide and/or a DNA-RNA hybrid polynucleotide.
• an adenosine deaminase incorporated into a base editor comprises all or a portion of adenosine deaminase acting on RNA (ADAR, e.g., ADAR1 or ADAR2).
• adenosine deaminase incorporated into a base editor comprises all or a portion of adenosine deaminase acting on tRNA (ADAT).
• a base editor comprising an adenosine deaminase domain can also be capable of deaminating an A nucleobase of a DNA
• an adenosine deaminase domain of a base editor comprises all or a portion of an ADAT comprising one or more mutations which permit the ADAT to deaminate a target A in DNA.
• the base editor can comprise all or a portion of an ADAT from Escherichia coli (EcTadA) comprising one or more of the following mutations: D108N, A106V, D147Y, E155V, L84F, H123Y, I157F, or a corresponding mutation in another adenosine deaminase.
• EcTadA Escherichia coli
• the TadA deaminase is an E.
• the truncated ecTadA may be missing one or more N-terminal amino acids relative to a full-length ecTadA.
• the truncated ecTadA may be missing 1, 2, 3, 4, 5 ,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 6, 17, 18, 19, or 20 N-terminal amino acid residues relative to the full length ecTadA.
• the truncated ecTadA may be missing 1, 2, 3, 4, 5 ,6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 6, 17, 18, 19, or 20 C-terminal amino acid residues relative to the full length ecTadA.
• the ecTadA deaminase does not comprise an N-terminal methionine.
• the TadA deaminase is an N-terminal truncated TadA.
• the TadA is any one of the TadA described in PCT/US2017/045381, which is incorporated herein by reference in its entirety.
• the adenosine deaminase can be derived from any suitable organism.
• the adenosine deaminase is from a prokaryote.
• the adenosine deaminase is from a bacterium.
• the adenosine deaminase is from Escherichia coli, Staphylococcus aureus, Salmonella typhi, Shewanella putrefaciens, Haemophilus influenzae, Caulobacter crescentus, or Bacillus subtilis.
• the adenosine deaminase is from E. coli.
• the adenine deaminase is a naturally-occurring adenosine deaminase that includes one or more mutations corresponding to any of the mutations provided herein (e.g., mutations in ecTadA).
• the corresponding residue in any homologous protein can be identified by e.g., sequence alignment and determination of homologous residues.
• the mutations in any naturally-occurring adenosine deaminase e.g., having homology to ecTadA
• any of the mutations identified in ecTadA can be generated accordingly.
• TadA tRNA adenosine deaminase A
• the TadA is any one of the TadAs described in
• a fusion protein of the invention comprises a wild-type TadA linked to TadA7.10, which is linked to Cas9 nickase.
• the fusion proteins comprise a single TadA7.10 domain (e.g., provided as a monomer).
• the ABE7.10 editor comprises TadA7.10 and TadA(wt), which are capable of forming heterodimers.
• the adenosine deaminase comprises anan amino acid sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any one of the amino acid sequences set forth in any of the adenosine deaminases provided herein. It should be appreciated that adenosine deaminases provided herein may include one or more mutations (e.g., any of the mutations provided herein).
• the disclosure provides any deaminase domains with a certain percent identity plus any of the mutations or combinations thereof described herein.
• the adenosine deaminase comprises an amino acid sequence that has 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 21, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, or more mutations compared to a reference sequence, or any of the adenosine deaminases provided herein.
• the adenosine deaminase comprises an amino acid sequence that has at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 110, at least 120, at least 130, at least 140, at least 150, at least 160, or at least 170 identical contiguous amino acid residues as compared to any one of the amino acid sequences known in the art or described herein.
• the TadA deaminase is a full-length E. coli TadA deaminase.
• the adenosine deaminase comprises the amino acid sequence: MRRAFITGVFFLSEVEFSHEYWMRHALTLAKRAWDEREVPVGAVLVHNNRVIGEGWN RPIGRHDPTAHAEIMALRQGGLVMQNYRLIDATLYVTLEPCVMCAGAMIHSRIGRVVF GARDAKTGAAGSLMDVLHHPGMNHRVEITEGILADECAALLSDFFRMRRQEIAQKKA QSSTD.
• adenosine deaminases useful in the present application would be apparent to the skilled artisan and are within the scope of this disclosure.
• the adenosine deaminase may be a homolog of adenosine deaminase acting on tRNA (AD AT).
• AD AT tRNA
• amino acid sequences of exemplary AD AT homologs include the following:
• Bacillus subtilis TadA Bacillus subtilis TadA:
• E. coli TadA (ecTadA):
• the adenosine deaminase comprises a D108X mutation relative to the TadA reference sequence, or a corresponding mutation in another adenosine deaminase, where X indicates any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase.
• the adenosine deaminase comprises a D108G, D108N, D108V, D108A, or D108Y mutation relative to the TadA reference sequence, or a corresponding mutation in another adenosine deaminase. It should be appreciated, however, that additional deaminases may similarly be aligned to identify homologous amino acid residues that can be mutated as provided herein.
• the adenosine deaminase comprises an A106X mutation relative to the TadA reference sequence, or a corresponding mutation in another adenosine deaminase, where X indicates any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase.
• the adenosine deaminase comprises an A106V mutation relative to the TadA reference sequence, or a corresponding mutation in another adenosine deaminase.
• the adenosine deaminase comprises a E155X mutation relative to the TadA reference sequence, or a corresponding mutation in another adenosine deaminase, where the presence of X indicates any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase.
• the adenosine deaminase comprises a E155D, E155G, or E155V mutation relative to the TadA reference sequence, or a corresponding mutation in another adenosine deaminase.
• the adenosine deaminase comprises a D147X mutation relative to the TadA reference sequence, or a corresponding mutation in another adenosine deaminase, where the presence of X indicates any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase.
• the adenosine deaminase comprises a D147Y, mutation relative to the TadA reference sequence, or a corresponding mutation in another adenosine deaminase.
• any of the mutations provided herein may be introduced into other adenosine deaminases, such as S. aureus TadA (saTadA), or other adenosine deaminases (e.g., bacterial adenosine deaminases).
• adenosine deaminases such as S. aureus TadA (saTadA)
• adenosine deaminases e.g., bacterial adenosine deaminases.
• any of the mutations provided herein may be made individually or in any combination in TadA or another adenosine deaminase.
• an adenosine deaminase may contain a D108N, a A106V, a E155V, and/or a D147Y mutation relative to the TadA reference sequence, or a corresponding mutation in another adenosine deaminase.
• an adenosine deaminase comprises the following group of mutations (groups of mutations are separated by a ";") relative to the TadA reference sequence, or corresponding mutations in another adenosine deaminase: D108N and A106V; D108N and E155V; D108N and D147Y; A106V and E155V; A106V and D147Y; E155V and D147Y; D108N, A106V, and E55V; D108N, A106V, and D147Y; D108N, E55V, and D147Y; A106V, E55V, and D147Y; and D108N, A106V, E55V, and D147Y. It should be appreciated, however, that any combination of corresponding mutations provided herein may be made in an adenosine deaminase (e.g., ecTadA).
• the adenosine deaminase comprises one or more of a H8X, T17X, L18X, W23X, L34X, W45X, R51X, A56X, E59X, E85X, M94X, I95X, V102X, F104X, A106X, R107X, D108X, K110X, M118X, N127X, A138X, F149X, M151X, R153X, Q154X, I156X, and/or K157X mutation relative to the TadA reference sequence, or one or more corresponding mutations in another adenosine deaminase, where the presence of X indicates any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase.
• the adenosine deaminase comprises one or more of H8Y, T17S, L18E, W23L, L34S, W45L, R51H, A56E, or A56S, E59G, E85K, or E85G, M94L, 1951, V102A, F104L, A106V, R107C, or R107H, or R107P, D108G, or D108N, or D108V, or D108A, or D108Y, K110I, Ml18K, N127S, A138V, F149Y, M151V, R153C, Q154L, I156D, and/or K157R mutation relative to the TadA reference sequence, or one or more corresponding mutations in another adenosine deaminase.
• the adenosine deaminase comprises one or more of a H8X, T17X, L18X, W23X, L34X, W45X, R51X, A56X, E59X, E85X, M94X, I95X, V102X, F104X, A106X, R107X, D108X, K110X, M118X, N127X, A138X, F149X, M151X, R153X, Q154X, I156X, and/or K157X mutation relative to the TadA reference sequence, or one or more corresponding mutations in another adenosine deaminase, where the presence of X indicates any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase.
• the adenosine deaminase comprises one or more of H8Y, T17S, L18E, W23L, L34S, W45L, R51H, A56E, or A56S, E59G, E85K, or E85G, M94L, 1951, V102A, F104L, A106V, R107C, or R107H, or R107P, D108G, or D108N, or D108V, or D108A, or D108Y, K110I, Ml18K, N127S, A138V, F149Y, M151V, R153C, Q154L, I156D, and/or K157R mutation relative to the TadA reference sequence, or one or more corresponding mutations in another adenosine deaminase.
• the adenosine deaminase comprises one or more of a H8X, D108X, and/or N127X mutation relative to the TadA reference sequence, or one or more corresponding mutations in another adenosine deaminase, where X indicates the presence of any amino acid.
• the adenosine deaminase comprises one or more of a H8Y, D108N, and/or N127S mutation relative to the TadA reference sequence, or one or more corresponding mutations in another adenosine deaminase.
• the adenosine deaminase comprises one or more of H8X, D108X, and/or N127X mutation relative to the TadA reference sequence, or one or more corresponding mutations in another adenosine deaminase, where X indicates the presence of any amino acid.
• the adenosine deaminase comprises one or more of a H8Y, D108N, and/or N127S mutation relative to the TadA reference sequence, or one or more corresponding mutations in another adenosine deaminase.
• the adenosine deaminase comprises one or more of H8X, D108X, and/or N127X mutation relative to the TadA reference sequence, or one or more corresponding mutations in another adenosine deaminase, where X indicates the presence of any amino acid.
• the adenosine deaminase comprises one or more of a H8Y, D108N, and/or N127S mutation relative to the TadA reference sequence, or one or more corresponding mutations in another adenosine deaminase.
• the adenosine deaminase comprises one or more of H8X, D108X, and/or N127X mutation relative to the TadA reference sequence, or one or more corresponding mutations in another adenosine deaminase, where X indicates the presence of any amino acid.
• the adenosine deaminase comprises one or more of a H8Y, D108N, and/or N127S mutation relative to the TadA reference sequence, or one or more corresponding mutations in another adenosine deaminase.
• the adenosine deaminase comprises one, two, three, four, five, or six mutations selected from the group consisting of H8X, D108X, N127X, D147X, R152X, and Q154X relative to the TadA reference sequence, or a corresponding mutation or mutations in another adenosine deaminase, where X indicates the presence of any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase.
• the adenosine deaminase comprises one, two, three, four, five, six, seven, or eight mutations selected from the group consisting of H8X, M61X, M70X, D108X, N127X, Q154X, E155X, and Q163X relative to the TadA reference sequence, or a corresponding mutation or mutations in another adenosine deaminase, where X indicates the presence of any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase.
• the adenosine deaminase comprises one, two, three, four, or five, mutations selected from the group consisting of H8X, D108X, N127X, E155X, and T166X relative to the TadA reference sequence, or a corresponding mutation or mutations in another adenosine deaminase, where X indicates the presence of any amino acid other than the corresponding amino acid in the reference or wild-type adenosine deaminase.
• the adenosine deaminase comprises one, two, three, four, five, or six mutations selected from the group consisting of H8X, A106X, D108X, mutation relative to the Tad reference sequence, or mutations in another adenosine deaminase, where X indicates the presence of any amino acid other than the corresponding amino acid in the reference or wild-type adenosine deaminase.
• the adenosine deaminase comprises one, two, three, four, five, six, seven, or eight mutations selected from the group consisting of H8X, R126X, L68X, D108X, N127X, D147X, and E155X relative to the TadA reference sequence, or a corresponding mutation or mutations in another adenosine deaminase, where X indicates the presence of any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase.
• the adenosine deaminase comprises one, two, three, four, or five, mutations selected from the group consisting of H8X, D108X, A109X, N127X, and E155X relative to the TadA reference sequence, or a corresponding mutation or mutations in another adenosine deaminase, where X indicates the presence of any amino acid other than the corresponding amino acid in the wild- type adenosine deaminase.
• the adenosine deaminase comprises one, two, three, four, five, or six mutations selected from the group consisting of H8Y, D108N, N127S, D147Y, R152C, and Q154H relative to the TadA reference sequence, or a corresponding mutation or mutations in another adenosine deaminase.
• the adenosine deaminase comprises one, two, three, four, five, six, seven, or eight mutations selected from the group consisting of H8Y, M61I, M70V, D108N, N127S, Q154R, E155G and Q163H relative to the TadA reference sequence, or a corresponding mutation or mutations in another adenosine deaminase.
• the adenosine deaminase comprises one, two, three, four, or five, mutations selected from the group consisting of H8Y, D108N, N127S, E155V, and T166P relative to the TadA reference sequence, or a corresponding mutation or mutations in another adenosine deaminase.
• the adenosine deaminase comprises one, two, three, four, five, or six mutations selected from the group consisting of H8Y, A106T, D108N, N127S, E155D, and K161Q relative to the TadA reference sequence, or a corresponding mutation or mutations in another adenosine deaminase.
• the adenosine deaminase comprises one, two, three, four, five, six, seven, or eight mutations selected from the group consisting of H8Y, R126W, L68Q, D108N, N127S, D147Y, and E155V relative to the TadA reference sequence, or a corresponding mutation or mutations in another adenosine deaminase.
• the adenosine deaminase comprises one, two, three, four, or five, mutations selected from the group consisting of H8Y, D108N, A109T, N127S, and E155G relative to the TadA reference sequence, or a corresponding mutation or mutations in another adenosine deaminase.
• the adenosine deaminase comprises one or more of the or one or more corresponding mutations in another adenosine deaminase.
• the adenosine deaminase comprises a D108N, D108G, or D108V mutation relative to the TadA reference sequence, or corresponding mutations in another adenosine deaminase.
• the adenosine deaminase comprises a A106V and D108N mutation relative to the TadA reference sequence, or corresponding mutations in another adenosine deaminase.
• the adenosine deaminase comprises R107C and D108N mutations relative to the TadA reference sequence, or corresponding mutations in another adenosine deaminase. In some embodiments, the adenosine deaminase comprises a H8Y, D108N, N127S, D147Y, and Q154H mutation relative to the TadA reference sequence, or corresponding mutations in another adenosine deaminase.
• the adenosine deaminase comprises a H8Y, R24W, D108N, N127S, D147Y, and E155V mutation relative to the TadA reference sequence, or corresponding mutations in another adenosine deaminase. In some embodiments, the adenosine deaminase comprises a D108N, D147Y, and E155V mutation relative to the TadA reference sequence, or corresponding mutations in another adenosine deaminase.
• the adenosine deaminase comprises a H8Y, D108N, and N127S mutation relative to the TadA reference sequence, or corresponding mutations in another adenosine deaminase. In some embodiments, the adenosine deaminase comprises a A106V, D108N, D147Y and E155V mutation relative to the TadA reference sequence, or corresponding mutations in another adenosine deaminase.
• the adenosine deaminase comprises one or more of a, S2X, H8X, I49X, L84X, H123X, N127X, I156X and/or K160X mutation relative to the TadA reference sequence, or one or more corresponding mutations in another adenosine deaminase, where the presence of X indicates any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase.
• the adenosine deaminase comprises one or more of S2A, H8Y, I49F, L84F, H123Y, N127S, I156F and/or K160S mutation relative to the TadA reference sequence, or one or more corresponding mutations in another adenosine deaminase.
• the adenosine deaminase comprises an L84X mutation adenosine deaminase, where X indicates any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase.
• the adenosine deaminase comprises an L84F mutation relative to the TadA reference sequence, or a corresponding mutation in another adenosine deaminase.
• the adenosine deaminase comprises an H123X mutation relative to the TadA reference sequence, or a corresponding mutation in another adenosine deaminase, where X indicates any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase.
• the adenosine deaminase comprises an H123Y mutation relative to the TadA reference sequence, or a corresponding mutation in another adenosine deaminase.
• the adenosine deaminase comprises an I157X mutation relative to the TadA reference sequence, or a corresponding mutation in another adenosine deaminase, where X indicates any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase.
• the adenosine deaminase comprises an I157F mutation relative to the TadA reference sequence, or a corresponding mutation in another adenosine deaminase.
• the adenosine deaminase comprises one, two, three, four, five, six, or seven mutations selected from the group consisting of L84X, A106X, D108X, H123X, D147X, E155X, and I156X relative to the TadA reference sequence, or a corresponding mutation or mutations in another adenosine deaminase, where X indicates the presence of any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase.
• the adenosine deaminase comprises one, two, three, four, five, or six mutations selected from the group consisting of S2X, I49X, A106X, D108X, D147X, and E155X relative to the TadA reference sequence, or a corresponding mutation or mutations in another adenosine deaminase, where X indicates the presence of any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase.
• the adenosine deaminase comprises one, two, three, four, or five, mutations selected from the group consisting of H8X, A106X, D108X, N127X, and K160X relative to the TadA reference sequence, or a corresponding mutation or mutations in another adenosine deaminase, where X indicates the presence of any amino acid other than the corresponding amino acid in the wild- type adenosine deaminase.
• the adenosine deaminase comprises one, two, three, four, five, six, or seven mutations selected from the group consisting of L84F, A106V, D108N, H123Y, D147Y, E155V, and I156F relative to the TadA reference sequence, or a corresponding mutation or mutations in another adenosine deaminase.
• the adenosine deaminase comprises one, two, three, four, five, or six mutations selected from the group consisting of S2A, I49F, A106V, D108N, D147Y, and E155V relative to the TadA reference sequence.
• the adenosine deaminase comprises one, two, three, four, or five, mutations selected from the group consisting of H8Y, A106T, D108N, N127S, and K160S relative to the TadA reference sequence, or a corresponding mutation or mutations in another adenosine deaminase.
• the adenosine deaminase comprises one or more of a E25X, R26X, R107X, A142X, and/or A143X mutation relative to the TadA reference sequence, or one or more corresponding mutations in another adenosine deaminase, where the presence of X indicates any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase.
• the adenosine deaminase comprises one or more of E25M, E25D, E25A, E25R, E25V, E25S, E25Y, R26G, R26N, R26Q, R26C, R26L, R26K, R107P, R07K, R107A, R107N, R107W, R107H, R107S, A142N, A142D, A142G, A143D, A143G, A143E, A143L, A143W, A143M, A143S, A143Q and/or A143R mutation relative to the TadA reference sequence, or one or more corresponding mutations in another adenosine deaminase.
• the adenosine deaminase comprises one or more of the mutations described herein corresponding to the TadA reference sequence, or one or more corresponding mutations in another adenosine deaminase.
• the adenosine deaminase comprises an E25X mutation relative to the TadA reference sequence, or a corresponding mutation in another adenosine deaminase, where X indicates any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase.
• the adenosine deaminase comprises an E25M, E25D, E25A, E25R, E25V, E25S, or E25Y mutation relative to the TadA reference sequence, or a corresponding mutation in another adenosine deaminase.
• the adenosine deaminase comprises an R26X mutation relative to the TadA reference sequence, or a corresponding mutation in another adenosine deaminase, where X indicates any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase.
• the adenosine deaminase comprises R26G, R26N, R26Q, R26C, R26L, or R26K mutation relative to the TadA reference sequence, or a
• the adenosine deaminase comprises an R107X mutation relative to the TadA reference sequence, or a corresponding mutation in another adenosine deaminase, where X indicates any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase.
• the adenosine deaminase comprises an R107P, R07K, R107A, R107N, R107W, R107H, or R107S mutation relative to the TadA reference sequence, or a corresponding mutation in another adenosine deaminase.
• the adenosine deaminase comprises an A142X mutation relative to the TadA reference sequence, or a corresponding mutation in another adenosine deaminase, where X indicates any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase.
• the adenosine deaminase comprises an A142N, A142D, A142G, mutation relative to the TadA reference sequence, or a corresponding mutation in another adenosine deaminase.
• the adenosine deaminase comprises an A143X mutation relative to the TadA reference sequence, or a corresponding mutation in another adenosine deaminase, where X indicates any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase.
• the adenosine deaminase comprises an A143D, A143G, A143E, A143L, A143W, A143M, A143S, A143Q and/or A143R mutation relative to the TadA reference sequence, or a corresponding mutation in another adenosine deaminase.
• the adenosine deaminase comprises one or more of a H36X, N37X, P48X, I49X, R51X, M70X, N72X, D77X, E134X, S 146X, Q154X, K157X, and/or K161X mutation relative to the TadA reference sequence, or one or more corresponding mutations in another adenosine deaminase, where the presence of X indicates any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase.
• the adenosine deaminase comprises one or more of H36L, N37T, N37S, P48T, P48L, I49V, R51H, R51L, M70L, N72S, D77G, E134G, S146R, S146C, Q154H, K157N, and/or K161T mutation relative to the TadA reference sequence, or one or more corresponding mutations in another adenosine deaminase.
• the adenosine deaminase comprises an H36X mutation relative to the TadA reference sequence, or a corresponding mutation in another adenosine deaminase, where X indicates any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase.
• the adenosine deaminase comprises an H36L mutation relative to the TadA reference sequence, or a corresponding mutation in another adenosine deaminase.
• the adenosine deaminase comprises an N37X mutation relative to the TadA reference sequence, or a corresponding mutation in another adenosine deaminase, where X indicates any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase.
• the adenosine deaminase comprises an N37T, or N37S mutation relative to the TadA reference sequence, or a corresponding mutation in another adenosine deaminase.
• the adenosine deaminase comprises an P48X mutation relative to the TadA reference sequence, or a corresponding mutation in another adenosine deaminase, where X indicates any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase.
• the adenosine deaminase comprises an P48T, or P48L mutation relative to the TadA reference sequence, or a corresponding mutation in another adenosine deaminase.
• the adenosine deaminase comprises an R51X mutation relative to the TadA reference sequence, or a corresponding mutation in another adenosine deaminase, where X indicates any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase.
• the adenosine deaminase comprises an R51H, or R51L mutation relative to the TadA reference sequence, or a corresponding mutation in another adenosine deaminase.
• the adenosine deaminase comprises an S146X mutation relative to the TadA reference sequence, or a corresponding mutation in another adenosine deaminase, where X indicates any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase.
• the adenosine deaminase comprises an S 146R, or S 146C mutation relative to the TadA reference sequence, or a corresponding mutation in another adenosine deaminase.
• the adenosine deaminase comprises an K157X mutation relative to the TadA reference sequence, or a corresponding mutation in another adenosine deaminase, where X indicates any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase.
• the adenosine deaminase comprises a K157N mutation relative to the TadA reference sequence, or a corresponding mutation in another adenosine deaminase.
• the adenosine deaminase comprises an P48X mutation relative to the TadA reference sequence, or a corresponding mutation in another adenosine deaminase, where X indicates any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase.
• the adenosine deaminase comprises a P48S, P48T, or P48A mutation relative to the TadA reference sequence, or a corresponding mutation in another adenosine deaminase.
• the adenosine deaminase comprises an A142X mutation relative to the TadA reference sequence, or a corresponding mutation in another adenosine deaminase, where X indicates any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase.
• the adenosine deaminase comprises a A142N mutation relative to the TadA reference sequence, or a corresponding mutation in another adenosine deaminase.
• the adenosine deaminase comprises an W23X mutation relative to the TadA reference sequence, or a corresponding mutation in another adenosine deaminase, where X indicates any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase.
• the adenosine deaminase comprises a W23R, or W23L mutation relative to the TadA reference sequence, or a corresponding mutation in another adenosine deaminase.
• the adenosine deaminase comprises an R152X mutation relative to the TadA reference sequence, or a corresponding mutation in another adenosine deaminase, where X indicates any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase.
• the adenosine deaminase comprises a R152P, or R52H mutation relative to the TadA reference sequence, or a corresponding mutation in another adenosine deaminase.
• the adenosine deaminase may comprise the mutations H36L, R51L, L84F, A106V, D108N, H123Y, S 146C, D147Y, E155V, I156F, and K157N.
• the adenosine deaminase comprises the following combination of mutations relative to TadA reference sequence, where each mutation of a combination is separated by a "_" and each combination of mutations is between parentheses:
• the fusion proteins provided herein comprise one or more features that improve the base editing activity of the fusion proteins.
• any of the fusion proteins provided herein may comprise a Cas9 domain that has reduced nuclease activity.
• any of the fusion proteins provided herein may have a Cas9 domain that does not have nuclease activity (dCas9), or a Cas9 domain that cuts one strand of a duplexed DNA molecule, referred to as a Cas9 nickase (nCas9).
• the adenosine deaminase comprises a D108X mutation relative to the TadA reference or wild type sequence, or a corresponding mutation in another adenosine deaminase (e.g., ecTadA), where X indicates any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase.
• the adenosine deaminase comprises a D108G, D108N, D108V, D108A, or D108Y mutation, or a corresponding mutation in another adenosine deaminase.
• the adenosine deaminse comprises an A106X, E155X, or D147X, mutation relative to the TadA reference or wild type sequence, or a corresponding mutation in another adenosine deaminase, where X indicates any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase.
• the adenosine deaminase comprises an E155D, E155G, or E155V mutation.
• the adenosine deaminase comprises a D147Y.
• any of the mutations provided herein can be introduced into other adenosine deaminases, such as S. aureus TadA (saTadA), or other adenosine deaminases (e.g., bacterial adenosine deaminases).
• adenosine deaminases such as S. aureus TadA (saTadA)
• adenosine deaminases e.g., bacterial adenosine deaminases.
• Any of the mutations identified based on the TadA reference sequence can be made in other adenosine deaminases that have homologous amino acid residues.
• any of the mutations provided herein can be made individually or in any combination relative to the TadA or another adenosine deaminase.
• an adenosine deaminase can contain a D108N, a A106V, a E155V, and/or a D147Y mutation relative to the TadA reference sequence, or a corresponding mutation in another adenosine deaminase.
• an adenosine deaminase comprises the following group of mutations (groups of mutations are separated by a“;”) relative to the TadA reference sequence, or corresponding mutations in another adenosine deaminase: D108N and A106V; D108N and E155V; D108N and D147Y; A106V and E155V; A106V and D147Y; E155V and D147Y; D108N, A106V, and E55V; D108N, A106V, and D147Y; D108N, E55V, and D147Y; A106V, E55V, and D147Y; and D108N, A106V, E55V, and D147Y. It should be appreciated, however, that any combination of corresponding mutations provided herein can be made in an adenosine deaminase (e.g., ecTadA).
• the adenosine deaminase comprises one or more of a H8X, T17X, L18X, W23X, L34X, W45X, R51X, A56X, E59X, E85X, M94X, I95X, V102X, F104X, A106X, R107X, D108X, Kl lOX, M118X, N127X, A138X, F149X, M151X, R153X, Q154X, I156X, and/or K157X mutation relative to the TadA reference sequence, or one or more corresponding mutations in another adenosine deaminase, where the presence of X indicates any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase.
• the adenosine deaminase comprises one or more of H8Y, T17S, L18E, W23L, L34S, W45L, R51H, A56E, or A56S, E59G, E85K, or E85G, M94L, 1951, V102A, F104L, A106V, R107C, or R107H, or R107P, D108G, or D108N, or D108V, or D108A, or D108Y, Kl10I, Ml18K, N127S, A138V, F149Y, M151V, R153C, Q154L, I156D, and/or K157R mutation relative to the TadA reference sequence, or one or more corresponding mutations in another adenosine deaminase.
• the adenosine deaminase comprises one or more of a H8X, D108X, and/or N127X mutation relative to the TadA reference sequence, or one or more corresponding mutations in another adenosine deaminase, where X indicates the presence of any amino acid.
• the adenosine deaminase comprises one or more of a H8Y, D108N, and/or N127S mutation relative to the TadA reference sequence, or one or more corresponding mutations in another adenosine deaminase.
• the adenosine deaminase comprises one or more of H8X, R26X, M61X, L68X, M70X, A106X, D108X, A109X, N127X, D147X, R152X, Q154X, E155X, K161X, Q163X, and/or T166X mutation relative to the TadA reference sequence, or one or more corresponding mutations in another adenosine deaminase, where X indicates the presence of any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase.
• the adenosine deaminase comprises one or more of H8Y, R26W, M61I, L68Q, M70V, A106T, D108N, A109T, N127S, D147Y, R152C, Q154H or Q154R, E155G or E155V or E155D, K161Q, Q163H, and/or T166P mutation relative to the TadA reference sequence, or one or more corresponding mutations in another adenosine deaminase.
• the adenosine deaminase comprises one, two, three, four, five, or six mutations selected from the group consisting of H8X, D108X, N127X, D147X, R152X, and Q154X relative to the TadA reference sequence, or a corresponding mutation or mutations in another adenosine deaminase, where X indicates the presence of any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase.
• the adenosine deaminase comprises one, two, three, four, five, six, seven, or eight mutations selected from the group consisting of H8X, M61X, M70X, D108X, N127X, Q154X, E155X, and Q163X relative to the TadA reference sequence, or a corresponding mutation or mutations in another adenosine deaminase, where X indicates the presence of any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase.
• the adenosine deaminase comprises one, two, three, four, or five, mutations selected from the group consisting of H8X, D108X, N127X, E155X, and T166X relative to the TadA reference sequence, or a corresponding mutation or mutations in another adenosine deaminase, where X indicates the presence of any amino acid other than the corresponding amino acid in the wild- type adenosine deaminase.
• the adenosine deaminase comprises one, two, three, four, five, or six mutations selected from the group consisting of H8X, A106X, D108X, mutation or mutations in another adenosine deaminase, where X indicates the presence of any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase.
• the adenosine deaminase comprises one, two, three, four, five, six, seven, or eight mutations selected from the group consisting of H8X, R126X, L68X, D108X, N127X, D147X, and E155X, or a corresponding mutation or mutations in another adenosine deaminase, where X indicates the presence of any amino acid other than the corresponding amino acid in the wild- type adenosine deaminase.
• the adenosine deaminase comprises one, two, three, four, or five, mutations selected from the group consisting of H8X, D108X, A109X, N127X, and E155X relative to the TadA reference sequence, or a corresponding mutation or mutations in another adenosine deaminase, where X indicates the presence of any amino acid other than the corresponding amino acid in the wild-type adenosine deaminase.
• the adenosine deaminase comprises one, two, three, four, five, or six mutations selected from the group consisting of H8Y, D108N, N127S, D147Y, R152C, and Q154H relative to the TadA reference sequence, or a corresponding mutation or mutations in another adenosine deaminase.
• the adenosine deaminase comprises one, two, three, four, five, six, seven, or eight mutations selected from the group consisting of H8Y, M61I, M70V, D108N, N127S, Q154R, E155G and Q163H relative to the TadA reference sequence, or a corresponding mutation or mutations in another adenosine deaminase.
• the adenosine deaminase comprises one, two, three, four, or five, mutations selected from the group consisting of H8Y, D108N, N127S, E155V, and T166P relative to the TadA reference sequence, or a corresponding mutation or mutations in another adenosine deaminase.
• the adenosine deaminase comprises one, two, three, four, five, or six mutations selected from the group consisting of H8Y, A106T, D108N, N127S, E155D, and K161Q relative to the TadA reference sequence, or a corresponding mutation or mutations in another adenosine deaminase.
• the adenosine deaminase comprises one, two, three, four, five, six, seven, or eight mutations selected from the group consisting of H8Y, R126W, L68Q, D108N, N127S, D147Y, and E155V relative to the TadA reference sequence, or a corresponding mutation or mutations in another adenosine deaminase.
• the adenosine deaminase comprises one, two, three, four, or five, mutations selected from the group consisting of H8Y, D108N, A109T, N127S, and E155G relative to the TadA reference sequence, or a corresponding mutation or mutations in another adenosine deaminase.
• any of the mutations provided herein and any additional mutations can be introduced into any other adenosine deaminases. Any of the mutations provided herein can be made individually or in any combination relative to the TadA reference sequence or another adenosine deaminase.
• Any of the mutations provided herein can be made individually or in any combination relative to the TadA reference sequence or another adenosine deaminase.
• a fusion protein of the invention comprises a cytidine deaminase.
• the cytidine deaminases provided herein are capable of deaminating cytosine or 5-methylcytosine to uracil or thymine.
• the cytosine deaminases provided herein are capable of deaminating cytosine in DNA.
• the cytidine deaminase may be derived from any suitable organism.
• the cytidine deaminase is a naturally-occurring cytidine deaminase that includes one or more mutations corresponding to any of the mutations provided herein.
• the cytidine deaminase is from a prokaryote. In some embodiments, the cytidine deaminase is from a bacterium. In some embodiments, the cytidine deaminase is from a mammal (e.g., human).
• the cytidine deaminase comprises an amino acid sequence that is at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99%, or at least 99.5% identical to any one of the cytidine deaminase amino acid sequences set forth herein. It should be
• cytidine deaminases provided herein may include one or more mutations (e.g., any of the mutations provided herein).
• the disclosure provides any deaminase domains with a certain percent identity plus any of the mutations or combinations thereof described herein.
• the cytidine deaminase comprises an amino acid sequence that has 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 21, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, or more mutations compared to a reference sequence, or any of the cytidine deaminases provided herein.
• the cytidine deaminase comprises an amino acid sequence that has at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 60, at least 70, at least 80, at least 90, at least 100, at least 110, at least 120, at least 130, at least 140, at least 150, at least 160, or at least 170 identical contiguous amino acid residues as compared to any one of the amino acid sequences known in the art or described herein. Additional Domains
• a base editor described herein can include any domain which helps to facilitate the nucleobase editing, modification, or altering of a nucleobase of a polynucleotide.
• a base editor comprises a polynucleotide programmable nucleotide binding domain (e.g., Cas9), a nucleobase editing domain (e.g., deaminase domain), and one or more additional domains.
• the additional domain can facilitate enzymatic or catalytic functions of the base editor, binding functions of the base editor, or be inhibitors of cellular machinery (e.g., enzymes) that could interfere with the desired base editing result.
• a base editor can comprise a nuclease, a nickase, a recombinase, a deaminase, a methyltransferase, a methylase, an acetylase, an acetyltransferase, a transcriptional activator, or a transcriptional repressor domain.
• a base editor can comprise a uracil glycosylase inhibitor (UGI) domain.
• UGI domain can, for example, improve the efficiency of base editors comprising a cytidine deaminase domain by inhibiting the conversion of a U formed by deamination of a C back to the C nucleobase.
• cellular DNA repair response to the presence of U:G heteroduplex DNA can be responsible for a decrease in nucleobase editing efficiency in cells.
• uracil DNA glyocosylase (UDG) can catalyze removal of U from DNA in cells, which can initiate base excision repair (BER), mostly resulting in reversion of the U:G pair to a C:G pair.
• BER can be inhibited in base editors comprising one or more domains that bind the single strand, block the edited base, inhibit UGI, inhibit BER, protect the edited base, and /or promote repairing of the non-edited strand.
• this disclosure contemplates a base editor fusion protein comprising a UGI domain.
• a base editor comprises as a domain all or a portion of a double- strand break (DSB) binding protein.
• a DSB binding protein can include a Gam protein of bacteriophage Mu that can bind to the ends of DSBs and can protect them from degradation. See Komor, A.C., et al.,“Improved base excision repair inhibition and
• a base editor can comprise as a domain all or a portion of a nucleic acid polymerase (NAP).
• NAP nucleic acid polymerase
• a base editor can comprise all or a portion of a eukaryotic NAP.
• a NAP or portion thereof incorporated into a base editor is a DNA polymerase.
• a NAP or portion thereof incorporated into a base editor has translesion polymerase activity.
• a NAP or portion thereof incorporated into a base editor is a translesion DNA polymerase.
• a NAP or portion thereof incorporated into a base editor is a Rev7, Rev1 complex, polymerase iota, polymerase kappa, or polymerase eta.
• a NAP or portion thereof incorporated into a base editor is a eukaryotic polymerase alpha, beta, gamma, delta, epsilon, gamma, eta, iota, kappa, lambda, mu, or nu component.
• a NAP or portion thereof incorporated into a base editor comprises an amino acid sequence that is at least 75%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99%, or 99.5% identical to a nucleic acid polymerase (e.g., a translesion DNA polymerase).
• a nucleic acid polymerase e.g., a translesion DNA polymerase
• Use of the base editor system comprises the steps of: (a) contacting a target nucleotide sequence of a polynucleotide (e.g., a double-stranded DNA or RNA, a single- stranded DNA or RNA) of a subject with a base editor system comprising a nucleobase editor (e.g., an adenosine base editor or a cytidine base editor) and a guide polynucleic acid (e.g., gRNA), wherein the target nucleotide sequence comprises a targeted nucleobase pair; (b) inducing strand separation of the target region; (c) converting a first nucleobase of the target nucleobase pair in a single strand of the target region to a second nucleobase; and (d) cutting no more than one strand of the target region, where a third nucleobase complementary to the first nucleobase base is replaced by a fourth nucleobase complementary
• the targeted nucleobase pair is a plurality of nucleobase pairs in one or more genes.
• the base editor system provided herein is capable of multiplex editing of a plurality of nucleobase pairs in one or more genes.
• the plurality of nucleobase pairs is located in the same gene.
• the plurality of nucleobase pairs is located in one or more genes, wherein at least one gene is located in a different locus.
• the cut single strand (nicked strand) is hybridized to the guide nucleic acid. In some embodiments, the cut single strand is opposite to the strand comprising the first nucleobase. In some embodiments, the base editor comprises a Cas9 domain. In some embodiments, the first base is adenine, and the second base is not a G, C, A, or T. In some embodiments, the second base is inosine.
• Base editing system as provided herein provides a new approach to genome editing that uses a fusion protein containing a catalytically defective Streptococcus pyogenes Cas9, a cytidine deaminase, and an inhibitor of base excision repair to induce programmable, single nucleotide (C®T or A®G) changes in DNA without generating double-strand DNA breaks, without requiring a donor DNA template, and without inducing an excess of stochastic insertions and deletions.
• C®T or A®G programmable, single nucleotide
• the base editor system comprises (1) a base editor (BE) comprising a polynucleotide programmable nucleotide binding domain and a nucleobase editing domain (e.g., a deaminase domain) for editing the nucleobase; and (2) a guide polynucleotide (e.g., guide RNA) in conjunction with the polynucleotide programmable nucleotide binding domain.
• the base editor system comprises a cytosine base editor (CBE).
• the base editor system comprises an adenosine base editor (ABE).
• the polynucleotide programmable nucleotide binding domain is a polynucleotide programmable DNA binding domain. In some embodiments, the polynucleotide programmable nucleotide binding domain is a polynucleotide programmable RNA binding domain. In some embodiments, the nucleobase editing domain is a deaminase domain. In some cases, a deaminase domain can be a cytosine deaminase or a cytidine deaminase. In some embodiments, the terms“cytosine deaminase” and“cytidine deaminase” can be used interchangeably.
• a deaminase domain can be an adenine deaminase or an adenosine deaminase.
• the terms“adenine deaminase” and “adenosine deaminase” can be used interchangeably. Details of nucleobase editing proteins are described in International PCT Application Nos. PCT/2017/045381 (WO2018/027078) and PCT/US2016/058344 (WO2017/070632), each of which is incorporated herein by reference in its entirety.
• the base editor inhibits base excision repair of the edited strand. In some embodiments, the base editor protects or binds the non-edited strand. In some embodiments, the base editor comprises UGI activity. In some embodiments, the base editor comprises a catalytically inactive inosine-specific nuclease. In some embodiments, the base editor comprises nickase activity. In some embodiments, the intended edit of base pair is upstream of a PAM site. In some embodiments, the intended edit of base pair is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides upstream of the PAM site.
• the intended edit of base-pair is downstream of a PAM site.
• the intended edited base pair is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides downstream stream of the PAM site.
• the method does not require a canonical (e.g., NGG) PAM site.
• the nucleobase editor comprises a linker or a spacer.
• the linker or spacer is 1-25 amino acids in length. In some embodiments, the linker or spacer is 5-20 amino acids in length. In some embodiments, the linker or spacer is 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 amino acids in length.
• the target region comprises a target window, wherein the target window comprises the target nucleobase pair.
• the target window comprises 1-10 nucleotides.
• the target window is 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, or 20 nucleotides in length.
• the intended edit of base pair is within the target window.
• the target window comprises the intended edit of base pair.
• the method is performed using any of the base editors provided herein.
• a target window is a
• the base editor is a cytidine base editor (CBE).
• CBE cytidine base editor
• non-limiting exemplary CBE is BE1 (APOBEC1-XTEN-dCas9), BE2
• BE4 extends the APOBEC1- Cas9n(D10A) linker to 32 amino acids and the Cas9n-UGI linker to 9 amino acids, and appends a second copy of UGI to the C terminus of the construct with another 9 amino acid linker into a single base editor construct.
• the base editors saBE3 and saBE4 have the S. pyogenes
• the base editor is an adenosine base editor (ABE).
• the adenosine base editor can deaminate adenine in DNA.
• the adenosine base editor can deaminate adenine in RNA.
• ABE is generated by replacing APOBEC1 component of BE3 with natural or engineered E.coli TadA, human ADAR2, mouse ADA, or human ADAT2.
• ABE comprises evolved TadA variant.
• the ABE is ABE 1.2 (TadA*-XTEN-nCas9- NLS).
• TadA* comprises A106V and D108N mutations.
• the ABE is a second generation ABE.
• the ABE is ABE2.1, which comprises additional mutations D147Y and E155V in TadA* (TadA*2.1).
• the ABE is ABE2.2, ABE2.1 fused to catalytically inactivated version of human alkyl adenine DNA glycosylase (AAG with E125Q mutation).
• the ABE is ABE2.3, ABE2.1 fused to catalytically inactivated version of E.coli Endo V (inactivated with D35A mutation).
• the ABE is ABE2.6 which has a linker twice as long (32 amino acids, (SGGS) 2 -XTEN-(SGGS) 2 ) as the linker in ABE2.1.
• the ABE is ABE2.7, which is ABE2.1 tethered with an additional wild-type TadA monomer.
• the ABE is ABE2.8, which is ABE2.1 tethered with an additional TadA*2.1 monomer.
• the ABE is ABE2.9, which is a direct fusion of evolved TadA (TadA*2.1) to the N-ternimus of ABE2.1.
• the ABE is ABE2.10, which is a direct fusion of wild type TadA to the N- ternimus of ABE2.1.
• the ABE is ABE2.11, which is ABE2.9 with an inactivating E59A mutation at the N-terminus of TadA* monomer.
• the ABE is ABE2.12, which is ABE2.9 with an inactivating E59A mutation in the internal TadA* monomer.
• the ABE is a third generation ABE.
• the ABE is ABE3.1, which is ABE2.3 with three additional TadA mutations (L84F, H123Y, and I157F).
• the ABE is a fourth generation ABE.
• the ABE is ABE4.3, which is ABE3.1 with an additional TadA mutation A142N (TadA*4.3).
• the ABE is a fifth generation ABE.
• the ABE is ABE5.1, which is generated by importing a consensus set of mutations from surviving clones (H36L, R51L, S146C, and K157N) into ABE3.1.
• the ABE is ABE5.3, which has a heterodimeric construct containing wild-type E. coli TadA fused to an internal evolved TadA*.
• the ABE is ABE5.2, ABE5.4, ABE5.5, ABE5.6, ABE5.7, ABE5.8, ABE5.9, ABE5.10, ABE5.11, ABE5.12, ABE5.13, or ABE5.14, as shown in below Table 2.
• the ABE is a sixth generation ABE. In some embodiments, the ABE is ABE6.1, ABE6.2, ABE6.3, ABE6.4, ABE6.5, or ABE6.6, as shown in below Table 2. In some embodiments, the ABE is a seventh generation ABE. In some embodiments, the ABE is ABE7.1, ABE7.2, ABE7.3, ABE7.4, ABE7.5, ABE7.6, ABE7.7, ABE7.8, ABE 7.9, or ABE7.10, as shown in below Table 2.
• the base editor comprises a polynucleotide programmable DNA binding domain and a cytidine deaminase domain for deaminating a cytidine nucleobase, wherein a guide polynucleotide targets the base editor to the target nucleotide sequence located in a coding region of a gene, such as a gene associated with a pathogenic mutation, for example, ACADM, HBB, PDS, SNCA, or SERPINA1, or in a regulatory region of a gene, such as a gene listed in Table 4 herein.
• a guide polynucleotide targets the base editor to the target nucleotide sequence located in a coding region of a gene, such as a gene associated with a pathogenic mutation, for example, ACADM, HBB, PDS, SNCA, or SERPINA1, or in a regulatory region of a gene, such as a gene listed in Table 4 herein.
• the base editor is a fusion protein comprising a polynucleotide programmable nucleotide binding domain (e.g., Cas9-derived domain) fused to a nucleobase editing domain (e.g., all or a portion of a deaminase domain).
• the base editor further comprises a domain comprising all or a portion of a uracil glycosylase inhibitor (UGI).
• the base editor comprises a domain comprising all or a portion of a uracil binding protein (UBP), such as a uracil DNA glycosylase (UDG).
• UBP uracil binding protein
• UDG uracil DNA glycosylase
• the base editor comprises a domain comprising all or a portion of a nucleic acid polymerase.
• a nucleic acid polymerase or portion thereof incorporated into a base editor is a translesion DNA polymerase.
• a domain of the base editor can comprise multiple domains.
• the base editor comprising a polynucleotide programmable nucleotide binding domain derived from Cas9 can comprise an REC lobe and an NUC lobe corresponding to the REC lobe and NUC lobe of a wild-type or natural Cas9.
• the base editor can comprise one or more of a RuvCI domain, BH domain, REC1 domain, REC2 domain, RuvCII domain, L1 domain, HNH domain, L2 domain, RuvCIII domain, WED domain, TOPO domain or CTD domain.
• one or more domains of the base editor comprise a mutation (e.g., substitution, insertion, deletion) relative to a wild type version of a polypeptide comprising the domain.
• a mutation e.g., substitution, insertion, deletion
• an HNH domain of a polynucleotide programmable DNA binding domain can comprise an H840A substitution.
• a RuvCI domain of a polynucleotide programmable DNA binding domain can comprise a D10A substitution.
• a linker domain can be a bond (e.g., covalent bond), chemical group, or a molecule linking two molecules or moieties, e.g., two domains of a fusion protein, such as, for example, a first domain (e.g., Cas9-derived domain) and a second domain (e.g., a cytidine deaminase domain or adenosine deaminase domain).
• a linker is a covalent bond (e.g., a carbon-carbon bond, disulfide bond, carbon-hetero atom bond, etc.). In certain embodiments, a linker is a carbon nitrogen bond of an amide linkage. In certain embodiments, a linker is a cyclic or acyclic, substituted or unsubstituted, branched or unbranched aliphatic or heteroaliphatic linker. In certain embodiments, a linker is polymeric (e.g., polyethylene, polyethylene glycol, polyamide, polyester, etc.). In certain embodiments, a linker comprises a monomer, dimer, or polymer of aminoalkanoic acid.
• a linker comprises an aminoalkanoic acid (e.g., glycine, ethanoic acid, alanine, beta-alanine, 3- aminopropanoic acid, 4-aminobutanoic acid, 5-pentanoic acid, etc.).
• a linker comprises a monomer, dimer, or polymer of aminohexanoic acid (Ahx).
• a linker is based on a carbocyclic moiety (e.g., cyclopentane, cyclohexane).
• a linker comprises a polyethylene glycol moiety (PEG).
• a linker comprises an aryl or heteroaryl moiety. In certain embodiments, the linker is based on a phenyl ring.
• a linker can include functionalized moieties to facilitate attachment of a nucleophile (e.g., thiol, amino) from the peptide to the linker. Any electrophile can be used as part of the linker. Exemplary electrophiles include, but are not limited to, activated esters, activated amides, Michael acceptors, alkyl halides, aryl halides, acyl halides, and isothiocyanates.
• a linker joins a gRNA binding domain of an RNA- programmable nuclease, including a Cas9 nuclease domain, and the catalytic domain of a nucleic acid editing protein.
• a linker joins a dCas9 and a second domain (e.g., cytidine deaminase, UGI, etc.).
• a linker is positioned between, or flanked by, two groups, molecules, or other moieties and connected to each one via a covalent bond, thus connecting the two.
• a linker is, thus connecting the two.
• a linker is an amino acid or a plurality of amino acids (e.g., a peptide or protein).
• a linker is an organic molecule, group, polymer, or chemical moiety.
• a linker is 2-100 amino acids in length, for example, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 30-35, 35-40, 40-45, 45-50, 50-60, 60-70, 70-80, 80-90, 90-100, 100-150, or 150-200 amino acids in length.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• Engineering & Computer Science (AREA)
• Genetics & Genomics (AREA)
• Organic Chemistry (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Zoology (AREA)
• Wood Science & Technology (AREA)
• Biomedical Technology (AREA)
• Molecular Biology (AREA)
• General Health & Medical Sciences (AREA)
• General Engineering & Computer Science (AREA)
• Biotechnology (AREA)
• Biochemistry (AREA)
• Medicinal Chemistry (AREA)
• Microbiology (AREA)
• Biophysics (AREA)
• Pharmacology & Pharmacy (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Animal Behavior & Ethology (AREA)
• Epidemiology (AREA)
• Plant Pathology (AREA)
• Physics & Mathematics (AREA)
• Gastroenterology & Hepatology (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Immunology (AREA)
• Cell Biology (AREA)
• Hematology (AREA)
• Mycology (AREA)
• Crystallography & Structural Chemistry (AREA)
• Diabetes (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Developmental Biology & Embryology (AREA)
• Virology (AREA)
• Enzymes And Modification Thereof (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Priority Applications (12)

Applications Claiming Priority (6)

Related Child Applications (2)

Publications (1)

Family

ID=68467606

Family Applications (1)

Country Status (8)

Cited By (41)